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ABSTRACT
The treatment of head and neck cancer is a complicated task which requires that 
many factors be considered before the best option can be chosen. The best treatment, 
providing the greatest efficacy with minimal side effects, is likely to be a localized 
nonsurgical treatment. Such a treatment would allow resolution of the primary tumor 
without the devastating systemic side effects associated with chemotherapy nor the social 
and psychological side effects associated with scarring and disfigurement resulting from 
surgical resection. Locally delivered gene therapy with viral vectors is a promising 
approach due to advances in delivery-enhancing materials. One such material is 
genetically engineered silk-elastinlike protein polymer (SELP), which due to its repeating 
structure and method of synthesis can be precisely modified to produce desired 
properties, such as pore size, swelling ratio, release rate, and mechanical strength. In this 
dissertation, it is shown that one particular analog of this polymer exhibits superior 
performance in the enhancement of adenoviral gene delivery, with enhancement of 
localization of gene expression of up to 55-fold, and reduction in acute immune response 
as measured by differential white blood cell count and hepatotoxicity due to viral 
administration. Further improvement of this material has been to include matrix- 
metalloproteinase (MMP)-sensitive sites in the polymer to provide it the capability to 
biodegrade more rapidly. Advantages to an MMP-responsive material include the ability
to respond to changes in the tumor environment, as increased MMP activity can correlate 
with increased invasiveness and, in many cases, metastasis. The insertion of the MMP- 
responsive sequence caused sensitivity to both MMP-2 and MMP-9, with 63% and 44% 
increases in protein loss from sensitive hydrogels exposed to MMP-2 and MMP-9, 
respectively, compared to unexposed control. Further, MMP-2 and MMP-9 exposure 
caused 41% and 24% reduction in compressive modulus, and 95% and 66% increased 
release of 100nm polystyrene nanoparticles, respectively. These results show the 
potential of SELPs in increasing the safety and efficacy of adenoviral gene therapy.
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Since the initial conceptualization of gene therapy, the problem of safe and 
efficient delivery of nucleic acids to target cells in vivo has continued to restrict the utility 
of this promising treatment approach.1-5 Innate biological mechanisms, likely developed 
over the course of the evolution of our species to protect against virulent infection, have 
now become the enemy of a seemingly infinite number of possible treatments for human 
disease. Researchers have been attempting strategies which will allow the power of gene 
therapy to be unlocked, for countless hours of unraveling the intricacies of the human 
genome to come to some fruition. Yet as our understanding of how human disease 
develops, the questions remain: Why do our bodies turn on themselves? How can 
debilitating genetic errors remain uncorrected? What possible methods may be employed 
to intervene? Arguably the most theoretically effective strategy, direct repair of 
“incorrect” genetic code by specific transduction of external genetic material, has 
remained an elusive ideal. How much easier would treatment of disease be if clinicians 
could simply “reprogram” the body to not have the disease? Much effort has gone into 
the development of natural or man-made vectors to facilitate the expression of external 
genes in cells.4, 6 However, even with successful identification of methods by which to 
introduce foreign genetic material, specificity of gene transduction to only specific cells 
remains an issue. Effective targeting of gene products is particularly important when the
gene of interest is used as a method to directly or indirectly initiate cell destruction, as in 
the case of cancer gene therapy. The expression of this type of gene in nontarget tissues 
has obvious ramifications, with the potential for organ damage or destruction along with 
many other undesirable side effects. There is a clear need to develop methods and 
strategies to increase the specificity of gene therapy for the treatment of cancer. However, 
while this remains fact, current clinical approaches to the treatment of cancer are faced 
with many similar challenges involving nonspecific exposure as well. Even with decades 
of research by thousands of investigators, there is still a drastic effect on quality of life as
7-1 4a result of many of the current state-of-the art cancer treatments. ~ In some cases, the 
consequences of receiving treatment for a life-threatening cancer outweigh their ability to 
prolong life15-17; it is the classical balance between quality of life and quantity of life. 
Properly controlled cancer gene therapy has the potential to alleviate adverse effects and 
allow for the best possible treatment conditions in terms of patient compliance, 
happiness, and efficacy, which when combined have the potential to revolutionize 
modern cancer treatment.
One method by which gene transfer can be controlled is using matrix-mediated 
gene delivery (MMGD).18-20 MMGD is the use of a biomaterial to control the delivery of 
a gene product in a spatiotemporal fashion. This may or may not occur by responding to 
stimuli present in the local environment, or stimuli provided externally. MMGD has 
advantages over other methods of gene delivery for many reasons. Most notably, 
MMGD systems can be designed to release their therapeutic gene products only in the 
presence of certain biological molecules, thereby giving these materials the ability to 
target their release to only certain sites of a tissue or only after an activating molecule or
2
enzyme has been released in the desired area. These materials could also potentially be 
designed to respond to environmental stimuli, such as temperature or pH, which would 
either restrict or enhance the release of therapeutic genes in a well-controlled manner. 
Another advantage to the use of MMGD is that instead of release being governed only by 
the diffusion of one molecule (the vector or naked DNA), the release rate is controlled by 
the diffusion of two molecules, the release stimulus and the vector, and the reaction 
kinetics between the stimulus and the tether. This allows the materials to be designed to 
precisely release at the rate desired by manipulating the sensitivity of the tether, the 
sensitivity of the material, or the material properties of the matrix governing the diffusion 
of solutes within the material. Further, administration of nucleic acids or nucleic acid 
delivery vehicles in matrices may potentially reduce the exposure of such constructs to 
the nuclease-rich extracellular environment. Such a protective effect would reduce the 
loss of gene expression activity due to degradation.
1.2 Aims and scope of this dissertation
The necessity for an effective and safe gene delivery system can be addressed 
through a number of possible strategies. In this work, we investigate the utility of a 
genetically engineered protein polymer to accomplish this goal. Silk-elastinlike protein 
polymers (SELPs) are a class of genetically engineered polymers which have been 
investigated for use in several different applications, including viral gene delivery.18, 21, 22 
This material is composed of repeating units of silk (GAGAGS) and elastin (GVGVP) 
units, which are arranged into blocks of several of each type of unit to form SELP 
monomers.23 One major advantage to using these polymers is the ability to precisely
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modify the length and arrangement to affect change in physicochemical properties.21, 24 
Three constructs of SELP have thus far been synthesized: SELP-47K, SELP-415K, and 
SELP-815K, so named for their arrangement of silk units and elastin units. Schematics of 
these three structures are shown in Figure 1.1. SELP-47K is composed of four silk units 
followed by eight elastin units per monomer, with one of these elastin units possessing a 
lysine substitution (GKGVP) denoted by “K”. SELP-415K has 4 silk and 16 elastin units 
per monomer, and SELP-815K has 8 silk and 16 elastin units. The number of monomers 
for each polymer is chosen such that the molecular weight of each polymer is 
approximately the same.
The central hypothesis of this dissertation is that by specifically manipulating the 
sequence and arrangement of the amino acid blocks comprising silk-elastinlike protein 
polymers in this way, a structure of this polymer can be identified and used as a material 
to enhance viral gene delivery. Increasing silk unit length and decreasing elastin unit 
length are hypothesized to decrease release rate, leading to more effective localization of 
viral gene transfection and consequently improved safety and efficacy of viral delivery 
when mediated by SELP. The ideal structure of SELP would show significant 
improvements in the physical distribution of adenoviral gene transfection and improve 
the safety of localized adenoviral gene therapy. The goal of this research is to take steps 
toward constructing such a material and using the highly specific modification capability 
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Figure 1.1: Schematics of three SELP analogs used for viral gene delivery. 
Blue=elastin blocks, red=silk blocks, black=crosslinks between silk blocks.
1.2.1 Compare the structure-dependence of viral delivery from 
silk-elastinlike protein polymers for duration and extent 
of gene transfection in vivo 
The three SELP structures in the context of viral delivery were compared for the 
distribution, magnitude, and longevity of viral gene expression in xenograft tumors 
grown in the flanks of athymic nude mice. Further, SELPs were compared in the context 
of degradation by elastase, a common protease found ubiquitously throughout the body. 
The hypothesis driving this research was that modifications to the structure of SELP 
would produce structure-dependent changes in adenoviral gene transfection and 
degradation of these polymers. Gene transfection was analyzed using two different 
assays, one an organ lysate colorimetric assay performed using a P-galactosidase reporter 
gene, and the other being a luciferin-luciferase reporter system for real-time gene 
expression detection. Tissue P-galactosidase expression was histologically analyzed to 
investigate the specific distribution of gene expression within tumor tissue. In addition to 
structure-dependence of gene expression, the relative degradability of these three 
constructs was assessed by incubation with human elastase, which revealed that 
degradability is dependent on hydrogel weight percentage, silk:elastin ratio, and silk unit 
length. This work revealed that SELP-815K and SELP-47K at 4 wt% offered the greatest 
enhancement in gene delivery efficiency, while degradability was highest in SELP-415K, 
followed by SELP-47K and SELP-815K. These studies set the stage for further 
assessment of SELPs-47K and-815K at 4 wt% in the improvement of efficacy and safety 
of viral gene delivery.
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1.2.2 Assess the safety of silk-elastinlike protein polymer- 
mediated gene-directed enzyme-prodrug therapy using 
adenoviral vectors in vivo 
This aim was intended to investigate the ability of SELP-815K at 4 wt% 
concentration to improve the safety of gene-directed enzyme-prodrug therapy (GDEPT). 
GDEPT is, in general, the use of a foreign gene introduced into cells to sensitize those 
cells to an ordinarily nontoxic or minimally toxic substance, the prodrug.25-28 In this case, 
the enzyme-prodrug system applied was herpes simplex virus thymidine kinase (HSVtk) 
as the activating enzyme, and ganciclovir (GCV) as the prodrug.26-28 The ability of SELP 
to improve the safety of this system was investigated by injecting adenovirus encoding 
for HSVtk suspended in 0.9% saline or SELP-815K at 4 wt% subcutaneously in an 
immunocompetent mouse model. Following viral injection, daily administration of GCV 
was performed and mouse weights were assessed daily to monitor overall well-being. At 
four selected time points (i.e., 1, 2, 4, and 12 weeks) animals were sacrificed and 
complete differential blood count and clinical chemistry panel were performed on all 
mice. The results revealed that delivery of adenovirus in SELP eliminated acute immune 
response observed at week 1 in the adenovirus + saline injection, as well as the apparent 
hepatotoxicity observed at week 4. Overall, the results of this study show that delivery of 
adenovirus in a SELP hydrogel eliminates many of the concerns which are associated 
with adenoviral delivery in this model. One unresolved issue which was observed in this 
study was an apparent limited biodegradability of SELPs, with almost the entire injected 
gel masses recoverable even at the 12 weeks postinjection time point.
7
1.2.3 Synthesize and characterize a novel, matrix-metalloproteinase 
responsive analog of SELP-815K 
In this aim, a new analog of SELP containing a matrix-metalloproteinase (MMP)- 
degradable amino acid sequence, GPQGIFGQ (single amino acid abbreviations are used), 
was genetically engineered and the degradation, release, and mechanical properties of the 
resulting protein polymer and hydrogel were assessed. The degradable sequence was 
inserted immediately at the C-terminal side of the lysine substitution due to its location 
within the elastin units, as this was thought to have the least effect on gelation. The 
individual polymer chains were observed to be degradable by MMP-2 and MMP-9, as 
were hydrogels composed of these polymers. The release of fluorescent nanoparticles of 
100nm was also affected by MMP-2 and MMP-9 treatment. These results indicate that 
the degradation of SELP can be controlled and optimized for viral delivery in response to 
MMPs present in the tumor microenvironment. The ability of these hydrogels to 
potentially respond to MMPs increases their utility as viral delivery materials for the 
treatment of cancer, as these enzymes are important to cancer survival, invasion, and 
propagation, and their expression level has been correlated with increased aggressiveness 
and propensity to metastasize.
This dissertation covers the work performed to accomplish these aims, as well as 
supplemental data which further aid in the understanding of how SELPs improve 
adenoviral gene delivery, and how these materials are constructed. Chapter 2 of this 
dissertation provides a broad review of literature applicable to this body of work, 
including gene delivery, head and neck cancer etiology and treatment, MMPs, genetically 
engineered protein polymers, and previous work on SELPs for viral delivery. Parts of this
8
chapter have been published elsewhere.18 Chapters 3,29 4,30 and 5,31 discuss the 
experimental results acquired towards the completion of Specific Aims 1, 2, and 3, 
respectively, while Chapter 6 provides a conclusion and discussion of future directions 
for this project, silk-elastinlike protein polymers, and genetically engineered polymers in 
general. The Appendix discusses the results of a pilot efficacy study which was 
performed in immunocompetent mice in order to compare results with previously 
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The enhancement of gene delivery with respect to both localization and 
magnitude is a key area of research with the potential to unlock a vast quantity of 
treatments for many diseases. Even with decades of research and significant funding, 
methods of delivering genetic material which result in effective treatment of disease are 
virtually nonexistent. This lack of success in the field as a whole calls for new materials, 
methods, and strategies for the enhancement of gene delivery. The careful use of 
adenoviral vectors, evolved over eons to be efficacious gene delivery machines, is a 
possible answer to the question of clinically useful gene delivery approaches. In order to 
enhance the capabilities and safety of adenoviral vectors, they must be protected from the 
body’s natural defenses for as long as possible before they reach their target, and this goal 
can be accomplished by physically segregating them in a hydrogel. The development of 
an ideal material from which to deliver adenoviral vectors must have several 
characteristics:
1. Highly controllable physicochemical properties: The pore size, mechanical 
properties, state of matter, and interactions with the adenovirus must be tightly 
controllable.
2. High level of biocompatibility: In the context of cancer, the material must not 
enhance the progression of the disease, nor cause undesirable systemic effects due 
to its administration. Further, the material must be degradable, and the products 
resulting from that degradation must not cause unacceptable toxicity.
3. Bioresponsiveness: The ideal material will have the capability to respond to 
changes in the local environment. Enhanced delivery with progressing disease 
state and vice versa would increase the efficiency and efficacy of the treatment.
The combination of the right target and delivery system for a given application has great 
potential to be successful. A platform which allows rapid development of such systems 
would greatly enhance the research into what characteristics or properties would be 
considered to be ideal.
2.2 C ancer gene therapy
Of all currently researched clinical targets for gene therapy, cancer is by far the 
most common, comprising 1107 out of 1714 (64.6%) total gene therapy clinical trials 
worldwide in 2011.1 Gene therapy approaches are particularly attractive to cancer 
treatment for many reasons, such as the current insufficiency of very effective, reliable, 
and nonintrusive treatments, and the high prevalence of the general disease. Despite 
extensive effort in clinical research in this area, there still does not exist a single approved 
gene therapy treatment in the United States, and only two treatments have been approved
2, 3worldwide, both in China. The concerns regarding gene therapy for the treatment of 
cancer have shifted from safety to efficacy. Thousands of clinical trials have successfully 
passed Phase I, but are stalling following Phase II, as evidenced by the fact that only
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3.6% of such trials have reached Phases III or IV.1 Currently, there are a wide range of 
strategies being employed to increase the efficacy of cancer gene therapy in hopes of 
producing a clinically viable, safe, and effective treatment.
2.2.1 Cancer gene therapy strategies and approaches 
Cancer gene therapy has been attempted using a diverse selection of techniques in 
terms of treatment strategy, vector, and delivery. The main approaches for cancer gene 
therapy include use of suicide genes,4, 5 oncolytic viruses,6, 7 tumor suppressor genes,8 
antiangiogenesis targets,9, 10 and immunotherapy.11, 12 The genes of interest for these 
different approaches are packaged in a vector, which is broadly defined as a chemical or 
organism intended to enhance the ability of the therapeutic genetic material to enter the 
cell and be expressed. Vectors are broadly classified in two categories: viral vectors, in 
which viruses are genetically modified to carry specific genes of interest; and nonviral 
vectors, which cover a broad range of complexation or encapsulation methods intended to 
aid in the delivery of genes. It is now quite uncommon that “naked plasmid” be delivered 
as a stand-alone gene therapy method, as plasmid DNA is susceptible to degradation by 
nucleases and clearance in vivo, in addition to having inefficient cell entry and 
subsequent expression profiles. In addition to the aforementioned vectors, there are 
specific methods by which researchers have aimed to improve the delivery of these 
vectors, and are generally referred to as physical delivery methods.13 When combined, 
the various options of biological targets, vectors, and delivery methods offer a powerful 
and highly diverse toolbox for the design and implementation of gene therapy for the 
treatment of cancer and other diseases.
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2.2.1.1 Suicide gene therapy
Suicide gene therapy is considered to be the introduction of genetic material into a 
tumor which is intended to directly result in cell death via apoptosis. One type of suicide 
gene therapy is gene-directed enzyme-prodrug therapy (GDEPT), in which a gene is 
introduced encoding for a protein which is able to convert a prodrug into an active 
compound. An example of this type of therapy is the herpes simplex virus thymidine 
kinase (HSVtk)-ganciclovir (GCV) system, depicted in Figure 2.1.14 In this approach, 
HSVtk is produced in target cells, imparting in them the ability to convert GCV into 
ganciclovir monophosphate. GCV monophosphate is further phosphorylated into 
diphosphate and triphosphate forms by normal cellular kinases. GCV triphosphate is a 
potent cytotoxic compound which competes with deoxyguanosine triphosphate during 
DNA synthesis, resulting in cell cycle interruption and cell death.15, 16 Further, the GCV 
monophosphate has been shown to transport between cells via gap junctions, resulting in 
what is known as the “bystander effect”,4, 16, 17 as these cells still produce the toxic GCV 
triphosphate and are killed as a result, but were not transfected with the therapeutic gene. 
Another common example of suicide gene therapy is the introduction of retinoblastoma 
94 (RB94), a truncated version of a native weak tumor suppressor protein. RB94 was 
shown to potently induce G2-M cell cycle arrest by reduction in telomerase activity, 
telomere erosion, and chromosomal crisis in several in vitro and in vivo cancer models.5,
18, 19 One disadvantage of this system compared to a bystander effect GDEPT approach is 
that each cell must be successfully infected by a virus in order to be killed, which is 
extremely difficult to induce.
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Figure 2.1: Gene-directed enzyme-prodrug therapy
2.2.1.2 Oncolytic viruses
Broadly defined, oncolytic viruses selectively or preferentially transfect cancer 
cells, resulting in selective killing. Oncolytic viruses in the context of this work are those 
which destroy target cells by lytic viral replication, i.e., the tumor cells are killed by 
physical lysis due to viral replication or depletion of intracellular resources used to 
replicate the virus.20 One example of this approach is the systemic administration of
attenuated vesicular stomatitis virus (VSV), which is able to rapidly and selectively
7, 21replicate in cancer cells while not affecting noncancerous cells. The mechanism for 
this activity is that this virus is very sensitive to interferon-mediated detection and 
clearance, but certain cancer cells do not possess the ability to respond to interferon 
signaling, resulting in their death by physical rupture due to viral replication. The biggest 
advantage to this system is that, due to the specificity of its effect, it can be administered 
systemically, thereby possibly infecting metastatic tumors along with a known primary 
tumor. However, and again due to its sensitivity, it may require physiologically toxic 
titers of virus to be administered in order for an effective initial dose of virus to reach the 
tumor. Further, VSV has been shown to cause a form of encephalitis in humans, causing 
the complete attenuation of VSV to be necessary for clinical translation.22 Recent 
developments in oncolytic VSV development include increasing the efficacy of this 
treatment by adding the cancer specific suicide gene p53,6 and by increasing the blockage 
of interferon pathways in target cells.23
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2.2.1.3 Tum or suppressor genes
Tumor suppressor gene therapy is typically intended to replace the function of a 
lost or mutated regulatory pathway protein which has resulted in the development of 
cancer. The classic example of tumor suppressor gene therapy is the introduction of a 
functional p53 gene into cancers which arose from a lack thereof.24 In normally 
functioning cells, p53 serves as a quality control protein for genome mutations: it can 
activate DNA repair mechanisms by arresting the cell cycle and activating repair 
proteins, or it can induce apoptosis if the damage to the DNA is too extensive to allow 
complete repair.25, 26 Mutations in the p53 gene resulting in ineffective or nontrafficked 
forms of p53 protein allow DNA damage to go unchecked, allowing errors in cell 
replication to occur, thereby resulting in cancer. Mutations in the p53 gene are observed 
in approximately 50% of all human tumors. and delivery of p53 genes has no effect on 
off-target cells as p53 is a naturally expressed protein and it is the lack of expression of 
functional p53 which leads to tumorigenesis in these cases.
2.2.1.4 Antiangiogenesis gene therapy
The classic 1971 publication by Dr. Judah Folkman revealing tumor angiogenesis 
as a potential target for the treatment of cancer27 has led to many strategies and attempts 
to inhibit or eliminate the ability of tumors to recruit or grow new vasculature, thereby 
causing the tumor to stop growing or regress as a result of insufficient nutrients to sustain 
living cells. In general, antiangiogenic cancer gene therapy is divided into two 
approaches: the inhibition of pro-angiogenic factors, or the enhancement of anti- 
angiogenic factors.9 The most common targets in inhibition type antiangiogenic gene
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therapy are related to the vascular endothelial growth factor (VEGF) receptor and its 
related downstream intracellular machinery.10 VEGF is very commonly implicated in the 
formation of neovasculature and there have already been approved antibody-based 
treatments which target the growth factor itself (Avastin).28 A recent example of gene 
therapy for VEGF pathway knockdown has targeted VEGF itself by encoding for soluble 
VEGF receptor.29, 30 A recent example of enhancement of an antiangiogenic factor is the 
delivery of endostatin-encoding, liposome-packaged adenovirus.31 Antiangiogenic gene 
therapy approaches have unfortunately faced difficulties in the clinic for a number of 
reasons. The two most significant are the fact that angiogenesis is not regulated by a 
single pathway, i.e., complete eradication of one mechanism is not sufficient to 
completely stop angiogenesis from occurring, and that successful blockage of 
angiogenesis is typically only cytostatic. Cytostatic treatments temporarily stop the 
growth of the tumor but do not reduce its size, and may actually select for cells which can 
live in hypoxic and low nutrient environments.10 There has also been some recent results 
suggesting that antiangiogenic therapy may actually increase invasiveness of the tumor 
and the likelihood of metastasis.32
2.2.1.5 Gene-mediated im m unotherapy
The overall goal of cancer immunotherapy is to use the patient’s own immune
system to attack an established tumor, typically done by administration of
immunostimulatory factors33 or administration of the patient’s own immune cells with or
11  1 0  'i/i '2 ^
without genetic modification. ’ ’ - Many current approaches to genetically enhanced 
cancer immunotherapy are centered around modifying the patient’s own T-cells ex-vivo
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to overcome difficulties faced by traditional unmodified autologous T-cell expansion and 
re-implantation. The three main challenges as laid out by Berry et al. are : 1. Difficulties 
in isolating and expanding endogenous, specific, tumor-reactive cells, 2. Poor survival of 
isolated and expanded cells following re-implantation, and 3. The immunosuppressive 
nature of the tumor microenvironment.36 Gene therapy is used to overcome these 
challenges in several ways. Introduction of genes into T-cells encoding for specific 
receptors to attack specific tumor types has been attempted for many types of cancer,36 
and the efficacy of such approaches is greatly increased when the receptor is designed as 
a chimera with a T-cell co-stimulatory factor such as CD28.37, 38 Survival of the newly 
implanted cells can be improved by several methods, for example, inducing 
overexpression of anti-apoptotic factors such as Bcl-2.39 The immunosuppressive nature 
of the tumor environment has been addressed in a similar manner as the difficulty in 
specificity, with chimeric tumor-specific antigen receptors overcoming many of these
38issues.
2.2.2 Delivery strategies for cancer gene therapy 
The delivery and expression of genetic material in target cells has long been the 
most significant challenge in gene therapy.40-42 To overcome these significant challenges, 
researchers have employed many different methods and designs for gene delivery 
systems. The design of gene delivery systems encompasses many levels, from vectors 
which interface directly with the therapeutic genetic material, to strategies for delivering 
either vector protected or “naked” DNA, and many combinations thereof. The vector 
which is selected for a particular application has drastic effects on the efficacy and safety
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of the gene delivery system as a whole. These carriers can be divided into two basic 
classes: viral vectors and nonviral vectors. Viral vectors are generally much more 
efficient and effective at delivering gene products to the nucleus and inducing expression 
of the desired protein. However, there are safety concerns revolving around this type of 
gene delivery. On the other hand, nonviral vectors generally are safe to administer and 
most of them are not known to elicit immune response to the same extent as viral vectors, 
but they exhibit greatly reduced transfection efficiency when compared to viral vectors.
2.2.2.1 Nonviral vectors
The basic strategy behind nonviral vector design is to engineer chemically 
synthesized carriers to both mask the DNA from the body’s response, thus increasing 
circulation time and safety, and additionally to aid in the trafficking of the genetic 
material into the cell for expression.43, 44 Nonviral vectors are faced with many 
challenges, as they must have mechanisms built in to overcome the biological barriers 
associated with gene transfer while maintaining the ability to transfer the genes of interest 
such that they will be expressed. This is to be done without compromising toxicity, and in 
the case of anticancer gene therapy, the complex would ideally be specifically targeted to 
cancer cells to avoid collateral transfection and potential cell death or organ destruction. 
The basic types of nonviral vectors from a materials standpoint are polymers,45, 46 lipids,47 
polypeptides,48 and nanoparticles.43, 49
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2.2.2.1.1 Polymers for gene delivery
2.2.2.1.1.1 Poly L-lysine (PLL). Pioneering work was performed investigating 
the DNA complexation capabilities of poly L-lysine (PLL) in 1975.50 PLL condenses 
DNA, and its ability to affect the expression of complexed nucleic acids was 
demonstrated both in vitro51 and in vivo.52 PLL has been shown to exhibit relatively high 
cytotoxicity and can be unstable and aggregate depending on salt concentration. Attempts 
have been made to circumvent both of these issues with some success, and targeting of 
PLL complexes has been employed to overcome the typical nonspecific gene 
transduction associated with polymeric carriers. Recent applications of PLL for gene 
delivery involve modifications to the architecture of the polymer complexes intended to 
increase the gene delivery efficiency while reducing the cytotoxicity, for example, 
forming dendritic structures of PLL with grafted poly(ethylene glycol) (PEG). 53 These 
complexes showed significantly increased transfection efficiency while displaying 
negligible cytotoxicity in vitro.
2.2.2.1.1.2 Poly(ethylenimine) (PEI). PEI is by far the most extensively 
investigated cationic polymer for gene delivery, and the initial demonstration of PEI’s 
nucleic acid transfer capabilities was performed in 1995 by Behr et al.54 PEI is 
particularly attractive as a gene delivery agent due to its very high positive charge 
density, allowing it to complex with a large amount of DNA, and its ability to be easily 
derivatized to impart specific properties. Early studies on gene delivery with PEI revealed 
that in general, increasing molecular weight of linear PEI causes greater transfection 
efficiency and cytotoxicity,55, 56 and it has been determined that in general, the optimal 
molecular weight of PEI for gene transfer ranges from 5kDa to 25kDa,57 More recent
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developments of PEI as a gene delivery agent have been largely focused on reducing the 
toxicity in vivo, which has been shown to be significant,58 with the strong positive charge 
density of the polymer being implicated59 as well as PEI-DNA complexes’ ability to 
activate complement.60 PEGylation of PEI-DNA complexes has been employed as a 
strategy to reduce this toxicity with some success.61 However, it has been demonstrated 
that the addition of PEG reduces cellular uptake and consequently gene expression.62 The 
development of a biodegradable, acid-labile PEI was a significant breakthrough in 
improving PEI-mediated delivery and was shown to have comparable transfection 
efficiency to 25kDa PEI while demonstrating greatly reduced cytotoxicity.63
2.2.2.1.1.3 Poly(methacrylate). Polymethacrylates represent another extensively 
studied category of cationic polymers for gene delivery. The initial use of these polymers 
for gene delivery was demonstrated using poly((2-dimethylamino)ethyl methacrylate) 
(PDMAEMA) complexed with plasmid DNA.64 These initial studies on PDMAEMA 
demonstrated a strong ability to transfect COS-7 cells in vitro. However, they also 
demonstrated very strong toxicity, with an IC50 of only 30^g/ml. The reason for this 
toxicity, like that of many cationic polymer-based gene delivery systems, was likely the 
highly positive zeta potential, measured at +30mV. Further developments in the use of 
polymethacrylates for gene delivery involve copolymerization of DMAEMA with methyl 
methacrylate (MMA), ethoxytriethylene glycol methacrylate (triEGMA), or N-vinyl 
pyrrolidone (NVP).65 These results showed that in the case of copolymerization with 
MMA, the cytotoxicity was significantly increased, accompanied by a decrease in 
transfection efficiency. In the case of polymerization with triEGMA, cytotoxicity and 
transfection efficiency both decreased, and copolymerization with NVP resulted in
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decreased cytotoxicity and increased transfection efficiency.65 More recent developments 
in the use of polymethacrylates for gene delivery involve the formation of nanoparticles 
from poly(lactide-co-glycolide) and poly(methacrylate) blends, which were shown to be 
safe and efficient in in vivo delivery of plasmid DNA encoding for IL-10.66
2.2.2.1.1.4 Cyclodextrins. Cyclodextrins are polysaccharides composed of 
glucose which have been joined via a(1,4) linkages.67 The attachment of glucose in this 
way forms a cyclic polymer which forms a shape similar to a truncated hollow cone, as 
steric effects due to the distribution of hydroxyls in relation to linkage points cause the 
glucose molecules to tilt inward. These materials have been used as copolymers in either 
an embedded configuration, in which the cyclodextrin is part of the polymer backbone, or 
in a pendant configuration, in which the cyclodextrin is grafted as a side chain.67 The 
initial work performed investigating the use of cyclodextrin-containing polymers 
evaluated the embedded configuration. Specifically, a cyclodextrin derivative 6A,6D- 
dideoxy-6A,6D-di(2-aminoethanethio)-P-cyclodextrin copolymerized with
dimethylsubermidate in an AABBAABB architecture showed improved transfection 
efficiency and significantly reduced cytotoxicity compared to PEI in BHK-21 cells and 
CHO-K1 cells. Recently, more complex architectures incorporating cyclodextrins have 
been used to improve the transfection efficiency and reduce the toxicity of gene delivery. 
An example of this is the formation of PEGylated supramolecular chitosan-graft-(PEI-P- 
cyclodextrin) copolymers.68 These constructs are formed by first forming a PEI-modified 
cyclodextrin, and then grafting it to a chitosan polymer. The cytotoxicity and transfection 
efficiency of this construct has been compared to 25kDa PEI, which was shown to be
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much less cytotoxic with comparable transfection efficiencies.68 PEGylation of these 
polymers reduced their transfection efficiency.
2.2.2.1.2 Liposomal gene delivery systems
The application of liposomes as gene delivery mediators was first demonstrated in 
1982,69 and since then, much work has been performed on the improvement and 
application of these vectors for gene delivery.70-72 The lipoplexes themselves are formed 
first by producing liposomes of cationic lipids, followed by their complexation with DNA 
to be delivered. Once the complexes are endocytosed, they escape the endosome by a 
proposed “flip flop reorganization of phospholipids”,43, 73 resulting in release of the 
complexed DNA into the cytoplasm and gene expression.
2.2.2.1.2.1 N-[1-(2,3,-dioleyloxy)propyl]-N,N,N-trimethylammoniumchloride 
(DOTMA). DOTMA was one of the earliest and commonly used cationic lipids for DNA 
complexation and delivery. Results from experiments investigating its transfection 
efficiency show that it performs better than DEAE-dextran and calcium chloride 
precipitation methods. However, cytotoxicity became an issue with increasing lipid 
concentration.74 Modifications have been made to DOTMA to try to mitigate this toxicity 
while maintaining or improving its gene delivery capabilities. In one case, a hydroxyethyl 
derivative of DOTMA in a 1:1 blend with 1,2-Dioleoyl-sn-Glycero-3- 
Phosphoethanolamine (DOPE) was shown to have increased in vitro transfection 
efficiency in addition to positive in vivo results, although the studies lacked a control by 
which to normalize and compare the results to standard DOTMA or other known 
transfection reagents.75
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2.2.2.1.2.2 LipofectAMINE®. LipofectAMINE is the trade name for a cationic 
liposome gene delivery system composed of a 3:1 ratio of 2,3-dioleyloxy-N- 
[2(sperminecarboxamido)ethyl] -N,N-dimethyl-1 -propanaminium trifluoroacetate 
(DOSPA) to DOPE.76, 77 LipofectAMINE exhibits efficient gene delivery in vitro; 
however, it also exhibits significant cytotoxicity,78 as is observed with many cationic 
DNA complexes. Further, studies have investigated the in vivo utility of LipofectAMINE, 
and the results have shown that delivery is very inefficient and in many cases 
nonexistent.79 Lipofectamine has been mostly used as an in vitro tool to investigate the 
effects of transfer of particular genes for experimental purposes, as it is commercially 
available, reliable, and easy to use.80, 81 Also, due to its status as one of the first widely 
available and most familiar transfection reagents, it is commonly used as a positive 
control for transfection in studies examining the efficiency of new gene delivery
79, 82complexes.
2.2.2.1.2.3 O ther lipoplexes. Issues with gene delivery with lipid-based systems 
are mostly related to efficiency of gene transduction, cytotoxicity, and the stability of the 
gene delivery complexes.83, 84 Recent attempts to overcome these issues have included the 
addition of PEG to the surface of DNA-carrying liposomes with specific targeting 
moieties also added for increased specificity,85 and the development of more 
“biomimetic” lipids for use in liposomes, such as phospholipids.83 Other attempts at 
improving the performance of lipoplexes include the functionalization of cholesterols 
with amino acids, producing increased transfection efficiency compared to 1,2- 
Dioleoyloxy-3-(trimethylammonio)-propane (DOTAP), another common commercially 
available liposomal transfection reagent.86
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2.2.2.1.3 Peptide-based gene delivery systems
The use of lipophilic or cationic polypeptides is another method by which DNA 
has been complexed for delivery to cells. The most common polypeptide for gene 
delivery is poly(L-lysine), as discussed previously, where its main mechanism of action is 
to serve as a polycationic DNA condensing agent. Much work has been done in the area 
of biointeractive peptides which allow targeting or specific activation of peptide-DNA 
complexes in specific locations, with some constructs combining these two approaches.87 
This ability to incorporate specifically activatable or targetable motifs into nonviral gene 
delivery constructs has made peptide-based gene delivery systems an exciting and 
attractive field of research.
2.2.2.1.3.1 Self-condensing systems. The ability to utilize precise synthetic 
techniques with a broad array of available chemistries allows interesting properties to be 
designed into peptide gene delivery systems. One example of this approach is the creation 
of a polypeptide Cysn-Trp-Lysi8, where n=1-4.88 The polylysine portion of this peptide 
serves to complex with DNA, and the cysteines spontaneously form disulfide bonds, 
thereby providing interpeptide crosslinks resulting in greater stability and smaller size. 
This system was investigated in vitro and resulted in significantly increased transfection 
compared to a noncrosslinking variety of the peptide, particularly for the peptide Cys- 
Trp-Lys17-Cys. An interesting aspect of these results is that this increased transfection 
was observed with no increased amount of reporter DNA entering the cell, suggesting 
that the peptides themselves had the ability to increase the efficiency of gene transfer 
inside the cell.88 This work was later built upon by using shorter polymers containing His 
residues (Cys-His-Lys6-His-Cys) in order to facilitate endosomal escape.88
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2.2.2.1.3.2 Cell-penetrating systems. Several cell-penetrating peptides have been 
used in fusion or complexes with cationic DNA-binding peptides to form cell-penetrating 
gene delivery systems. In general, cell-penetrating peptides are predominantly composed 
of cationic amino acids, which are thought to promote binding to the cell surface and aid 
in the complexation of DNA.89 Many of these systems are derived from viruses, such as 
INF derived from influenza90, 91 and the tat peptide derived from HIV.92, 93 The INF 
peptide was first reported as a gene delivery mediator in 1992 as a fusion peptide with 
polylysine and polylysine-transferrin with positive results.91 The tat peptide derived from 
HIV has been used as a gene delivery enhancing peptide on its own and in combination 
with other vectors and showed clear transfection advantages.93 Another example of a cell- 
penetrating peptide is the KALA peptide, which was specifically designed for gene 
delivery and not derived from nature.94 The KALA peptide exhibits a random coil 
structure at low pH, and as pH is increased to physiological, it assembles into a a-helical 
structure. This a-helical structure was used to complex DNA and showed the ability to 
destabilize model liposomes of anionic and neutral charge, and mediate reporter gene 
transfer into several cell types.94
2.2.2.1.3.3 Targeted systems. The concept of specific cellular targeting has been 
applied to gene delivery in several ways. Examples of targeted gene delivery include 
using the Arg-Gly-Asp (RGD) ligand as part of a DNA-complexing fusogenic peptide 
system95 and as part of targeted polyplex systems.96, 97 RGD is a commonly used ligand 
in drug delivery which targets avp3 integrins among several others, and is generally used 
to target sites of angiogenesis, as these integrins are overexpressed on endothelial cells in 
these situations.98 Another example of a targeted peptide-based system is targetable Lys-
29
His polypeptides, which have been functionalized with fibroblast growth factor 2 (FGF- 
2)99 to target cells overexpressing fibroblast growth factor receptor, which is common 
among certain types of cancer cells.100
2.2.2.2 V iral vectors for gene delivery
Studies have found that even with advances in nonviral gene delivery systems, 
viral vectors exhibit higher transfection efficiency with virtually no cytotoxicity.101 
Additionally, studies comparing many nonviral systems have shown that all of those 
which have good transfection efficiency also are very cytotoxic.102 This trade-off in 
efficiency and toxicity is due to the high positive charge density required by nonviral 
systems to form complexes with DNA. Viral vectors take advantage of millennia of 
evolution to very efficiently transfect cells while keeping them alive, and with advances 
in genetic engineering techniques, viruses can be reprogrammed to transfect cells with 
genes of interest. Even with this distinct advantage of purpose-built machinery for 
getting foreign genetic material into cells, the application of viruses for gene therapy has 
resulted in disappointing few successes. These issues are primarily related to the efficacy 
of such treatments in vivo, which is attributed to several factors, including lack of long­
term gene expression, low level of transfection in target cell populations, and immune 
clearance by the host prior to transfection.103
2.2.2.2.1 Early problems with viral gene delivery
Viral vectors have been shown to possess very high transfection efficiency in 
vitro, and are by far the most common gene delivery vectors in worldwide clinical trials;
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nearly 75% of the 1714 gene therapy clinical trials underway as of March 2011 use one 
of many types of viral vectors to aid in gene transfer.1 While viral vector-assisted 
delivery is the most efficient and effective method for gene delivery, the safety and 
immunogenicity of these vectors are concerns. The stigma surrounding gene therapy 
treatments, particularly those employing viral vectors, is due to a combination of 
unfortunate adverse events in gene therapy clinical trials and a lack of accurate reporting 
on these events to the general and scientific public. The first event which is commonly 
referenced by opponents of viral gene delivery occurred at the University of 
Pennsylvania, where an 18-year-old patient suffering from ornithine transcarbamylase 
deficiency suffered a fatal acute systemic immune response following administration of 
adenoviral gene therapy.104 It was later revealed that the investigators committed several 
transgressions of protocol and procedure which led to this event, including the 
administration of an extremely high titer of virus on multiple occasions, and the inclusion 
of the patient in the trial in spite of the fact that several of his preprocedure biomarker 
levels should have excluded him from the study.105
Another event which caused the safety of viral vectors to be initially questioned 
occurred during a clinical trial for the retroviral treatment of X-linked Severe Combined 
Immune Deficiency (X-SCID).106, 107 Initially, results were reported in the New England 
Journal of Medicine indicating that the gene therapy successfully treated X-SCID in the 
majority of patients by employing an ex-vivo bone marrow treatment procedure.106 
However, in the months following treatment, four of nine initially treated patients 
developed leukemia due to insertional mutagenesis caused by the retroviral treatment.107 
Later, the same treatment would be used in another trial for X-SCID, in which similar
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events were observed and the cause of leukemia was determined to be the result of 
insertional mutagenesis in combination with several other genetic mutations which were 
required to develop the secondary disease.108 The reasoning behind performing the 
second trial is unclear. However, the motivation could possibly have been that the 
specific form of leukemia which developed in the initial trial, T-cell acute lymphoblastic 
leukemia (T-ALL) has a cure rate of 80%. X-SCID renders the patient defenseless against 
all infection, and requires isolation from the external environment as protection from 
potential infection if bone marrow transplantation is not successful.
The 2007 passing of a patient undergoing adeno-associated virus (AAV)- 
mediated treatment for rheumatoid arthritis109 is another event which is commonly and 
incorrectly referenced as a viral gene therapy adverse event. The patient had received two 
intra-articular injections of AAV encoding for a TNF-a antagonist, which are commonly 
given as injections of the purified antagonist (i.e., etanercept). In the weeks following the 
second injection, the patient experienced several systemic symptoms and passed away 3 
weeks following the second administration. After extensive investigation into the cause 
of death in this trial, it was determined that disseminated histoplasmosis, a fungal 
infection, was responsible for the fatality.109 While it is uncommon that this type of 
infection is fatal, the patient had been on immunosuppressive therapy for several years 
leading up to her death, and it was determined that this allowed the infection to grow to 
unmanageable size, resulting in “bleeding complications and multiple organ failure”.109 
The misrepresentation of these results as having emanated from the use of viruses to 
deliver gene therapy has led to misperceptions for viral gene delivery. However, the 
actual pathogenesis in these cases was not caused by the vectors themselves.
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2.2.2.2.2 Adenoviral vectors
The most common viral vector currently in gene therapy clinical trials is 
adenovirus, comprising 24.2% of all gene therapy clinical trials as of March 2011.1 
Structurally, adenoviruses are nonenveloped, with capsids composed of 240 hexon bases 
and 12 penton bases, and a dsDNA carrying capacity of 36-40kb.110 Attached to each 
penton base there is a fiber protein, the knob domain of which interacts with the 
Coxsackievirus and Adenovirus Receptor (CAR). Additionally, there is a specialized 
motif in the penton base which interacts with integrin as a coreceptor, most commonly 
avp3.m  The virus is endocytosed via clathrin-coated pits, stimulated by the integrin 
binding event. Following endocytosis, the decreasing pH of the endosome causes 
dissociation of fiber proteins from the surface of the virus, thus exposing the penton 
bases. The penton bases facilitate endosomal escape via a conformational change 
resulting in an increased exposure of hydrophobic residues,112 thus allowing escape of the 
virus from the endosome. Endosomal escape of the virus is followed by trafficking of the 
viral genome via traversing microtubules and entry into the nucleus via nuclear pores, 
allowing gene expression.110 Due to the episomal nature of the genetic material following 
nuclear transport, the gene expression of adenovirus is transient, and is typically gone 
after 1-2 weeks following initial infection.
There are many important considerations in the delivery of adenovirus-mediated 
gene therapy, possibly the most important of which is that there is a high prevalence of 
immunity to adenoviruses in the human population.110, 113 This causes systemically 
delivered adenoviruses to be rapidly cleared or in some cases can cause a severe immune 
response, both of which are detrimental to the efficacy of the treatment and the latter of
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which can be extremely dangerous to the patient’s health. Another limitation to the use 
of adenoviruses in gene delivery is that adenoviruses infect nonspecifically; any cell 
expressing Coxsackievirus and Adenovirus Receptor (CAR) on its surface can potentially 
be infected by the virus and thus subject to its therapeutic effect, whatever it may be. 
Additionally, there are significant differences in CAR receptor density among the tissues 
of the body, and even among cancers of the same tissue type.114 This complicates the 
determination of the necessary dose for therapeutic effect, along with potentially causing 
unforeseen consequences in nontarget tissues if they happen to express a high density of 
CAR receptors.
The most significant advances in cancer gene therapy have been made with 
adenoviral vectors, with the only two approvals worldwide being for adenovirus-
2, 3mediated cancer gene therapy in China. These two approved treatments both work with 
the p53 tumor suppressor gene, which was discussed previously.
2.2.2.2.3 Retroviral vectors
Retroviral vectors, including lentiviruses, are the next most common vector for 
gene therapy clinical trials as of March 2011, representing 23% of trials.1 Retroviruses 
are distinctly different from adenoviruses in that they integrate their own genome into 
that of the host cell, resulting in permanent expression of the viral genes. Retroviruses are 
enveloped viruses, meaning that the capsid is contained within a lipid vesicle which is 
obtained from the host during budding/cellular exit. The retroviral genome is 7-10kb 
single-stranded RNA, with two identical copies per virus particle. Retroviral vectors have 
been used to deliver the HSV-tk gene for the treatment of malignant brain tumors.115
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However, the efficacy results were disappointing, with only five of fifteen patients 
responding, and the responders having small average tumor size when compared to the 
rest of the group. Further work examined the retroviral administration of a hepatoma- 
specific version of thymidine kinase, and was demonstrated in vitro to specifically 
sensitize hepatoma cell lines to a prodrug.116 Retroviruses were also used in the X-SCID 
clinical trial conducted in France, which as previously discussed cured the patients of X- 
SCID but caused a type of curable leukemia in a significant percentage of patients.106, 107
2.2.2.2.4 Adeno-associated virus vectors
Adeno-associated viruses, or AAVs, represent another heavily researched type of 
viral vector. AAVs are physically much smaller than most other viruses, with the virion 
having a typical diameter of 25 nm, and a single-stranded DNA genome of only 4.7 kb.117 
AAVs are also unique in that they are a helper-dependent virus, meaning that in order to 
effectively reproduce and infect a tissue, there must be a residing adenovirus or herpes 
simplex virus infection.117 One major advantage to AAVs as gene delivery vectors is that 
in spite of high incidences of pre-existing immunity to many AAV serotypes,118 cytotoxic 
T-cell responses to AAVs are not common following administration.110 Early work on 
AAVs as gene delivery vectors showed high levels of prolonged gene expression in 
muscle tissue, with no humoral immune response to the reporter protein being expressed 
and only a low-level humoral response to the vector itself, allowing re-administration.119 
A recent example of gene therapy using AAV is the long-term expression of 
neuropeptide Y via AAV-mediated gene therapy.120 This treatment has been shown to 
effectively knock down kianic acid-induced epileptic seizures in rats which have had a
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viral administration to the hippocampus, and the long duration of gene expression of 
AAVs allows this effect to continue over long periods of time.120 Another interesting 
application of AAVs in gene delivery is ocular delivery of AAVs for the treatment of 
congenital childhood blinding disorders.121
2.2.2.2.5 Other viral vectors
There are many other classes of viral vectors being researched for gene delivery 
applications, including vaccinia virus, poxvirus, and herpes simplex virus.1 These vectors 
have been used for very diverse applications and combined, make up almost 17% of gene 
therapy clinical trials.1 Vaccinia virus in particular has gained a lot of recent attention as 
an oncolytic viral vector, with several clinical trials underway, including a recombinant 
vaccinia virus encoding for GM-CSF.122 Exciting efficacy data were gathered from 
several Phase I and Phase II trials, with response rates up to 75% observed particularly in 
melanoma,122 and a large Phase II study of this treatment for first-line treatment of 
refractory hepatocellular carcinoma is currently recruiting.123
2.2.2.3 Delivery of vectors and naked DNA
There is a diverse selection of tools available for the delivery and expression of 
genetic material in cells and tissues. These range from directly mechanical methods 
which physically force new genetic material into target cells, biological approaches 
which employ microorganisms or cellular receptors to deliver gene products into cells, 
and chemical methods designed to mask or target the gene products from the body’s 
defenses. In addition to these types of systems, there are numerous cross-over or hybrid
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methods using two or more of these basic types of approaches to generate a more 
efficacious gene delivery device.
2.2.2.3.1 Physical methods
2.2.2.3.1.1 Gene gun. Developed in the 1980s, the gene gun represents an 
example of using direct mechanical force to introduce foreign gene products into a 
population of target cells.124 The earliest designs of the gene gun employed 1-4^m 
tungsten pellets coated with the DNA of interest, which were loaded into an air pistol and 
projected at a colony of cells in a petri dish. Following designs used a .22 caliber charge 
to shoot quite literally a bullet, with the microparticles deposited on the end of the bullet 
and thus launched with high velocity at the target.125, 126 The bullet would be stopped by 
a disk of Lexan placed at the end of the barrel, and the particles would be projected 
towards the cells of interest at 1000-2000 feet per second. Since that initial design, the 
gene gun has evolved into a more refined tool, however still based on the forcible 
projection of heavy metal particles coated with plasmid DNA into target cells. Current 
versions of the gene gun are distributed by Biorad and use a helium pulse to project gold 
microparticles coated with genetic material.127, 128
The gene gun has shown good efficacy in transfecting plant cells 129 and has been 
a very common method for this purpose since the 1990s.130-134 Predictably, however, the 
gene gun’s hopes for use as a therapeutic delivery device in animals are jeopardized by 
the tendency of a certain population of cells within the target area to be immediately 
destroyed by the impact of the metallic particles, and the limited depth to which the DNA
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will be delivered by the gun. It is, however, useful for research purposes when applied to 
animals as it provides rapid and localized gene expression.135, 136
2.2.2.3.1.2 Electroporation. Electroporation for gene transfer, first reported in 
1982 by Neumann, et al.,137 uses pulsed electric fields to temporarily and nonlethally 
disrupt the membranes of cells to allow the passage of materials into the interior of the 
cells. This method works on the principle that, by charging a cell to the point where its 
capacitance is exceeded, the cell membrane will open pores and thereby allow the 
electrophoretic delivery of DNA, which will move in a predictable manner in the electric 
field. The extent, duration, and location of the permeabilization can be controlled 
precisely by changing the orientation and amplitude of the electrical current, and by using 
a pulsed electric field as opposed to a constant one.138 One example of this type of control 
is that small structures, i.e., organelles, require higher amplitudes of electrical field to 
cause permeabilizaiton. Unfortunately, the levels of applied electric field required to 
electroporate organelles would cause damaging or lethal levels of poration to occur in the 
cell membrane. This problem was solved using nanosecond pulses of amplitude sufficient 
to open the membranes of the organelles, but due to the considerably higher charging 
time required to open the cell membrane than the organelles, the nanosecond pulses do 
not disrupt the cell as a whole.139
Electroporation is a highly efficient method of delivering material into cells, 
particularly DNA, as it moves in electric field and therefore can be delivered much more 
rapidly than materials requiring diffusion to enter the cells. This short time required to 
deliver the genes of interest reduces the risk of damage to the cells by the applied electric
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field. Current and historical clinical progress in the use of electroporation to aid in the 
delivery of tumor chemotherapy is reviewed extensively elsewhere.140
2.2.2.3.1.3 H ydrostatic pressure-driven gene delivery. Another physical 
method used to assist in the delivery of gene therapy is to simply cause an increase in the 
local hydrostatic pressure in the area of interest, which essentially forces small molecules 
into cells and the interstitium. There are several methods by which this increase in 
hydrostatic pressure has been achieved, including the delivery of an extremely large 
volume dose of pDNA (approximately equal to blood volume) by tail vein injection in 
mice,141 and the clamping of blood vessels to cause the necessary increase in pressure to 
increase transfection.142 There are obvious limitations to this method’s utility in humans, 
particularly the large-dose method, as an increase in blood volume of that magnitude 
would likely cause rupture of any number of blood vessels throughout the body, in 
addition to heavily straining the kidneys.
2.2.2.3.2 Depot release methods
In order to minimize potentially harmful effects and to make gene delivery a more 
viable clinical option, there has been a large quantity of research into how to make the 
administration of viral and nonviral vectors safer and more effective. Each of these 
approaches has specific advantages and limitations, and for each individual application, 
there is likely one approach which will produce the best results. The main advantage to 
these methods is that, with proper design considerations, these materials can very 
precisely control the release of a wide range of materials to a highly localized area with 
minimal escape of the therapeutic agent, and thus a reduced chance of treatment-
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associated side effects. This makes these methods an attractive option for situations in 
which highly localized delivery is desired, such as the treatment of solid tumors or single­
organ diseases.
2.2.2.3.2.1 M atrix-m ediated gene delivery. Matrix-mediated gene delivery 
(MMGD) is the use of a depot which interacts directly with the gene carrier, be it a virus, 
polyplex, liposome, etc., with the goal of control over spatial and temporal gene delivery. 
A general schematic of various approaches to MMGD is shown in Figure 2.2. The most 
common approaches for this purpose are to either tether the carriers to a material for 
localized expression,143-146 complex the carriers with a secondary material,147-149 or place 
the carrier in a matrix to control spatial and temporal release.150-157 Materials designed 
for matrix-mediated gene delivery are most commonly either entirely synthetic or natural 
polymers which have been modified in some way to interact with the pDNA complex or 
viral vector being delivered. One example of this approach is the use of poly(amido 
amine) (PAMAM) dendrimers complexed with DNA, delivered from a collagen scaffold, 
for in vitro transfection.158 Other materials which have been used include collagen 
modified with avidin,145 polylysine-biotin and poly(ethylenimine)-biotin complexes,159 
hyaluronic acid-collagen hydrogels,160 and functionally terminated self-assembled 
monolayers.144 Antivirus antibodies are also commonly used to tether viral vector 
particles to biomaterial surfaces for enhanced control of gene expression.143, 146
2.2.2.3.2.2 Polymers for m atrix-m ediated gene delivery. Far more common and 
widely used are the polymeric gene delivery scaffolds, which usually employ simple 
diffusion sometimes in combination with enzymatic degradation to release either naked 
DNA, viral vectors, or nonviral complexes with nucleic acids. Natural polymers are
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Figure 2.2: Types of matrix-mediated viral gene delivery
widely used in this type of application, as they tend to limit the immune response to the 
material in vivo. One common natural material is collagen that has been used for delivery 
of viral vectors,153, 161 naked plasmid,162-166 and nonviral vectors.167 Modifications of 
collagen are also used for delivery of various vectors and plasmid DNA.168-170 Fibrin is 
also used for matrix-mediated gene delivery150, 152, 171, 172 and is especially useful for 
wound healing applications as it is a natural component of the clotting cascade in addition 
to having a pore structure conducive to controlled-release.
Several different synthetic polymers are also used for polymeric gene delivery. 
One example is PLGA microspheres151, 173 designed as a potential delivery system for the 
treatment of brain tumors. By encapsulating the adenoviral vectors in PLGA, the viral 
vector was less recognizable by the local immune cells, thus allowing for more than one 
administration of the treatment and greater efficiency. PLGA has also been used as a 
stationary depot for plasmid DNA release.174 Another example of synthetic polymers in 
polymeric gene delivery is a thermosensitive triblock copolymer of PEG-PLGA-PEG175, 
176 which was used to deliver a TGF-P1 encoding gene directly to a wound site. 
Photocrosslinked PEG hydrogels have also been used to encapsulate and release DNA in 
a controlled manner,156, 177 as have PLGA scaffolds.178
Polymeric delivery systems possess the ability to relatively easily control release 
of gene products because there are a limited number of factors influencing release from 
this type of material. The types of materials used to make these matrices are not limited 
to only those which DNA or vectors can be attached to, widening the range of matrices 
which can be designed. This reduces the risk of unforeseen interactions and side effects 
and increases the chances of an effective treatment. Polymeric delivery systems can also
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be designed to be mechanically and environmentally sensitive, enabling a release trigger 
to be incorporated which is independent of chemical reaction or enzyme activity and their 
associated design constraints. By simplifying the design in this way, release can be 
controlled tightly via many parameters, for example degradation, temperature-dependent 
self-assembly/disassembly, and porosity among many other possibilities, without the 
need for specific biological conditions to be present.
2.3 H ead and neck squamous cell carcinom a: Disease and 
implications of m atrix-m etalloproteases (M M Ps)
2.3.1 Introduction
Head and neck cancer is described as any epithelial cancer which occurs in the 
sinuses, nose, mouth, pharynx, or larynx, most of which are head and neck squamous cell 
carcinomas (HNSCCs).179 There are an estimated 350,000 new cases of HNSCC 
(including laryngeal cancer) diagnosed worldwide, comprising about 3% of all new 
cancer cases.180 In the United States, it is estimated to be the sixth most common new 
cancer diagnosis in 2011 with 52,140 new cases, and resulting in 11,460 deaths.181 The 
primary risk factors for HNSCC are alcohol and tobacco consumption,182-185 which have 
a multiplicative combined effect, in addition to family history186, 187 and environmental 
factors. A relatively recently discovered and significant risk factor for HNSCC has been 
identified as human papilloma virus (HPV) infection, specifically with HPV type 16,188­
190 the same HPV type which is commonly implicated in cervical cancer191-193 and the 
vaccine for which is considered a great success and is now commonly administered.191, 
194, 195 While the incidence and fatality rates of HNSCC are not as significant as more
common cancers, HNSCC presents a challenging problem for clinicians, with many 
factors to consider before a treatment is decided upon. Much of this complication is due 
to the site of the disease, as the clinician must consider factors beyond just the 
elimination of the cancer, including preservation of the patient’s ability to swallow, 
breathe, and speak normally. Further, the location of these cancers is a socially sensitive 
area: it has been shown that permanent scarring or disfigurement to a patient’s face 
significantly increases their risk for depression and anxiety disorders.196
2.3.2 Current treatment options for HNSCC
2.3.2.1 Surgery
Cases of HNSCC in which the tumor is considered resectable are most commonly 
treated surgically. The resectability of a tumor is determined by the surgeon performing 
the procedure. However, in general, a tumor is considered unresectable if it involves 
invasion of the carotid artery, the base of the skull, or the prevertebral musculature.179 
While surgery is the current standard of care, it is common for some tumors which would 
normally be considered resectable to be treated with other approaches if they involve an 
organ which is particularly sensitive to surgical intervention. Examples of this would be 
disease significantly involving the larynx (voice loss) or pharynx (swallowing loss).197
2.3.2.2 Radiation therapy
Radiation therapy is a very common postsurgical adjuvant treatment option as 
well as a primary treatment option in patients in which surgery is not possible or not the 
best option due to side effects and organ preservation concerns.179 Standard radiotherapy
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techniques for the management of HNSCC involve once daily dosing in a 5 day on, 2 day 
off arrangement. However, research and meta-analysis has shown that there is significant 
benefit to altered fractionation approaches, which are given 7 days per week either once 
daily in the normal daily dose or twice daily in half-doses179, 197-199 with the general trend 
being that administering more frequently results in greater management and survival 
outcomes. It is likely that this is due to recovery of the cancer cells during the rest 
periods, allowing establishment of greater populations of cells which are less sensitive to 
the radiotherapy. Another improved form of radiotherapy is called intensity modulated 
radiation therapy (IMRT), and is essentially a more focused and localized approach to 
radiotherapy which involves image-guided administration of radiation to improve 
efficacy and reduce damage to surrounding tissue structures.179, 197
2.3.2.3 Chem oradiotherapy
The combination of chemotherapy and radiation therapy has proven to be an 
effective treatment modality for HNSCC patients, and concomitant chemoradiotherapy 
has emerged as the most preferred treatment in patients with unresectable tumors. 
Concomitant chemo and radiation therapy exhibits significant survival and localized 
control benefit over radiotherapy alone, chemotherapy alone, or induction chemotherapy, 
in which chemo is administered prior to radiation.179, 200-202 Cisplatin and derivatives are 
the most common chemotherapeutic agents to be delivered with radiotherapy, and have 
been successfully used in combination with radiotherapy for other types of cancer.203-205
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2.3.2.4 O ther approaches
In addition to traditional treatment approaches for HNSCC such as surgery, 
radiotherapy, chemotherapy, and combinations thereof, there has been significant 
research into advanced therapies which specifically target the tumor. One common target 
for HNSCC is the epithelial growth factor receptor, which has been shown to be 
overexpressed in many cases of HNSCC. ’ Examples of drugs which have been 
developed to target EGFR are Cetuximab, Gefitinib, Erlotinib, and Lapatinib.197 Another 
notable advance in the management of HNSCC was the approval of two adenovirus- 
mediated therapies for HNSCC, both of which target the p53 gene and were discussed
2, 3previously.
2.3.3 MMPs and their role in HNSCC
2.3.3.1 Overview of MMPs
Matrix metalloproteases, or MMPs, are a family of structurally related 
endopeptidases, which exist in a dynamic balance with tissue inhibitors of 
metalloproteases (TIMPs) to control myriad biological functions requiring ECM 
degradation. Proper function and regulation of MMPs is responsible for diverse 
biological functions such as angiogenesis, embryonic development, and wound healing. 
The major structural features of MMPs include the signal domain, the propeptide, the 
catalytic domain, and the hemopexin domain. The propeptide domain is characterized by 
the highly conserved “cysteine switch” motif, PRCGXPD, which is responsible for the 
suppression of the activity of the MMP proenzyme, while the catalytic domain has a 
characteristic HEXGHXXGXXH motif, which binds a Zn2+ ion and serves as the active
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site for protein cleavage. 208, 209 There are over 20 known specific MMPs, divided into 
subgroups based on their additional domains and known biological functions. The main 
classes of MMPs are collagenases, gelatinases, stromelysins, matrilysins, membrane-type 
MMPs, and other unclassified MMPs.210 Table 2.1 shows a summary of the known 
functions of MMPs of each type.210 Collagenases (MMP-1, -8, -13, and -18) are generally 
known to cleave interstitial collagen types I, II, and III, and structurally are composed of 
the four basic domains: signal, propeptide, catalytic, and hemopexin, with no further 
modifications. The gelatinases, MMP-2 and MMP-9, are unique from other MMPs in that 
they have three fibronectin type II repeats in their catalytic domain structure which 
mediate binding to various ECM proteins including gelatin, collagen, and laminin.208, 210 
MMPs -2 and -9 are important for various normal biological functions, but are also 
commonly implicated in the escape and formation of metastases in many tumor types, 
including HNSCC.202, 208, 211 Stromelysins, the third class of MMPs, have similar 
structures to the collagenases and perform standard ECM-degradative processes, but are 
additionally involved in the activation of the proenzymes for other MMPs.208, 210 The 
stromelysins are composed of MMPs -3, -10, and -11. The matrilysins are a unique group 
of MMPs (MMP-7 and MMP-26) which lack the hemopexin domain. MMP-7 digests a 
variety of ECM molecules. However, it is also responsible for interaction and activation 
of several cell-surface proteins.208, 210 MMP-26 is expressed at the highest levels in 
endometrial tissue with particularly high expression in endometrial cancer and other 
epithelial cancer cell lines. However, its exact function has yet to be elucidated.208, 212 The 
membrane-type MMPs are further subclassified based on their attachment to the cell 
surface, with four being transmembrane proteins (MMP-14, -15, -16, and -24), and two
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Known human MMPs and their biological substrates210
Table 2.1










MMP-1 Collagens (type I, II, III, VII, VIII, X, and
XI), gelatin, fibronectin, vitronectin,
laminin, entactin, tenascin, aggrecan, link
protein, myelin basic protein, versican 
MMP-8 Collagens (type I, II, and III), aggrecan
MMP-13 Collagens (type I, II, III, IV, VI, IX, X, and 
XIV), collagen telopeptides, gelatin, 
fibronectin, SPARC, aggrecan, perlecan, 
large tenascin-C 
MMP-2 Collagens (type I, II, III, IV, V, VII, X, and 
XI), gelatin, elastin, fibronectin, vitronectin, 
laminin, entactin, tenascin, SPARC, 
aggrecan, link protein, galectin-3, versican, 
decorin, myelin basic protein
MMP-9 Collagens (type IV, V, XI, and XIV), 
gelatin, elastin, vitronectin, laminin, 
SPARC, aggrecan, link protein, galectin-, 
versican, decorin, myelin basic protein
Autolytic, C lq, a2-Macroglobulin, ovostatin, al-PI, a l-  
antichymotrypsin, ILl-p, proTNFa, IGFBP-2, IGFBP-3, 
casein, serum amyloid A, proMMP-1, proMMP-2, 
proMMP-9
Autolytic, C lq, a2-Macroglobulin, ovostatin, al-PI, 
substance P, fibrinogen, angiotensin I, angiotensin II, 
bradykinin, plasmin Cl-inhibitor 
Autolytic, C lq, a2-Macroglobulin, casein, fibrinogen, 
factor XII, al-antichymotrypsin, proMMP-9
Autolytic, al-PI, a2-Macroglobulin, al-antichymotrypsin, 
ILl-p, proTNFa, IGFBP-3, IGFBP-5, substance P, serum 
amyloid A, proMMP-1, proMMP-2, proMMP-9, 
proMMP-13, latent TGFp, MCP-3 (monocyte 
chemoattractant protein-3), FGFR1 (fibroblast growth 
factor receptor 1), big endothelin-1, plasminogen 
Autolytic, a2-Macroglobulin, ovostatin, al-PI, ILl-p, 
proTNFa, substance P, casein, carboxymethylated 
transferrin, angiotensin I, angiotensin II, plasminogen, 
proTGFp29, IL-2Ral3, release of VEGF -p-
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Collagens (type III, IV, V, VII, IX, X, and 
XI), collagen telopeptides, gelatin, elastin, 
fibronectin, vitronectin, laminin, entactin, 
tenascin, SPARC, aggrecan, link protein, 
decorin, myelin basic protein, perlecan, 
versican, fibulin
MMP-10 Collagens (type III, IV, and V), gelatin,
elastin, fibronectin, aggrecan, link protein,
MMP-11 gelatin, fibronectin, collagen type IV, 
laminin
MMP-7 Collagens (type I, and IV), gelatin, elastin, 
fibronectin, vitronectin, laminin, entactin, 
tenascin, SPARC, aggrecan, link protein, 
decorin, myelin basic protein, fibulin, 
versican,
MMP-26 Collagen type IV ±, gelatin, 
fibronectin, vitronectin
MMP-14 Collagens (type I, II, and III), gelatin,
fibronectin, tenascin, vitronectin, laminin, 
entactin, aggrecan, perlecan
Autolytic, a  2-Macroglobulin, ovostatin, a l-  
PI, a2antiplasmin, al-antichymotrypsin, ILl-p, 
proTNFa, IGFBP-3, substance P, T-kininogen, casein, 
carboxymethylated transferrin, antithrombin-III, serum 
amyloid A, fibrinogen, plasminogen, osteopontin, 
proMMP-1, proMMP-3, proMMP-7, proMMP-8, 
proMMP-9, proMMP-13, IGFBP-3, E-cadherin, 
pro-HB-EGF, u-PA, fibrin, PAI-1 
Autolytic, casein, proMMP-1, proMMP-7, proMMP- 
8, proMMP-9
al-PI, a2-Macroglobulin, ovostatin, IGBFP-1, casein,
a2-antiplasmin, plasminogen activator inhibitor-2, casein,
carboxymethylated-transferrin
Autolytic, al-PI, a2-Macroglobulin, proTNFa, casein,
carboxymethylated transferrin, osteopontinl8,
proMMP-1, proMMP-2, pro-MMP-7 proMMP-9,
plasminogen,
al-PI, a2-Macroglobulin, fibrinogen, proMMP-9
a 2-Macroglobulin, ovostatin, a  1-PI, proTNF-a 
fibrinogen, factor XI, fibrin, CD44, tissue 
transglutaminase, proMMP-2, proMMP-13
Table 2.1 (Continued)
Enzyme MMP ECM Substrates Other Substrates
MT2-MMP MMP-15 Fibronectin, tenascin, entactin, laminin, 
aggrecan, perlecan
ProTNFa, tissue transglutaminase, proMMP-2
MT3-MMP MMP-16 Collagen type III, gelatin, fibronectin, 
vitronectin, laminin
al-PI, a2-Macroglobulin, casein, proMMP-2, 
tissue transglutaminase
MT5-MMP MMP-24 Fibronectin, gelatin, chondroitin sulphate 
proteoglycan, dermatan sulphate 
proteoglycan
ProMMP-2, tissue transglutaminase
MT4-MMP MMP-17 gelatin Fibrinogen, fibrin, proTNFa, proMMP-2 ±
MT6-MMP MMP-25 Collagen type IV, gelatin, fibronectin, 
chondroitin sulphate proteoglycan, dermatan 
sulphate proteoglycan
Fibrinogen, fibrin, al-PI, proMMP-2
i
Macrophage MMP-12 Collagens (type I, V, and IV), gelatin, a2-Macroglobulin, al-PI, proTNFa, fibrinogen, factor XI,
Elastase elastin, fibronectin, vitronectin, laminin, 
entactin, osteonectin46, aggrecan, myelin 
basic protein
casein, plasminogen
MMP-19 Collagen type IV, gelatin, laminin, entactin, Autolysis, fibrinogen, fibrin 
lg tenascin-C, fibronectin, aggrecan, COMP
Enamelysin MMP-20 Amelogenin, aggrecan, COMP Autolysis
CA-MMP MMP-23 gelatin Autolysis, casein
Epilysin MMP-28 Casein
being attached via glycosylphosphatidylinositol (GPI) (MMPs -17 and -25).210 All 
membrane-type MMPs except MMP-17 can activate pro-MMP2, and all membrane type 
MMPs can act on ECM proteins. Structurally, the membrane-type MMPs differ from the 
other soluble MMP groups due to their transmembrane domain or GPI anchor domains, 
but still have the highly conserved catalytic site, propeptide, and hemopexin region.208, 210
2.3.3.2 MMP-2 and MMP-9: Function in cancer
MMPs -2 and -9 are known as gelatinase type A and B, respectively, due to their 
known ability to degrade gelatin (denatured collagen). MMP-2 is also known as 72-kDa 
type IV collagenase, and MMP-9 as 92-kDa type IV collagenase, due to their expression 
as 72-kDa and 92-kDa pro-enzymes, respectively. Structurally, MMPs -2 and -9 are 
composed of the standard conserved MMP-domains: signal, propeptide, catalytic domain, 
and hemopexin domain, but differ from other MMPs in that their catalytic domains 
contain three repeats of the fibronectin type II domain, which is implicated in collagen
binding.213
Activation of proMMP-2 can occur by several different mechanisms, but most 
commonly, proMMP-2 is activated by other surface bound MMPs.210 MT1-MMP, also 
known as MMP-14, is often implicated in the activation of proMMP-2 via a well-studied 
and characterized mechanism requiring the binding of TIMP-2 to proMMP-2, followed 
by the activation of proMMP-2 by MMP-14 which has not bound TIMP-2.214 
Interestingly, it has also been shown that if MMP-14 is bound to TIMP-2, this complex 
can bind proMMP-2 which is subsequently activated by a nearby MMP-14 which has not 
bound TIMP-2.215 The functional activation of MMP-2 by MMP-14 is important to the
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role of MMP-14 in cancer and has led to research investigating the inhibition of MMP-14 
as a potential therapeutic approach.202 ProMMP-9 has been shown to be activated by 
MMP-3216 or by bacterial proteases.217 Interestingly, proMMP-9 can also be activated by 
active MMP-2, and this activation is inhibited by TIMP-1 and TIMP-2.218
In normal situations, MMPs -2 and -9 contribute to many processes involving cell 
migration and signaling, for example, angiogenesis219, 220 and inflammation/innate 
immunity.221, 222 In the context of cancer, the role of MMP-2 and MMP-9 are primarily 
implicated in angiogenesis, with many of the in vitro studies suggesting a link between 
MMP-2, MMP-9, and cellular invasion not holding up in vivo.223 MMP-9 contributes to 
cancer angiogenesis by liberation of VEGF from the extracellular matrix,224 and by 
processing of the VEGF-A isoform, removing the domains responsible for ECM 
association and therefore increasing bioavailability.225 Further, MMP-9 has been shown 
to be involved in the maturation of neovasculature by a mechanism related to pericyte 
recruitment.226 MMP-9 is also involved in the liberation of hematopoietic cells from the 
stem cell niche and incorporation of these bone marrow derived cells into the tumor 
vasculature.227, 228 MMP-2 has been shown to have a strong effect on angiogenesis by its 
interaction with intratumoral avp3 integrin, enabling endothelial cell migration.229 This 
effect has been further shown in a study which specifically disrupted the avp3-MMP-2 
interaction, in which angiogenesis was significantly diminished.230 Overall, studies which 
genetically or chemically inhibit the activities of MMP-2 and MMP-9 show significantly 
reduced angiogenesis, highlighting their importance in this vital cancer development 
process.
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These results are additionally supported by the work of Stokes et al., who 
carefully and extensively mapped MMP-2 and MMP-9 levels, along with all other known 
MMPs and many other proteases, in excised HNSCC tissue and subsequently correlated 
these findings with disease state.231 Specifically, MMP expression levels for inside the 
tumor, at the tumor margin, and in adjacent healthy tissues were compared, with 
expression levels in healthy nonadjacent tissues serving as a control. This study revealed 
many important findings: 1) both MMP-2 and MMP-9 are significantly overexpressed in 
and around primary HNSCC tumors compared to normal healthy tissues; 2) MMP-3 (an 
activator of MMP-9), MMP-14 (an activator of MMP-2), and TIMP-2 (a necessary 
cofactor for MMP-14-mediated activation of proMMP-2) were additionally found at high 
levels in and around tumors; 3) MMP-2 mRNA levels decreased with increasing tumor 
grade; and 4) MMP-9 levels decreased significantly in the primary tumor with the 
appearance of lymph node metastasis.231 There are several important conclusions which 
can be drawn from these findings. First of all, the increased presence of MMP-2 and 
MMP-9 in primary tumors justifies the use of these proteases as activating enzymes for a 
therapeutic treatment. The increase in MMP-3, MMP-14, and TIMP-2 levels further 
supports this strategy, as this increases the likelihood of proMMP-9 and proMMP-2 
activation. The decrease in MMP-2 and MMP-9 expression as the tumor progresses does 
diminish their utility as an activator for treatment of advancing disease; however, the 
expression levels do not return to normal as long as the tumor is present.
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2.4 Genetically engineered protein polymers: Overview
2.4.1 Introduction
Genetically engineered polymers are materials which are encoded by DNA, 
synthesized in living microorganisms or cells, and are composed of block repeats. 
Original descriptions of genetically engineered polymers were first published in 1990.232, 
233 Since these initial works, several researchers have explored the benefits of 
programming microorganisms to produce polymers.234-237 The most significant benefit to 
this method is the high degree of control over the polymer sequence, block arrangement, 
and length which are determined by the DNA sequence. With further advances in the area 
of noncanonical amino acids, it has become possible to genetically synthesize polymers 
with functional groups not found on natural amino acids, opening the field up to creating 
materials which were never before possible.238 Further, upon completion of the DNA 
encoding for the desired material, it can be produced at any scale starting with a single 
clone of the original DNA. Advances in purification and bioprocessing procedures have 
streamlined the production of these materials. With the promise of this field of research, 
novel approaches of delivering bioactive agents employing genetically engineered 
polymers are emerging and have been reviewed extensively.48, 234’ 235, 239-245
2.4.2 Cloning and synthetic strategies for genetically engineered polymers
Broadly, the creation of the necessary genetic material to produce a genetically 
engineered protein-based polymer requires the following progression: The creation of a 
monomer gene, encoding for a single repeat of the desired material, followed by the 
“polymerization” of this monomer gene to produce a large piece of DNA encoding for
the entire polymer. Depending on the synthetic strategy, the polymerization occurs in an 
expression vector,232 or the “polymer gene” is digested out of a cloning vector and ligated 
into an expression vector,246 which is transformed into a production organism and grown 
to high density. Protein production is induced during this growth. Purification of the 
newly synthesized protein can occur by various methods, but commonly by affinity 
chromatography or specific phase transitioning at a small laboratory scale. The culture 
expansion and protein purification procedures are usually system-specific, but the 
polymer gene synthesis is done by one of three methods: random concatamerization,232 
recursive directional ligation,246 or overlap extension rolling circle amplification 
(OERCA).247
2.4.2.1 Random  concatam erization
The synthesis of polymer genes by random concatamerization is the earliest 
synthesis method reported,248 and is outlined in Figure 2.3. The design of a synthetic 
strategy for this type of approach involves the insertion of complimentary, 
nonpalindromic restriction sites at each end of the desired monomer, typically designed 
into the original oligonucleotide synthesis. This monomer is then inserted into a high- 
copy cloning vector, scaled up in E.coli, purified at high concentration, and digested out 
of the cloning vector using a single restriction enzyme. The resulting monomer genes are 
purified from the vector DNA via preparative agarose gel electrophoresis followed by gel 
extraction of the monomer gene fragment. The monomer gene population is then ligated 
in a high ratio with purified expression vector which has been linearized with a restriction
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1: Digest cloning vector - 
monomer gene segment 
(CV+MGS) with enzyme 
A
2: Linearize expression 
vector (EV) with enzyme 
A, dephosphoryleate with 
SAP
3: Ligate linearized EV 
with MGS obtained in 
Step 1
4 Transform E.coli with 
ligation mixture, screen 
for colonies containing 
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Figure 2.3: Random concatamerization (adapted from248)
enzyme which produces ends compatible with the monomers, and has been 
dephosphorylated to eliminate autoligation and recircularizaion. The ligation reaction is 
used to transform E.coli and the transformed bacteria are plated on selective medium. 
Following ample time for growth, single colonies are selected and must be screened for 
the length of polymer which they contain. This method is advantageous in that it is not 
difficult to design and implement, and may produce the desired polymer length rapidly. 
The disadvantages of this method become evident when large monomers are used to form 
large polymers, as the probability of the desired polymer lengths forming is quite low and 
can require months of colony screening to obtain the desired polymer.
2.4.2.2 Recursive directional ligation
Recursive directional ligation (RDL) is a process which was developed to produce 
an entire library of polymer lengths for a given system and employs a stepwise approach, 
adding one monomer at a time.246 A schematic of this approach is shown in Figure 2.4. In 
this approach, oligonucleotides are designed with two different enzyme specificities at 
their sticky ends, but with the two sticky ends compatible. The monomer is ligated into a 
cloning vector and expanded as in random concatamerization. For multimerization, the 
monomer is digested out of the cloning vector with a double digest, for example, Enzyme 
A and Enzyme B. A separate population of vector containing monomer is digested by 
Enzyme A only, dephosphorylated, and the monomer population from the double digest 
is ligated to the Enzyme A-linearized vector. This yields a dimer at this step, which is 
then used at subsequent steps to add one more monomer per step until a polymer of 
desired length is reached. Appropriate selection of enzymes and recognition sites is
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1: Digest cloning vector + 
monomer gene segment 
(CV+MGS) with enzyme 
A. Sticky ends are A- and 
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Figure 2.4: Recursive directional ligation (adapted from246)
essential to the success of this approach. The specific strategy published previously 
employed a creative approach in which two enzymes were used that recognize distant 
sequences, and cut degenerate bases downstream.246 Specifically, BglI and PflMI were 
used. BglI has a recognition and cut sequence of GCCNNNNANGGC, where the 
underlined portion represents the recognition site, a represents the top strand cut site, N 
can represent any nucleotide, and PflMI has a recognition/cut sequence of 
CCANNNNANTGG. By designing the degenerate sites to be compatible with one 
another, it allows specific cutting of only one end of the monomer, with the same sticky 
end resulting. The overhang was “GGC” for the top strand (5’-3’) and “CCG” for the 
bottom strand (3’-5’). One monomer insert per step is encouraged statistically by ligating 
the monomers and vectors in a low molar ratio (1:1-1:5). Once the desired polymer 
length is achieved, the polymer gene is transferred to an appropriate expression plasmid, 
transformed into an expression cell line, and scaled up. Purification and downstream 
processing following RDL is protein and expression system specific.
2.4.2.3 Overlap Extension Rolling Circle Amplification (OERCA)
OERCA represents a new approach to the one-step synthesis of an entire library 
of polymer gene lengths, which combines the precision of RDL with the convenience and 
speed of random concatamerization.247 This method is depicted in Figure 2.5. The general 
approach of OERCA is that the initial template is a single-stranded circular DNA, which 
encodes for the desired monomer gene. Primers directed at the 3’ and 5’ ends of the 
monomer are reacted with the template circle in PCR. During the first step of this 
reaction, the polymerase synthesizes several different lengths of the polymer by rolling
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1: Circularized monomer gene is 
added with forward and reverse 
primers to a standard PCR reaction
2: Annealing and extension create 
multimers via unidirectional rolling 
circle amplification
3: Denaturing produces various 
polymer gene lengths
4: Annealing and extension now 
occurs bidirectionally on newly 
synthesized polymer gene fragments, 
and unidirectionally on circularized 
monomer gene as in (2)
5: A full range of polymer gene lengths is 
produced by PCR cycling, after which polymer 
genes are ligated in to expression vectors, 
transformed into E.coli, and colony screened
Figure 2.5: Open-ended rolling circle amplification (adapted from247)
circle amplification. Subsequently, these polymer genes are able to hybridize with one 
another by their ends, producing longer gene segments. While this lengthening is 
occurring, the original circular ssDNA template is being amplified repeatedly, resulting 
in shorter lengths of polymer gene. This process has been shown to be controllable by 
several different process parameters.247 Decreasing primer concentration while keeping 
cycle number constant increases the average length of the synthesized gene products. 
Increasing cycle number while keeping primer concentration constant increases the 
average length of gene products. The addition of further primer during the reaction serves 
to “fill in” lower polymer lengths which were expanded to high molecular weight with 
increasing cycle number. Following this reaction, the desired polymer genes can be 
inserted into any expression vector as a blunt fragment, and downstream protein 
production/purification can be initiated. OERCA is a very powerful tool for producing a 
large quantity of varying gene lengths, and while it does require colony screening to 
determine the length of each polymer gene, the ability to tune a process to produce a 
large fraction of the desired polymer length presents a distinct advantage over random 
concatamerization. Further, the one-step gene polymerization approach makes OERCA 
much faster than RDL, and again by tuning the reaction to the desired size ranges, a 
complete library of a range of polymer lengths can be obtained.
2.4.3 Classes of genetically engineered protein polymers 
Much of the work done in genetically engineered protein polymers has been in the 
areas of elastinlike polypeptides (ELPs235, 242), silklike protein polymers of both 
silkworm232, 237 and spider dragline 249-251 silks, collagen,252, 253 and silk- elastinlike
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protein polymers (SELPs).232, 234, 237 Other notable advances in the field include the 
advent of noncanonical amino acids and their incorporation into protein polymers, as 
these open the field of protein polymers to chemistry which has never before been 
available,238 as well as alanine-rich helical polypeptides,245 and cationic recombinant 
polymers for systemic gene delivery, as previously discussed in Section 2.2.2.1.3.3.48, 99
2.4.3.1 Elastinlike protein polymers (ELPs)
Elastinlike protein polymers are generally defined by a repeating sequence of 
VGVXP, where X is referred to as the “guest residue” and can be any amino acid other 
than proline.235, 254, 255 Extensive work has been done on the characterization of structure 
dependence of properties in these materials and the physical chemistry behind these 
properties.235, 255 The base sequence of ELP is derived from a common repeating unit in 
mammalian elastin.256 The main property of ELPs which has made them an attractive 
protein polymer for both basic and applied sciences is their ability to undergo a phase 
transition with changing temperature. ELPs are water-soluble below their lower critical 
solution temperature (LCST), and rapidly respond to temperatures exceeding their LCST 
by losing solubility, aggregating, and falling out of solution.255 The temperature at which 
this transition occurs can be tuned by modification of the guest residue: more 
hydrophobic guest residues result in lower LCSTs.255 This effect is observable for 
homopolymers of ELP as well as block copolymers, where systems have been created 
which have different regions of temperature sensitivity and hydrophobicity.
The ability to reliably produce highly specific stimuli-responsive materials has 
garnered an active field of research into the design of stimuli-sensitive nanoparticulate
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systems using ELPs as a base polymer. One example is taking advantage of this tunable 
temperature dependence to produce thermally responsive drug delivery systems.257-259 In 
these systems, an ELP was designed which had an LCST of approximately 40°C, which 
allowed it to remain soluble in circulation at physiological temperature. By heating the 
target site, in this case a tumor, to 42°C, the ELP undergoes a phase transition 
preferentially in the tumor, causing accumulation.257-259 Another drug delivery system 
developed using ELPs has taken advantage of the ability to produce specific changes to 
the polymers to impart desired properties. For example, chimeric ELPs primarily 
composed of Val-Ala-Gly guest residue compositions at a ratio of 1:8:7 with a (Gly-Gly- 
Cys)8 motif at one end were produced.260 This motif was used to attach the cytotoxic 
chemotherapeutic drug doxorubicin, and to impart a hydrophobic character to that end of 
the polymer such that it self-assembled into a nanoparticle. These nanoparticles were 
used to treat a subcutaneous colon cancer model in BALB/c mice, and showed a greatly 
improved survival benefit and was able to reduce the size of the established tumors over 
the entire course of the study, with no observable tumor recovery. This work has further 
expanded into encoding specific modifications to polymers used for nanoparticle 
formation intended to improve their effect, specifically adenovirus knob domain.261
2.4.3.2 Silk-based polymers
Another natural polymer which has attracted attention in the area of genetically 
engineered protein polymer design is silk. In nature, there are two distinct forms of silk, 
coming from spider dragline or the common silkworm, b. mori. The silk produced by b. 
mori is produced as a very strong, thin fiber coated in a glue-like protein called sericin,
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which allows it to adhere to itself and form a tight cocoon during metamorphosis from 
worm to moth.262 This fine thread is valued in the textile industry but has also been used 
in medical applications, most commonly as nondegradable suture. The primary structure 
of silkworm silk is dominated by repeats of the hexapeptide GAGAGS, which self- 
assemble into P-sheet type structures when produced as a linear polymer.232 Use of 
genetically engineered silkworm silk-based materials has been limited. One example of 
genetic engineering of silkworm silk is the genetic engineering of a silkworm which was 
modified to produce cocoon silk containing the fibronectin-derived RGD cell adhesion 
sequence. 263
Spider dragline silk most commonly used in research applications is derived from 
Nephila clavipes, an orb weaver spider.244 N. clavipes dragline is composed of two 
different but structurally similar proteins, which are both used to form the natural 
dragline. The first successful cloning and expression of these two proteins as a 
genetically engineered protein polymer was published in 1995,250 based on a consensus 
repeat sequence derived from the amino acid sequences of each of the proteins. These 
two consensus sequences were determined to be GQGGYGGLGGQGAGRGGLGGQ 
GAGA(An)GGA for the first discovered, termed NCMAG1 or Spidroin 1,251 and 
GPGGYGPGQQGPGGYGPGQQGPSGPS(An) for NCMAG2, or Spidroin 2.249 Current 
research employing these structural motifs for the production of protein polymers 
includes gene delivery vehicles,264 burn dressings,265 and bone tissue engineering 
scaffolds.266
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2.4.3.3 Silk-elastinlike protein polymers
Cappello et al. first reported the design and synthesis of recombinant silk- 
elastinlike protein polymers in 1990.232 Silk-elastinlike polymers are made up of 
repeating “blocks” of amino acids, referred to as “silk blocks” (Gly-Ala-Gly-Ala-Gly- 
Ser) and “elastin blocks”(Gly-Val-Gly-Val-Pro). The silk blocks consist of the sequence 
GAGAGS, and are based on the naturally occurring fibrillar silk of b. mori, the common 
silkworm.232, 267 The design of the elastin blocks is based on mammalian elastin, a very 
common connective tissue in the body which gives skin its elasticity. ’ A significant 
body of research has been focused on manipulating the “guest residue” position of the 
elastin blocks, and changing the silk:elastin ratio, to observe how modifications to the 
structure of SELP affect its properties. Table 2.2 summarizes all versions of SELPs 
which have been publicly disclosed, and briefly summarizes known properties, where 
such information is available. Additionally, this table provides structural information and 
nomenclature to serve as a reference for the coming section.
2.4.3.3.1 Original SELP structures: Valine guest residue
Studies performed on these early SELPs were focused on the changes in 
crystallinity of the polymers as peptides were inserted into the sequences of SLPs which 
were composed entirely of GAGAGS repeats. It was found that pure SLP, which was 
composed of 168 repeats of GAGAGS (~76kDa), had a very crystalline structure, 
characterized by X-ray diffraction and FTIR-dichroism.232 In order to observe structure- 
dependent effects on the P-sheet structure, either elastin groups (GVGVP) or tyrosine- 
containing motifs were inserted into the sequence. The elastin groups provide a periodic
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Table 2.2: SELP Structures and Properties
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interruption by forming kinked coil structures, while the tyrosines provide a bulky side 
chain which is capable of interrupting the P-sheet stabilizing hydrogen bonding between 
neighboring peptide backbones. The structures produced were called SLP4 
[(GAGAGS6)]28, SLP3 [(GAGAGS)9GAAGY]i9, SELP1 [(GAGAGS^GAA 
(VPGVG)4VAAGY]i4 , and SELP3 [(GAGAGSM GVGVP^n. It was observed that 
SLP4, the unmodified silk-only polymer, was the most crystalline. The next most 
crystalline structure was that of SELP1, which contained both the elastin motifs and a 
tyrosine residue in close proximity to the silk repeats. The least crystalline structures 
were those of SLP3 and SELP3, which contained a tyrosine residue near the silk repeat 
and elastin repeats, respectively. This result was confirmed by both X-ray crystallography 
and circular dichroism. It was expected that the SELP1, which contained both the steric, 
P-sheet interrupting modification and the long elastin motif interruption would have been 
the least crystalline, and the reason for these results is unclear. Macroscopically, the 
SLP4 and SLP3 powders appeared to be of similar crystallinity, with the SELP1 and 
SELP3 powders appearing more amorphous and fluffy.
2.4.3.3.2 Synthesis and characterization of lysine-containing SELPs
While the earlier work with comparing protein polymer structure with varying 
valine-containing SELPs provided insight into how modifications of primary structure 
affected downstream network formation, uses for these polymers were primarily as 
research tools. Later versions of SELP investigated the effects of adding a charged 
residue, lysine, in the guest residue position of the elastin-like sequence. For example 
SELP-47K is a structure in which instead of four silk units to eight elastin units per
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monomer repeat, contained four silk units to seven elastin units in the monomer, with one 
elastin unit having the sequence GKGVP.268 The amino acid sequence for this polymer 
was MDPVVLQRRDWENPGVTQLVRLAAHPPFASDPMGAGSGAGS [(GVGVP)4 
GKGVP (GVGVP)3(GAGAGS)4]12 [(GVGVP)4 GKGVP (GVGVPMGAGAGS^ 
GAGAMDPGRYQDLRSHHHHHH, depicted in Figure 1.1. This polymer formed a 
stable hydrogel network, and did so at a much more rapid rate than did the standard 
valine guest SELP of the same silk:elastin ratio (see Table 2.2 SELP-48, 
[(GVGVP)8(GAGAGS)4]13). With the only modification of this sequence being the 
addition of a single lysine per monomer repeat (13 per polymer chain in this case), it is 
apparent that the lysine groups were responsible for this increased gelation rate and 
extent. The precise mechanism of this change has not been investigated, however there 
are several possible reasons. One possible reason is a hydrogen bonding interaction 
between the primary amine group on the lysine, and the oxygen atom in the peptide 
backbone of adjacent polymer strands. This interaction would stabilize the normally 
mobile elastin group and anchor it to any peptide chain that may be nearby, holding the 
structure together until more permanent and stable P-sheet structures could form. Another 
potential explanation of this stabilization is the formation of salt bridges between the 
lysine and any of the three aspartic acids or one glutamic acid in the head sequence, or 
the two aspartic acid residues in the tail sequence. This is a strong interaction which 
would be capable of anchoring the individual peptide chains together, thereby bringing 
the P-sheet forming silk units in closer contact and encouraging rapid self-assembly. This 
polymer forms a stable hydrogel network at concentrations equal to or greater than 4 
wt%, with the rate of hydrogel formation increasing with increasing temperature.
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Gelation properties of SELP-47K are also concentration and time dependent, and the 
polymer showed release properties which depended on polymer concentration and 
molecular weight of the drug.268 Further physicochemical characterization of these 
hydrogels was performed to evaluate their swelling ratio and its dependence on factors 
such as pH, temperature, media ionic strength and cure time.272, 284 As a result of the 
rheological properties of these polymers and their temperature-induced gelation, 
experiments were performed to evaluate the ability of SELP-47K to control the release of
O l ' l  0 1 A 0 1  O i l
plasmid DNA, ’ adenovirus, ’ and drugs ranging from low molecular weights up 
to 500kDa dextran conjugates,268, 279 which will be discussed later.
Based on initial physicochemical characteristics and release profiles of SELP- 
47K, two new analogs, namely SELP-415K (four silk units and fifteen elastin units with 
an additional elastin unit containing a lysine residue)275 and SELP-815K (eight silk units 
and fifteen elastin units with an additional elastin unit containing a lysine residue)282 were 
synthesized by genetic engineering techniques. The rationale is that by controlling the 
sequence and length of silk and elastin blocks while keeping the molecular weight of the 
polymer constant, it is possible to tailor gelation, mechanical strength, release and 
transfection efficiency. The three constructs varied in sequence of silk and elastin blocks 
while keeping their molecular weights consistent. It was found through physical 
characterization that increased silk block content in SELPs rendered a hydrogel with 
greater crosslinking density, and increased elastin block content resulted in a softer gel 
with lower mechanical strength.282 For the purposes of gene delivery with adenoviral 
carriers, this translates to faster and more complete release as silk block content decreases 
and elastin block content increases.
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As an example of the overall synthetic strategy of SELPs the biosynthesis of 
SELP-815K is outlined in Figure 2.6.282 Synthesis is performed via random 
concatamerization, as discussed in Section 2.4.2.1. In brief, the monomer gene segment 
(DNA encoding for a single 8-silk, 15-elastin, 1-Lys-modified elastin monomer) was 
produced by digesting plasmid pPT340, encoding for SELP-415K, with BanII restriction 
enzyme to produce a plasmid encoding for SELP-215K. Plasmid pSY1378, encoding for 
six silk units, was then linearized using BanII, purified, and treated with shrimp alkaline 
phosphatase (SAP). Following removal of SAP, pPT340 and pSY1378 were ligated at a 
1:1 molar ratio using T4 ligase. The resulting mixture was then used to transform Dh5a 
chemically-competent E.coli, which were plated with chloramphenicol. Following 
formation of colonies, they were isolated, propagated, and plasmid DNA was purified. 
Restriction digestion was followed by agarose gel electrophoresis to visualize a fragment 
of 384bp, representing the SELP-815K monomer gene segment. Following production of 
the SELP-815K monomer gene segment, they were excised from their parental plasmids 
as BanI fragments and self-ligated using T4 DNA ligase, forming SELP-815K multimers. 
The expression vector, pPT317, was digested with BanI and treated with SAP, then 
randomly multimerized with the SELP-815K insert using T4 DNA ligase. This ligation 
mixture was used to transform Dh5a chemically-competent E.coli, which were plated 
with kanamycin. The 6-mer was isolated via colony PCR and restriction digestion 
procedures, and plasmids encoding for the 1-, 2-, 3-, 4-, and 5-mer were also isolated. 
The 6-mer was chosen because this number of 815K repeats yields a polymer with the 
most similar molecular weight (65,374 Da) 282 to the previous analogs (SELP-47K 13- 
mer, 69,814 Da,284 SELP-415K 8-mer, 71,500 Da 275). The “polymerization” for
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Figure 2.6: Synthetic strategy for SELP-815K (adapted from282)
recombinant polymers takes place at the genetic level, and can therefore be closely 
evaluated before large-scale protein production. Large-scale production is performed 
using only specific plasmids encoding for the polymer of desired length, thus largely 
eliminating polydispersity of the resulting polymer population and maintaining precise 
control over the polymer’s amino acid sequence.
2.4.3.3.2.1 M olecular methods. SELPs have been well-characterized in terms of 
structure and composition, using common protein analysis methods. The molecular 
weights of hydrogel-forming SELPs used for gene delivery studies275, 282 were confirmed 
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), amino acid 
analysis, and matrix-assisted laser desorption-ionization-time-of-flight (MALDI-TOF) 
mass spectrometry. Typical mass spectrometry and amino acid analysis data for SELP- 
815K are shown in Figures 2.7 and 2.8, respectively. As observed, distinct molecular 
weights of the polymer can be obtained using recombinant techniques. The analyses of 
each structure of SELP showed that their molecular weights were within reasonable 
margin of error based on expected amino acid sequence. Amino acid analysis was also 
performed on SELP-815K, and the results agreed with the projected values based on the
expected amino acid sequence and gene sequencing data for the monomer and polymer
282gene segments.
2.4.3.3.2.2 Atomic force microscopy (AFM) of SELP self-assembly. In order to 
investigate the self-assembly properties of SELPs at the molecular level, AFM was 
performed on low polymer concentrations, well below hydrogel-forming values.285 The 
initial studies were only performed on SELP-415K as among the analogs under 



































Figure 2.8: Amino acid analysis of SELP-815K282
assembly was concentration-dependent and tended towards the formation of nanofibers as 
concentration was increased. Additionally, these results showed that the size of the 
nanofibers was not affected by SELP concentration. However increasing concentration 
yielded increased density of fibers. Further, AFM studies indicated the strong dependence 
of fiber formation on ionic strength. A known fiber-forming concentration (1ug/ml) of 
SELP-415K was incubated in NaCl concentrations ranging from 5 mM to 100 mM and 
imaged using AFM. Lower ionic strength solutions supported more robust fiber 
formation, and the effect of ionic strength on fiber formation was concentration 
dependent as opposed to a rapid transition to an absence of fibers with increasing ionic 
strength. Further studies were performed to investigate the kinetics of SELP nanofiber 
formation. These studies revealed rapid formation of fibers at low ionic strength on a 
mica surface, while higher ionic strength conditions caused slower fiber formation with a 
more typical lag, burst, plateau type of kinetics as observed for other proteinaceous 
fibers.286-288 This suggests that fiber formation on the mica surface is driven by 
electrostatic interactions between the surface and the SELP chains, and increasing salt 
concentration provides shielding of these interactions, thereby reducing formation of 
fibers on the surface.
A more recent analysis of SELP by AFM revealed a very interesting behavior of 
SELP adsorbed to mica surfaces.289 SELP-815K was adsorbed to a mica surface for 30 
minutes at a concentration of 5^g/ml, after which the SELP solution was removed and 
the surface was washed three times with DI water. Following washing, the surface was 
probed with an AFM in tapping mode, and a sparse network of nanofibers was observed. 
Following the initial scan, the surface was scanned at several later time intervals, and it
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was observed that over time, many more nanofibers were forming. In order to examine 
whether or not this was due to the nanomechanical stimulus of the AFM tip, a stimulus 
intensity study was performed, as well as a condition in which a field of view was 
stimulated with the AFM, allowed to incubate for 30 minutes, and then zoomed out and 
re-scanned. It was shown that increasing the magnitude of the stimulus correlated directly 
with increased surface coverage by the nanofibers, and in the field-of-view experiment it 
could easily be observed that the additional formation of fibers was confined just to the 
areas which were physically stimulated with the AFM tip. These results correlate with 
observations that in order to form stable hydrogels reliably and quickly, SELP must be 
exposed to a significant shearing event, with increasing shear resulting in more rapid 
gelation.
2.4.3.3.2.3 Gelation properties of SELPs. The rate, mechanism, concentration, 
and required environment for gelation were studied at length for the hydrogel-forming 
structures of SELP. Early studies of these properties revealed that the gelation of SELPs 
is a mildly exothermic reaction, the properties of which are characteristic of a 
“nonreversible crystallization event”.268 The gelation of SELP was also confirmed by 
viscometry, which showed an increase in viscosity of the polymer solution with time,268 
suggesting that the individual SELP polymers were associating with one another. One 
very important property revealed by the viscometry experiments is that the time for 
gelation is strongly dependent on the number of silk units per monomer repeat. Under 
isothermal conditions at 37°C and at identical protein concentrations, it was observed that 
SELP-816 reached the upper maximal limit of the viscometer after approximately 57 
minutes, while SELP-47K took approximately 108 minutes and SELP-27K did not show
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a significant increase in viscosity during the 125 minute measurement time.268 The 
structural arrangement of these polymers is described in Table 2.2. While it has since 
been established that the addition of a lysine guest residue greatly reduces gelation times 
in static gelation conditions, the shear applied to the SELP-816 sample by the rheometer 
overcame this property and induced more rapid gelation correlated with silk unit content. 
This result combined with the AFM results 289 suggest that the physical stimulation of 
these polymers induces self-assembly of the GAGAGS silk unit repeats, resulting in 
nanofiber (2-D) or hydrogel formation (3-D). In later experiments, where the SELP-47K 
was allowed to gel in a mechanical stimulus-free environment, it was observed that 
gelation began to occur as early as 5 minutes after being placed in a 37°C environment.
Included in these rheological gelation studies was an investigation into the 
temperature dependence of SELP gelation. In addition to the 37 degree condition, SELP- 
47K and SELP-816 were measured at 23°C and 4°C.268 As expected, it was observed that 
the gelation time was temperature dependent, with significant increases in gelation time 
as the temperature was decreased. The effect was so profound that at 4°C, SELP-47K 
first showed signs of gelation at approximately 24 hours after the start of the 
experiment.268 Another characteristic of SELP gelation examined whether or not solutes 
expected to aid or inhibit crystallization had an effect on SELP gelation. To answer this 
question, SELP-47K gelation was measured in the presence of 6M urea, precrystallized 
SELP-47K, and PBS only (control). It was hypothesized that the urea would disrupt the 
ability of SELP to form gels by preventing hydrogen-bond formation, while the 
precrystallized SELP-47K in solution would serve as attractive nucleation sites and 
therefore accelerate gelation. This hypothesis was shown to be correct, as SELP in the
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presence of SELP seed crystals gelled approximately 30 minutes faster than the control 
condition (110 minutes), and the SELP in the presence of urea had not shown signs of 
gelling up to 6 hours from the start of the experiment.268
The critical gelation concentration (CGC) of each of the hydrogel-forming, 
lysine-substituted SELP compositions has not been experimentally determined, but can 
be estimated. The use of SELP-47K and SELP-815K at concentrations as low as 4 wt% 
and SELP-415K as low as 10.8% has been published.282, 290 In unpublished experiments, 
SELP-415K has been observed to gel at concentrations as low as 8 wt%, and SELPs -47K 
and -815K are considered likely to be able to gel at concentrations lower than 4 wt% 
although this has not been used for any experiments. These differences are attributable to 
the density of silk units per monomer repeat, as they are responsible for crosslinking 
events in SELP gelation. An increase in silk units therefore increases the theoretical 
concentration of crosslinks and decreases the amount of polymer necessary to form a 
fully crosslinked network.
Previous experiments demonstrated the strong dependence of physical properties 
on the molecular sequence of the linear SELPs. Extending this to three-dimensional 
networks, studies were performed to investigate the specific effects that each 
modification of SELP has on the physical properties of resulting hydrogels.
2.4.3.3.2.4 Factors influencing swelling of SELP hydrogels. Hydrogel swelling 
ratio (q) is a measure of the weight of a hydrated hydrogel divided by its dry weight that 
has been measured for SELPs.278, 282, 284 This parameter is useful in predicting the ability 
of a hydrogel to ‘soak up’ potentially useful solutions, delivery via diffusion, pore size, 
and mechanical properties. Extensive studies have been performed to evaluate swelling
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ratio of SELP hydrogels over a range of polymer concentrations and compositions along 
with the effects of pH, temperature, ionic strength of media, solutes, and gelation time of 
the sample. It was found that changes in pH had little or no effect on the swelling ratio 
between pH 2 and pH 12.275, 282, 284 Studies on SELP-415K at 12 wt% showed that there is 
temperature dependence, with an observed swelling ratio of approximately 16 at 4°C with 
a steady decrease in swelling ratio to less than 10 at 47°C.275 This is contrary to findings 
with SELP-47K and SELP-815K, which showed no appreciable temperature dependence 
over the range of 4°C to 47°C and had swelling ratios of approximately 10 for 12 wt% 
gel in both cases. The reason behind this is most likely due to the fact that SELP-415K 
has a higher elastin:silk ratio than SELP-47K and SELP-815K and long elastin blocks, 
which allow the temperature-dependent self-assembly of the elastin blocks to occur, as 
they are not as rigidly confined as they would be in the case of the higher silk content 
SELPs. Similar effects were seen with other SELP structures.283
The largest factor for swelling ratio in the same SELP structure was, not 
surprisingly, hydrogel cure time. All three polymers showed cure time dependence at 12 
wt%, with SELP-415K showing stronger cure time dependence than SELP-47K 275 and 
SELP-815K.282 In another study, SELP-47K was shown to have stronger cure time 
dependence at 8 wt% than at 12 wt%.284 This can be explained by the changes in overall 
concentration of the crosslinking beta-sheet forming silk blocks. Because all of the 
polymers are synthesized to have approximately the same molecular weight, the overall 
concentration of silk blocks in a solution of SELP-415K at 12 wt% is much lower than 
that of SELP-47K. The number of silk blocks in SELP-815K is also significantly higher 
than in SELP-415K, therefore explaining the intermediate swelling ratios in all
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conditions. The reduced number of silk blocks in SELP-415K causes the beta-sheets to 
form more slowly in this polymer than both SELP-47K and SELP-815K, thus producing 
a much looser network during a short cure time. Over an extended period of time, more 
beta sheets are given time to form, and therefore, the relative reduction in swelling ratio 
becomes higher for SELP-415K than for SELP-47K and SELP-815K. The reduction of 
weight percentage from 12 wt% to 8 wt% also reduces this silk block concentration, 
therefore similarly increasing the amount of time required for an equivalent number of 
crosslinks at 12 wt%.
Another factor which was shown to influence swelling ratio of SELP-47K gels at 
low weight percentages was the incorporation of adenoviruses.277 The changes in 
swelling ratio in general were not extreme. However, there is a trend suggesting that 
swelling ratio of 4 wt% hydrogels of SELP-47K decreases as adenovirus count increases. 
277 This implies that there is some interaction between the viruses and SELPs, likely 
occurring at a high enough frequency to create simulated crosslinks in the polymer which 
are not a result of the interaction of silk blocks on different polymer chains. While this 
phenomenon is true of low weight percentage SELPs, similar studies performed on 11.7 
wt% SELP-47K and SELP-415K hydrogels did not show the same trend.277
2.4.3.3.2.5 Soluble fraction of SELPs. Due to the proposed application of SELP 
hydrogels in vivo, it was necessary to assess the amount of polymer soluble fraction 
generated with each formulation in order to draw conclusions about possible side effects 
based on the amount of free polymer chains released. This property of SELP was 
assessed in several different experiments. Hydrogels of SELP-47K (4, 8, and 11.7 wt%) 
and SELP-415K (11.7 wt% only) were produced by drawing liquid polymer solutions
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into a 1cc syringe, followed by gelation for particular lengths of time.277 Following 
gelation time, the gel cylinders were cut into 50^l disks, placed into release media (1X 
Dulbecco’s phosphate buffered saline with 0.01% sodium azide) and agitated at 120RPM 
in a shaking incubator at 37°C. Solubilized protein was assessed by removing all release 
media and performing a bicinchoninic acid (BCA) protein assay to determine soluble 
polymer weight.277 It was shown that after a 4-hour cure time, the soluble fraction of 
SELP-47K hydrogel at 11.7 wt% was approximately 15%, meaning that at least 15% of 
the protein in the original sample did not participate in the crosslinking and formation of 
the hydrogel network.
Due to the adjustment of the number of monomer repeats, it is true that the total 
silk content per polymer strand will be similar between the two; however, the longer 
contiguous silk units are statistically more likely to leave “open” crosslinking sites than 
are the shorter units found in SELP-47K structure, increasing the likelihood that 
completely noncrosslinked polymer can randomly associate with another strand. SELP- 
415K at 12 wt% was also investigated in this study277 and it showed nearly identical 
soluble fraction amounts to SELP-47K over the time of the study, with a slightly slower 
release rate in the beginning. This observation is likely related to the mechanism of 
gelation of these polymers. Crosslinks are formed due to association of silk units into 
beta-sheets, which requires the polymer strands to be within close proximity of one 
another in order for the hydrogen bonds to form between the adjoining silk units. In the 
case of SELPs -47K and -415K, the short silk blocks, while allowing some crosslinks to 
form in high density, it is likely that the adjoining elastin units could sterically hinder 
attachment of a large number of chains. In the case of SELP-815K however, the longer
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silk units are likely to allow more polymer strands to attach to each other. While it is true 
that the elastin units will theoretically hinder some of the silk units, the 100% longer silk 
unit of SELP-815K is likely to compensate for this effect. It was shown that after 24 
hours of gelation, the soluble fraction was much lower, with approximately 8 wt% 
soluble fraction for the same polymer at the same concentration.284 These results give 
information regarding the time-dependence of the physical interactions which cause the 
crosslinks to form, as the same polymer conditions gave 25% soluble fraction after a 1- 
hour gelation time.284 It would appear that there is a fast initial crosslinking which occurs 
shortly after the temperature of liquid solution is raised, followed by a leveling off of the 
rate of crosslink formation most likely due to steric hindrance of the crosslinking sites 
actually being able to locate one another.
Another study on the soluble fraction of SELP hydrogels was an investigation into 
the effects of adenovirus incorporation into the liquid polymer solution on the amount of 
soluble fraction.277 This is particularly applicable as SELPs are currently being 
investigated as a possible delivery device for adenovirus-mediated anticancer gene 
therapy. These studies showed that there is little to no effect on the amount of protein 
soluble fraction released from the hydrogel by incorporating adenoviruses into the liquid 
polymer before gelation.277 Results are encouraging as they imply that SELPs can be 
applied in vivo as an adenovirus delivery device with no added material-related side 
effects due to the inclusion of the viruses. These results also suggest that there is minimal 
chemical interaction between the monomers and adenoviruses, as it would be expected 
that interaction between the virus and monomer would cause an increase in soluble 
fraction. It is thought that this complex would be more likely to be sterically hindered
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and thus blocked from forming crosslinks, which would likely interfere with the pore 
network formed by the polymerization of the SELPs.
2.4.3.3.2.6 Therm al analysis of w ater in SELPs. Using differential scanning 
calorimetry, SELP hydrogels were characterized for their nonfreezable water content, 
heat capacity, and temperature dependence of both.291 This information is very important 
to the application of SELP as a polymeric delivery depot, as the nonfreezable water has 
been hypothesized to be partially bound to the polymer chains by hydrogen bonding, 
which would have implications in diffusive release of solutes from the hydrogel if the 
solutes were contained in this area of the fluid. It was found in these studies that up to 
27% of the water in SELP-47K hydrogels is nonfreezable, and is approximately in a 1:1 
ratio by weight with the polymer.291 These studies also revealed some interesting 
information regarding the freezable water contained within the hydrogels. It was revealed 
that the melting of water entrapped in SELP hydrogels occurred over a 25 degree range, 
which is highly atypical of bulk water. It was stated that this very broad melting curve 
was possibly a result of either segregation of small water clusters which melted at 
different rates, or that the heat energy put into the system was shared between the melting 
of the freezable water and the mixing of the polymer chains and liquid water.291
This study also investigated the overall effects of hydration of the hydrogels on 
the melting of frozen entrapped water, and the effect on heat capacity of the entrapped 
water. For the heat capacity measurements, it was shown that there is little or no 
dependence of heat capacity on hydration of the polymer for temperatures below 0°C, 
while there is a linear dependence for temperatures above 0°C. The heat capacity values 
were also compared based on temperature, and a similar trend was observed, with very
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little dependence observed for freezing temperatures and a linear dependence observed 
for higher temperatures. These values mostly agreed with accepted literature values, 
indicating that the nonfreezable water in SELP-47K hydrogels is not likely to be 
completely bound to the polymer strands.
2.4.3.3.2.7 M echanical properties of SELP hydrogels. In order to be 
successfully applied as localized gene delivery systems, it is desirable that SELPs be 
injected directly into a tumor, and therefore be liquid in their initial form. Following 
gelation, the material cannot be mechanically weak, as this will make it susceptible to 
flow which will affect release rate of the therapeutics from the hydrogel. Also, a material 
which is very pliable or soft will allow the gel to migrate from the injection site, which is 
likely to reduce its utility as a localized delivery system. As an initial assessment of the 
material properties of SELP hydrogels, cone and plate rheology was used to measure the 
shear modulus of SELP-47K and SELP-415K hydrogels, both at 12 wt%.275 Shear 
modulus is a parameter describing the ability of a material to resist shear strain under 
exposure to shear stress. This information is useful for the application of SELP hydrogels 
in vivo because it provides some insight into their ability to resist deformation and 
migration from the injection site, which could have negative consequences for the 
delivery of bioactive agents. Using cone and plate rheology, the shear modulus of SELP- 
47K hydrogel was found to be 1.3 MPa, while the same value for SELP-415K hydrogel 
was 0.37 MPa.275 This large difference in modulus can be explained by the fact that 
SELP-47K has a significantly higher density of beta sheet and crosslink-forming silk 
units than does SELP-415K, and therefore is expected to exhibit increased mechanical 
strength in this assessment. This is another example of the tunable property of SELP
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hydrogels which can be controlled precisely at the molecular level to make these 
materials suitable for matrix-mediated gene delivery.
In order to assess the mechanical strength of SELP hydrogels, studies were 
performed using dynamic mechanical analysis (DMA).282 A sinusoidal compression of 
the sample at controlled frequency was used to assess the storage and loss moduli of 
SELP hydrogels. The storage modulus is related to the stiffness of the material and is 
typically associated with the elastic properties, while the loss modulus is related to the 
dampening and energy dissipation of the material due to its viscous properties. A direct 
comparison between SELP-47K, -415K, and -815K at 12 wt% was performed in order to 
assess the structure-dependent differences in mechanical properties among these three 
polymers.282 In this study, gels were subject to a strain range of 0.2-2%, and all samples 
were tested at 1Hz. The results showed that of the three gels tested, SELP-47K had the 
highest storage modulus, followed by SELP-815K and SELP-415K, respectively. These 
results suggest that mechanical properties are primarily determined by the number of 
elastin blocks per monomer repeat, and the length of the silk blocks also contribute to 
some extent. The results of this study also illustrate the fact that the contribution of silk 
blocks to the mechanical properties is mostly stiff, noncompliant regions of the gel, as the 
SELPs with higher silk fractions (SELP-47K and SELP-815K) fractured at strains greater 
than 1.5%, while SELP-415K, with about 30% fewer silk blocks per monomer, was able 
to resist fracture throughout the tested range of 0.2-2%.
In a separate study, DMA was performed on hydrogels formed from SELP-47K at 
4 wt%, 8 wt%, and 12 wt%, and SELP-415K at 12 wt%,276 to examine the concentration- 
dependence of mechanical properties of these polymers. In this study, a frequency sweep
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was used to examine the differences in the properties of the hydrogels at various strain 
rates. It was shown that there is very little frequency-dependence and a very strong 
concentration-dependence for the storage modulus in SELP hydrogels, with 12 wt% 
SELP-47K having a storage modulus of 1.6 MPa, compared to 8 wt% and 4 wt% gels 
which had moduli of 0.5 MPa and 0.075 MPa, respectively. The result was expected as 
there is a much higher density of crosslinking silk units at higher concentration, and 
therefore, it is very likely that there is a higher density of crosslinks, leading to an 
increase in mechanical strength. This trend is also observed when the modulus for SELP- 
415K at 12 wt% is compared to these figures. 12 wt% SELP-415K hydrogel yielded a 
value of 0.07 MPa, very similar to 4 wt% SELP-47K. This is likely due to the 
significantly shorter elastin blocks found in SELP-47K, which allow more rapid and 
frequent self-assembly of silk units to occur than in the case of SELP-415K. The reduced 
silk block composition does not, however, have a direct 1:1 relationship with decreases in 
storage modulus, suggesting that there are other factors which contribute to the properties 
of SELP hydrogels aside from the density of crosslinking units. Among possibilities for 
such differences are the specific arrangement of the crosslinking units with one another,
i.e., doubling crosslinking units does not necessarily mean doubling the number of 
crosslinks. In this case, this reduction in crosslinking density would be caused by 
elastin’s interruption of the silk’s crystallization. Further, the self-assembly 
characteristics of the elastin blocks could be responsible for the decrease in mechanical 
properties as the elastin does not form stiff beta sheet structures as silk does.
2.4.3.3.2.8 Transmission Electron Microscopy (TEM) of SELP hydrogels. 
TEM was employed to provide a picture of what the microstructure of SELP hydrogels
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looks like as a function of SELP composition (SELP-47K vs. SELP-415K) and 
concentration (SELP-47K at 4%, 8%, and 12%.). TEM studies were particularly useful 
in determining the crystal structure of SELPs along with the interfibril spacing in a SELP 
hydrogel.277 The TEM images show that interfibril spacing has an obvious dependence on 
SELP composition, with higher concentrations exhibiting lower interfibril distances, 
although for all concentrations, the interfibril distances were highly variable. Another 
interesting piece of information given by the TEM images was an image of an adenovirus 
virion, which showed that the interfiber spacing is significantly larger (~93nm) than the 
diameter of the virion (~22nm).277 This suggests that viruses inside the hydrogel network 
should not be completely immobilized by the SELP material; however, completely 
unimpeded diffusion should not occur either. This makes SELP a strong candidate for 
the controlled release of virus particles over an extended period of time.
2.4.3.3.2.9 Small-Angle Neutron Scattering (SANS) of SELP hydrogels. To 
gain further insight into the hydrogel pore structure, network properties were examined as a 
function of polymer sequence by small angle neutron scattering (SANS) techniques. SANS 
allows the examination of microstructures in the range 1-100nm through the analysis of 
elastic neutron scattering.292 SANS analysis was used to examine the correlation between the 
observed macroscopic properties of SELPs such as equilibrium swelling and mechanical 
modulus with the underlying network structure. The data were fit using a combined Debye- 
Bueche power law model which revealed trends in the SELP fibril correlation length that 
confirm observations about structural effects.293 SELP hydrogels conformed closely with a
u 9 9 9modified gel model of the general form I(Q) = AQ + (BQ s ) + C, which uses a power-law 
fit for the high q scattering combined with the Debye-Bueche model at low to intermediate Q
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O _1(above Q = 0.02 A~). The combined Debye-Bueche/power law model provided a nearly 
complete fit over the full q-range of collected data. This analysis of SELP-47K, -415K, and -
815K revealed scattering profiles that, while similar in form, showed a characteristic trend in
2 2low q power-law scattering and Debye-Bueche correlation length ((4nKs corrL )/(1 +
2 9 9Q corrL ) ). The calculated correlation length depicts a trend in the observation that is in the 
order SELP-415K > SELP-815K > SELP-47K. This is consistent with the dynamic 
mechanical analysis (DMA) data showing that SELP-47K had the highest storage modulus. 
Presence of shorter elastin blocks separating the crystallized silk blocks of the SELP-47K 
compared with the other analogs (-415K and -815K) resulted in a stiffer hydrogel with 
smaller spacing of the crystalline silk units. In contrast, SELP-415K had the longest 
correlation length and the lowest storage modulus. The silk blocks of SELP-415K are 
separated by elastin blocks twice the length as SELP-47K, and as these cross-linking blocks 
move further apart, the elastinlike nature of the SELP becomes more pronounced and the 
storage modulus decreases. SELP-815K presents an interesting case where the silk blocks are 
doubled in length over SELP-47K while also having a long elastin block as in SELP-415K. 
While the larger silk blocks provide improved cross-linking when combined with a 15-unit 
elastin block, the correlation length and storage modulus falls between those of SELP-47K 
and -415K. The combination of SANS and DMA data together suggest that the elastin block 
of the SELPs predominantly influence the effective pore size.
2.4.3.3.2.10 Release properties of SELP hydrogels. In order to assess the ability 
of SELP hydrogels to deliver therapeutic agents in a spatial- and temporally controlled 
manner, a series of in vitro release experiments were performed. These studies were a 
prelude to extensive in vivo studies which assessed the delivery, localization, and efficacy
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of bioactive agents from SELPs. Several investigations have been performed on the 
ability of SELP hydrogels to control the release of many simulated traditional therapeutic 
agents, ranging in molecular weight from 180 Da (theophylline)272 to 500kDa 
(fluorescein-dextran).268 In general, all of the solutes tested showed size-dependent 
release from SELP-47K. The rates of release from the hydrogels as a function of solute 
size yield some important information regarding the applicability of SELP as a controlled 
release system for molecular therapeutics. The molecules released from SELP-47K 12 
wt% (theophylline, MW180, Vitamin B12, MW1355, and cytochrome c, MW 12384) 
were all completely recovered by 4 hours after the start of the release study.272 A similar 
study, however, revealed that 20 wt% SELP-47K was able to release 85% of the 
originally loaded amount of 500 kDa fluorescein-dextran in a controlled manner over the 
course of 10 days, suggesting that this size range of therapeutics would be a good 
candidate for long-term controlled release from SELP-47K hydrogels.268 This study also 
showed that a 40 kDa conjugate dansyl-dextran was released steadily over approximately 
3 days, which could also be a useful time period of release for some applications.
Further studies performed by Dinerman et al. investigated the release properties of 
small molecule species based on charge.279 Specifically, the fluorescent dyes fluorescein 
(negative charge), rhodamine B (amphoteric), and rhodamine 6G (positive charge) were 
used as model molecules of approximately identical molecular weight but differing 
charge. It was shown that the positively charged dye, rhodamine 6G, had the slowest 
release rate, while the negatively charged dye released fastest. This is likely due to 
hydrophobic interactions between the dye and the hydrophobic amino acids in the 
polymer chain. This was supported by visual observations of the diffusion front
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characteristics in the gels containing each of the dyes, as the most hydrophilic dye 
exhibited a visually distinct diffusion front, while this was absent in the other, more 
hydrophobic dyes.
These studies additionally encompassed the release of poly(amido amine) 
(PAMAM) dendrimers of differing generation and functionality. Dendrimers of G3 and 
G4 were compared directly and exhibited almost no difference in release properties, as 
their hydrodynamic radii differed only by 0.26nm.294 Surface functionality was shown to 
play an important role in the rate and extent of release of dendrimers however, with 
amine terminated G3 dendrimers being released at a rate of nearly 100% by 6 hours, and 
carboxyl terminated G3 dendrimers only reaching about 70% release in the same time 
period. The difference between the two types of surface functionalization was narrower 
for G4 dendrimers, with carboxyl terminated systems reaching about 85% release and 
amine-terminated G4 reaching the same level as for G3. These observations, coupled 
with a large increase in release rate and extent of carboxyl-terminated dendrimers 
following addition of salt to the system, suggests that amine terminated dendrimers do 
not interact with the SELPs, while carboxyl terminated dendrimers interact with the 
positive charges (likely the lysine groups), slowing their release.
The in vitro bioactivity of therapeutic molecules released from SELPs was also 
evaluated, to examine the impact of interaction with the polymer on the efficacy of the 
released molecules. Pantarin, a genetically engineered mitotoxin,268 was used for the 
bioactivity studies. To conduct the experiments, radioactively labeled Pantarin was 
added to the SELP-47K solution, and allowed the liquid to form a gel. After gelation, the 
polymer was placed in an elution tube and the remaining Pantarin in the hydrogel was
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measured using a gamma counter. The bioactivity of the released Pantarin was assessed 
by analyzing the Pantarin content in the elution sample, and exposing cells to the sample 
or fresh Pantarin. Using these methods, it was shown that Pantarin was stable and 
retained nearly 100% of its bioactivity after release from the SELP hydrogel. These 
results are encouraging as they suggest that delivery via a SELP hydrogel would not 
require an increased dose of therapeutic molecule to compensate for inactivation via 
interaction with the gel.
2.4.3.3.2.11 Biodegradability of SELP hydrogels. It is essential to characterize 
the degradation properties of SELPs if they are to be used as gene and drug delivery 
systems. Degradation of SELP hydrogels in vivo could have significant effects on release 
properties of bioactive agents, as the decreasing gel density will cause further and faster 
release over time. Biodegradation analysis also allows further insight into the potential 
for long-term effects of using the material.
Another aspect of SELP degradability examined the effects of elastase-dependent 
degradation on the release of plasmid DNA from the hydrogels. To assess these effects, 
SELP hydrogels containing plasmid DNA were produced and incubated in the presence 
and absence of elastase, with DNA content periodically measured in the release media. 
278 A substantial effect on DNA release was observed when hydrogels were incubated in 
the presence of elastase compared to an elastase-free control, likely owing to degradation 
of the SELP over time. The effect for SELP-47K was a nearly 30% increase in DNA 
release, while the increase in DNA release from SELP-415K was almost 40%.278 This 
information combined with the structure-dependent degradability data reveal another
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variable which can be manipulated on the molecular level to produce SELPs with desired 
properties.
Swelling ratio is another property of SELP hydrogels which is influenced by 
biodegradation.278 It was shown that after only 24 hours of exposure to elastase, 
significant increase in swelling ratio was observed, and this effect was more profound in 
higher elastin-containing polymers. This suggests that for applications in which 
degradation is favorable, control over elastin content will allow control over degradation 
properties.
2.4.3.3.2.12 Biocompatibility of injected SELPs. The biocompatibility of SELP- 
47K has been investigated by direct injection of liquid polymer to guinea pigs 
subcutaneously and intradermally.268 After rapid gelation, the guinea pigs were closely 
monitored for signs of an immune response, material migration, or excessive irritation. 
Histology was performed on the tissue around and including the injection site to look for 
signs of toxicity, allergy, or inflammation, of which none were found to be significantly 
present. The histology also allowed observations of the nature of the gel mass after 
injection, which showed that the gel tends to either interpenetrate dermal collagen, or 
remain isolated in subcutaneous pockets.268 The only signs of response to the material 
after injection were observed at day 28, when there was some cellular infiltration into the 
outside edges of the gel along with occasional clusters of foreign body giant cells which 
appeared to be associated with SELPs. Notably, even at 28 days postinjection, there were 
no signs of significant, harmful immunological reaction or inflammation.
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2.4.3.3.3 Synthesis and characterization of tyrosine-containing SELPs
Recently, a series of three SELPs with similar molecular weights were 
synthesized with a tyrosine in the guest residue position of one elastin unit per polymer 
repeat.283 These polymers were intended to be used to study the self-assembly properties 
of SELPs. The sequences of the three new SELPs were:
SE8Y: [(GAGAGS)(GVGVP)4 (GYGVP)(GVGVP)3]14 
S2E8Y: [(GAGAGS)i(GVGVP)4(GYGVP)(GVGVP)3]x2 
S4E8Y: [(GAGAGS)4(GVGVP)4(GYGVP)(GVGVP)3]9
Tyrosine was chosen for the guest residue in this case because it caused the transition 
temperature of the elastin block portion of this polymer to be in the physiological range 
and allowed temperature-dependent properties to be investigated, although the tyrosine 
SELPs did not actually demonstrate physiological temperature transitions. For initial 
studies, the polymers were diluted to a concentration of 0.2 mg/ml, then dried on a silicon 
substrate and analyzed under SEM. It was found that the polymers formed globular 
structures which were assumed to be micelles, which had similar sizes between the three 
polymers (60nm, 55nm, and 70nm average radius for polymers SE8Y, S2E8Y, and 
S4E8Y, respectively). The likelihood of micelle formation in this case is rather low, as 
the radii of the formed particles were disproportionately large as compared to their 
molecular weights and therefore their likely single-particle hydrodynamic radii. Further, 
DLS measurements estimated the RH of the polymers to be 4.5nm for SE8Y, about 38nm 
for S2E8Y, and about 68nm for S4E8Y. Based on these results, it is much more likely 
that the observed particles were random agglomerates of many protein strands, the 
assembly of which are structure-dependent. In cases of low silk content, these
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interactions were likely mediated by random hydrophobically-driven self-assembly for 
the elastin units, while increasing silk unit composition shifts to the formation of small P- 
sheet structures randomly associated with neighboring P-sheets or elastin units via 
hydrophobic interactions. The initial application of a low concentration of protein to the 
substrate may have resulted in a single molecule suspension; however, by drying the 
solution, the concentration of the protein increased, thereby resulting in the forced 
interaction of several polymer chains. The fact that this interaction occurred at a 
temperature at which silk blocks are likely to assemble into P-sheet structures supports 
the conclusion that these were random agglomerates. Further experiments presented on 
these polymers showed that two of the polymers possessed a fully reversible temperature 
transition, which began at a temperature of 41°C and completed at about 60°C. These two 
polymers were the SE8Y and the S2E8Y polymers, with the S4E8Y polymer showing 
negligible temperature response even up to 100°C. These results agree with results from 
lysine-containing SELPs (to be discussed) which show temperature dependence of 
hydrogel properties for high elastin:silk ratios, with this effect disappearing as the silk 
content is increased.
2.4.3.4 Noncanonical amino acids
The field of genetically engineered polymers has often taken cues from nature to 
aid in the design of polymer systems, which have lead to significant advances in the 
understanding of self-assembly, protein folding, and other structural insights. 
Unfortunately, working exclusively with the 20 naturally occurring amino acids leaves 
the bioengineer with somewhat of a limited toolbox. The availability of chemistries and
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substitutions on amino acid side chains has been expanded in part due to the advent of 
noncanonical amino acids (NCAAs). NCAAs are introduced by modification of transfer 
RNAs (tRNAs), which are used to assemble proteins based on an mRNA template, in 
addition to selective depletion of tRNAs which are desired to be replaced.238
NCAAs have proven to be very useful to many fields of research. One notable 
example is referred to as bio-orthogonal noncanonical amino acid tagging (BONCAT).295 
This method uses the inducible incorporation of the noncanonical azidohomoalanine that 
provide azide chemistry to proteins following induction, allowing easy separation and 
identification by alkyne affinity chromatography followed by tandem mass spectrometry. 
In the initial publication of this method, 192 proteins synthesized in a 2-hour window by 
HEK293 were tagged and identified.295 This is a very powerful method for studying 
biological processes, as it allows the spatial and temporal identification of protein 
expression in response to environmental stimuli to be studied. Another research tool 
developed using NCAAs is the creation of epidermal growth factor (EGF) with p- 
azidophenylalanine substitution.296 By incorporating this NCAA into EGF, it became 
photoreactive and was bound to glass slides by UV irradiation. The mechanisms of cell 
adhesion for an epidermoid carcinoma cell line were then studied by comparing the 
adhesion of these cells to the EGF-immobilized surface before and after pretreatment 
with soluble EGF.296 Also it was shown that in hepatocytes, the EGF-immobilized 
surface was able to maintain hepatocyte function for 3 days, while soluble EGF 
incubation resulted in no hepatocyte function.296
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2.4.3.5 O ther genetically engineered polymers
Aside from the previously discussed materials, several specifically designed and 
multifunctional recombinant polymers have been reported. One example of this type of 
material is the alanine-rich helical polypeptides, which are composed of repeating 
sequences of alanine, glutamine, and glutamic acid.245, 297 The spacing of the glutamine 
and glutamic acid residues causes these peptides to self-assemble into folded P-sheet 
structures, which associate with one another head-to-head, tail-to-tail causing the 
histidine tags by which the peptides are purified to be adjacent to one another.298 This 
arrangement of peptide chains causes this material to have very interesting properties 
related to their ability to associate with gold nanoparticles specifically at these histidine- 
rich regions, allowing the possibility of creating highly ordered gold nanoparticle
arrays.298
Other interesting materials have been developed by incorporating specific cell 
binding motifs from nature into existing recombinant polymers. One example of this is 
the incorporation of the CS5 binding motif from fibronectin into the sequence of an 
elastinlike polymer.299-301 It was found in these studies that the incorporation of the CS5 
domain promoted HUVEC cell adhesion, spreading, and soluble factor release 
comparable to culture on fibronectin surfaces,299 although when compared to RGD- 
modified polymers, the RGD sequence appeared to perform better.301
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2.5 Silk-elastinlike protein polymers for controlled gene delivery
Due to the favorable release properties of macromolecules from SELP hydrogels, 
these controlled release systems were investigated as potential gene delivery depots. 
Early studies focused on the delivery of naked plasmid DNA from these hydrogels in 
vitro and in vivo, while later studies investigated the release of adenovirus in vitro and in 
vivo.
2.5.1 In vitro gene delivery from SELPs
2.5.1.1 Release of plasmid DNA from SELP hydrogels
As an initial assessment of the utility of SELP hydrogels for gene therapy, the 
ability of these copolymers to deliver plasmid DNA was evaluated, as were the effects of 
DNA size, configuration, concentration, polymer cure time, and ionic strength of the 
release media. Influence of DNA configuration on release was examined for three forms 
of DNA: open circular, supercoiled, and linear. The experiments were performed by 
loading 12 wt% SELP-47K with a known concentration of DNA of a particular form, 
creating gels from the DNA-laden polymer, and incubating in release media of 1X PBS 
with 0.01% sodium azide.274 DNA detection was performed using the PicoGreen reagent. 
It was shown that the linear DNA was most readily released with 30% release after 28 
days, followed by supercoiled (24%) and open circular (~2%). The reasoning behind this 
dramatic decrease in DNA release from linear and supercoiled to open circular is thought 
to be impalement of the ring-shaped DNA on the fibers of the SELP hydrogel, which is 
supported by studies which have shown a similar phenomenon during gel electrophoresis 
of open circular plasmid DNA.274, 302, 303
The effect of the size of plasmids on the rate and extent of release was also 
examined by evaluating release of DNA in the range of 2.6 kbp to 11 kbp from SELP- 
47K hydrogels.274 It was shown that release rate and extent are both highly dependent on 
the size of the DNA, with the 2.6 kbp molecule giving over 30% release over 1 month, 
while the largest molecule, 11 kbp, was less than 5% recovered after a month.274 This is 
to be expected as all of the DNA molecules theoretically would have similar charge and 
therefore similar types of interaction with the SELPs, leaving size as the only determining 
factor for release rate. Larger sizes of DNA would be more impeded in their movement 
through the hydrogel for several reasons, including increased frequency of physical 
interaction with the polymer and the decreased diffusivity of larger molecules compared 
to smaller ones of similar composition and structure.
Another aspect of DNA release studied was the physical environment to which 
the DNA-laden hydrogels were subject. This includes investigation into the effects of 
hydrogel cure time, DNA concentration, and ionic strength of the release medium.273 It 
was shown that the release of pDNA is highly dependent on ionic strength, with nearly 
zero release of DNA from hydrogels in ionic strength 0.10 M or lower, and greatly 
increased (~75%) release from hydrogels in ionic strength of 0.17 M or higher. This is 
explained by an increased incidence of interaction between the DNA and SELP hydrogel 
at ionic strengths which do not provide adequate counterions for shielding interactions 
between protonated primary amine groups on the SELP chain and negatively charged 
phosphate groups on the DNA.273
Other experiments investigated the effects of hydrogel cure time on the release of 
pDNA from SELP-47K. It was observed that for 8 wt% SELP-47K, there was very little
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difference between release rate after 4 hours of cure time vs. 1 hour of cure time, with 
both of the samples reaching approximately 75-80 wt% release after the 1 month 
incubation. This was not the case with the 12 wt% hydrogels, which showed a stronger 
dependence on hydrogel cure time. The 12 wt% gel which was cured for 1 hour had both 
a faster rate and higher quantity of overall release (70%) than did the 12 wt% gel which 
was cured for 4 hours (50% release).273 This is likely due to the decrease in swelling 
ratio and thus pore size observed as a function of cure time in previous studies,284 which 
is likely to impede the release of the large DNA molecules. Along with this experiment, 
the effect of DNA concentration on release was investigated. These studies showed that 
in the range studied, there was no dependence of release rate or extent on the 
concentration of DNA loaded into the hydrogel.273 The bioactivity of pDNA released 
from SELP-47K hydrogel was also examined using an in vitro cell transfection assay.274 
It was shown that there is little or no effect on the bioactivity of released pDNA from the 
hydrogels, as the expression levels for the SELP release samples were very close to those 
observed for DNA incubated in PBS over 1 month.274
2.5.1.2 Release of adenoviruses from SELP hydrogels
A promising application of SELP hydrogels is for controlled spatial and temporal 
delivery of viral carriers for gene therapy. Initial studies on the release of viruses from 
SELP investigated the release of a green fluorescent protein (GFP)-carrying adenovirus 
from SELP-47K hydrogels.274 This experiment was performed by loading virus into 
liquid SELP solution at 4 wt%, 8 wt%, or 12 wt% to a concentration of 6x105 plaque 
forming units (PFU)/50^l. SELP-47K was allowed to cure for 4 hours at 37°C, then cut
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into cylindrical disks of 50^l each. Gels were placed into 1ml of release media (PBS) 
and agitated for 29 days in a shaking incubator. At days 1, 8, 15, 22, and 29, the release 
media was removed and an aliquot was used to transfect HEK-293 cells. The results of 
this study showed a very strong dependence of release on polymer concentration, with 4 
wt% polymer showing release for 22 days, 8 wt% releasing over 15 days, and 11.3 wt% 
polymer showing virtually no release. While these studies were not quantitative, they 
illustrated the importance of polymer concentration on controlled viral release from 
SELP hydrogels.
Another study on the release of adenoviruses from SELPs was performed in a 
similar manner, but used a much higher concentration of virus (1x109PFU) and RT-PCR 
to quantify release.157 Controlled release was observed over 28 days from SELP-47K at 6 
wt% for the standard 50 ^l gel, and steady linear release for 4 wt% SELP as a 100 ^l gel. 
These results indicated that SELP-47K can effectively control the location and duration 
of transfection when used as a delivery system for adenoviruses. This study also 
investigated the bioactivity of the released viruses. It was shown that, while the number 
of released viruses could be controlled using SELP matrices, there appeared to be a 30­
40% reduction in virus infectivity after incubation in SELPs.157 It was hypothesized that 
this reduction in infectivity was due to inactivation of the virus by media components, 
specifically fetal bovine serum.
A study was performed to compare the characteristics of adenovirus release from 
SELP-47K and SELP-415K.277 As expected, SELP-415K showed much higher rates of 
release than did an equivalent concentration of SELP-47K, most likely due to the increase 
in the length of the elastin blocks of SELP-415K compared to SELP-47K. The results of
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this study indicate a structure dependence for release of adenovirus particles which shows 
that either higher lengths of the elastin blocks or a lower silk:elastin ratio in SELPs 
contribute to higher release rates and more complete release of viral load from the 
hydrogels. It is the manipulation of these two parameters which allows the release 
characteristics of SELPs to be fine-tuned for the delivery of specific therapeutic agents, 
including adenoviruses.
2.5.2 Silk-elastinlike polymers for gene delivery in vivo 
The in vitro characterizations performed on SELPs and their ability to control the 
release of therapeutic agents yielded important information regarding not only the 
characteristics of the polymer itself, but also the changes in these characteristics resulting 
from manipulations of the polymer. It is also extremely important to evaluate the safety 
and biocompatibility of these polymers, as failure in this area can hamper their clinical 
translation for gene delivery. Finally, the efficacy of the polymer-virus approach needs 
to be evaluated in a disease state to clarify whether or not the level of control exercised 
on bioactive agent release is sufficient to give therapeutic effect with minimal adverse 
effects.
2.5.2.1 Release of luciferase -  encoding pDNA from SELP hydrogels
In order to evaluate the ability of SELP polymer to effectively control the release 
of plasmid DNA, a study was performed using a reporter gene (renilla luciferase) to 
attempt to locally transfect a MDA-MB-435 tumor xenograft in athymic nude mice.274 
The studies were performed by first injecting the mice with a concentrated cell solution
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containing 1e6 cells in 100^l of Hank’s Balanced Salt Solution. Tumors were allowed to 
grow until they reached a size of ~8mm, after which they were injected with 100^l of 
polymer 47K with pDNA encoding for r. luciferase. At days 3, 7, 14, 21, and 28, animals 
were euthanized and the tumors were resected along with the area of skin immediately 
surrounding the tumor for analysis of luciferase expression. It was found that in the 
earlier time points, there was a large difference between the luciferase expression in the 
tumor vs. the skin for the hydrogel-mediated delivery cohort, while there was very little 
difference between transfection in the tumor and transfection in the skin around the 
tumor. As the study moved further along, however, this difference diminished and the 
hydrogel showed reduced benefit beyond 7 days postinjection for most formulations. 
These results show that SELP is able to localize the release of pDNA over the period of 
approximately 1 week, after which point the intratumoral expression levels become more 
similar to the expression levels in the skin. While a longer period of localized transfection 
would be desirable, these results are positive in that localized, controlled delivery was 
observed. For pDNA delivery applications, it would be desirable to manipulate the 
polymer formulation to control the location of the transfection for longer than 1 week.
2.5.2.2 Biodistribution of released adenoviral particles
The main motivation behind delivering adenoviruses using SELPs is twofold. 
First, controlled delivery of therapeutics inside a tumor will likely improve efficacy, as 
more drug is likely to reach the target cells than systemic administration and uncontrolled 
intratumoral injection Second, by controlling distribution, some of the major 
toxicological concerns with viral delivery can be reduced, as high titers of adenovirus
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throughout the body can cause massive immunological problems and possibly death.104 
Off-target distribution of virus also is likely to cause hepatotoxicity due to both the high 
concentration of coxsackie and adenovirus receptors (CAR) and the high level of 
vascularization in the liver. A series of experiments were performed in order to compare 
the ability of SELPs to free viral injection in terms of increased transfection in a 
xenograft tumor and reduced distribution of virus to the liver. The initial transfection 
study was performed using tumor xenografts of MB-435 and FaDu cells.157 The reporter 
gene used for these studies was GFP. Ad-GFP was injected into the tumors in 50^l of 
SELP-47K at a concentration of 5x10 PFU. The results showed that there was, in fact, 
GFP expression in both types of tumors, although the MDA-MB-435 tumor showed more 
even distribution of transfection than did the FaDu tumors, due to preexisting barriers 
within the FaDu tumors. It was also shown that the expression of GFP lasted for 
approximately 11 days at a high level, after which expression depleted in the bulk of the 
tumor tissue and was localized around the injection site. It was hypothesized that this 
reduction in expression level was due to either entrapment of virus particles, release of 
particles into the bloodstream and eventual degradation by the liver, or virus inactivation 
by the mouse’s humoral immune system.
2.5.2.3 Efficacy of SELP-mediated adenoviral gene therapy
SELP’s application as a gene delivery system for the treatment of cancer faces 
several challenges. While the structure and physicochemical properties of the polymer 
will influence its release characteristics, a perhaps more important aspect of this 
treatment’s efficacy is the choice of therapeutic virus. The least traumatic and lowest-risk
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application of SELP would be in a cancer which is readily accessible by needle without 
having to surgically open the patient to access the affected site. Additionally, the 
cancerous cells would be most vulnerable to the type of treatment being proposed if they 
expressed high levels of CAR receptor, as this would encourage rapid uptake of the 
viruses, leading to higher cell death. HNSCC is located in a very accessible area of the 
body, allowing simple injection of SELP directly into the tumor mass. Additionally, 
HNSCC cells have high CAR receptor density,114 making them vulnerable to this type of 
treatment. For these reasons, combined with the significantly high incidence and low 5- 
year survival rate of this cancer, HNSCC was determined to be a viable and worthwhile 
target for SELP-mediated gene therapy. For in vivo studies on the efficacy of this 
treatment, a variety of different approaches were necessary due to the lack of a long-term 
immunocompetent HNSCC model which does not violate standards for animal treatment. 
In order to develop a comprehensive assessment of the efficacy of SELP-mediated gene 
therapy in the treatment of HNSCC, an initial efficacy study was performed using human 
xenograft tumors in nude mice, followed by mouse fibrosarcoma S-180 tumors grown in 
immunocompetent CD-1 mice.
Several cell lines were evaluated for the human xenograft study due to concerns 
about the effects of CAR receptor density on the ability of the adenoviruses to gain 
entrance into the target cells.114 Two primary HNSCC cell lines, JHU-012 and JHU-022, 
which are isolated from the oral cavity and larynx, respectively, and a third cell line FaDu 
sourced from the pharynx of an HNSCC patient were used. It was shown that CAR 
density increases in the order of FaDu, JHU-012, JHU-022, and preliminary studies were 
performed on xenografts of each of these tumors. JHU-022 xenografts were chosen due
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to their growth rate and ease to scale up in culture, in addition to their high CAR density. 
However, in experiments investigating the distribution and intensity of gene expression, 
it was observed that JHU-012 and JHU-022 showed very comparable intratumoral 
transfection levels. The reasons for this are currently under investigation; however, 
results are indicating that the density of the tumor’s extracellular matrix has an important 
effect on the susceptibility of the tumor to high transfection levels.
2.6 Conclusions
The use of recombinant polymers for gene therapy is at very early stages. The 
high degree of control over polymer sequence and length enables precise correlation of 
polymer structure with function. This has profound implications in both systemic and 
matrix-mediated gene therapy. In the context of matrix-mediated gene therapy, function 
of the polymeric network relates to gelation, mechanical properties, release, transfection, 
efficacy, degradation, elimination, and biocompatibility of the polymers. As discussed 
above, it has been shown that recombinant SELPs can be precisely tailor-made to control 
gelation time, mechanical strength, adenoviral and plasmid DNA release, temporal and 
spatial transfection, degradation, and efficacy in murine tumor models. In order for 
matrix-mediated viral gene therapy to become a viable treatment option however, it is 
essential that the safety and efficacy of such systems be further improved. It is imperative 
that a delivery strategy be found which can fully take advantage of the high transfection 
efficiency of viruses; however, this must be done in a manner which does not cause 
unreasonably high toxicity or inflammatory response to the viral vector. The role of the
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immune response to the SELP/adenoviral system as related to antitumor efficacy and safety 
will need further detailed examination in animal models with intact immune functions. 
Although SELPs show promise in improving both the safety and efficacy of adenoviral 
gene delivery, the hydrogels that were studied to-date were not completely degraded over 
the desired period of time. Hence, incorporation of additional motifs in the polymer 
backbone that further facilitate degradation of the hydrogels in the tumor environment is 
essential. Engineering degradable sequences or sequences which will increase the 
effective pore size of SELP hydrogels can improve release and allow more rapid 
degradation and elimination of the polymers following treatment.
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CHAPTER 3
SILK-ELASTINLIKE RECOMBINANT POLYMERS FOR 
GENE THERAPY OF HEAD AND NECK CANCER:
FROM MOLECULAR DEFINITION TO 
CONTROLLED GENE EXPRESSION
3.1 Introduction
The analysis of the performance of SELP hydrogels as adenoviral delivery materials 
in vivo is a necessary next step towards the evaluation of this gene delivery system as a 
clinically viable treatment for HNSCC. The systemic variation of structure in SELPs 
allows their evaluation as a highly tunable matrix in the context of gene delivery, and will 
additionally allow the identification of which construct of SELP is best suited for 
intratumoral delivery of adenoviral vectors. Further, in order to investigate the ability of 
SELP to protect nontarget tissues from adenoviral transfection, hepatic expression levels 
of reporter adenovirus needs to be evaluated. The liver is specifically targeted as it is the 
most common site of off-target adenoviral infection.1 This is due primarily to interaction 
with coagulation factor IX and complement factor C4 binding protein, and interaction 
with CAR, although the lack of correlation between CAR expression and tissue tropism 
in vivo combined with similar in vivo expression patterns between CAR-binding and
nonbinding adenovirus4, 5 suggests that CAR plays a more diminished role than 
previously thought when adenovirus is administered in vivo.
Based on the in vitro and in vivo results for adenoviral release from SELP 
hydrogels, studies were designed to investigate the structure-dependence of adenoviral 
delivery from SELPs. Adenovirus carrying the reporter gene LacZ, encoding for P- 
galactosidase, was injected into JHU-022 tumors growing on the flanks of nude mice. 
The viruses were suspended in either 0.9% injection saline or SELP solution, which was 
either SELP-47K, SELP-415K, or SELP-815K, and was additionally diluted to varying 
concentrations. Upon completion of each time point (1, 2, or 3 weeks) the animals were 
sacrificed, and the tumors and livers were removed and assayed for P-gal content. 
Further, histological staining for P-gal was performed on some tumor tissue from each 
time point. In order to support these studies, a parallel study was performed using a 
luciferase reporter adenovirus. Virus was injected into induced JHU-022 tumors in the 
flanks of nude mice, but instead of evaluating P-gal colorimetrically, luciferase 
expression was evaluated by luminescent imaging, which was performed every 3-4 days. 
Further work performed in this study investigated the degradability of SELP-815K by 
human leukocyte elastase, which was incubated with SELP hydrogels of different 
structure and concentration. Degradation was evaluated by bicinchoninic acid (BCA) 
assay performed on the 0.9% saline release medium, allowing quantification of released 
protein.
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3.2 M aterials and methods
3.2.1 Materials
SELP-47K was obtained from Protein Polymer Technologies, Inc. (San Diego, 
CA, USA). Linear SELP-415K 6 and -815K 7 were biosynthesized and characterized as 
described previously. Replication defective human adenoviruses (Ad) Type 5 with 
E1/E3 deletion, under the control of the CMV promoter, encoding for either P- 
galactosidase (P-gal) or firefly luciferase (Luc) reporter genes were purchased from 
Vector Biolabs (Philadelphia, PA, USA). JHU-022 oral cavity cancer cell line was a 
kind gift from Professor David Sidransky of Johns Hopkins University (Baltimore, MD, 
USA). Human Leukocyte Elastase was purchased from Elastin Products Company 
(Owensville, MO) and solubilized in Phosphate Buffered Saline (Sigma Aldrich, St. 
Louis, MO). Bicinchoninic acid protein assay was purchased from Thermo Scientific 
(Waltham, MA, USA) and the optical density (OD) measurements were performed using 
the SpectraMax M2 micro plate reader from Molecular Devices (Sunny Vale, CA, USA) 
coupled with a Softmax analytic software package. For bioluminescent imaging studies, 
luciferin was obtained from Gold Biotech (St. Louis, MO, USA). Animals were 
evaluated for luciferase expression using a Xenogen IVIS100 bioluminescent imaging 
system from Caliper Life Sciences (Hopkinton, MA, USA) coupled with analytical 
software, Igor PRO v.2.2.0, Wavemetrics Inc. (Lake Oswego, OR, USA). For 
establishing xenografts JHU-022 cells were cultured in Advanced Roswell Park 
Memorial Institute (RPMI 1640) medium containing 2mM L-Glutamine and 10% fetal 
calf serum (Gibco, Carlsbad, CA, USA). Chlorophenol Red-P-D-Galactopyranoside 
(CPRG) P-gal quantitative kit was purchased from Imgenex (San Diego, CA, USA). P-
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Galactosidase Reporter Gene Staining Kit was purchased from Sigma-Aldrich, Inc. (St. 
Louis, MO, USA ). Luciferase assay system was purchased from Promega (Madison, 
WI, USA). Six-week-old female athymic (nu/nu) mice were purchased from Charles 
River Laboratories (Davis, CA, USA) and were used for the animal studies in 
accordance with the Institutional Animal Care and Use Committee (IACUC) protocol of 
the University of Utah.
3.2.2 Quantitative evaluation of viral gene expression in vivo 
Head and neck cancer xenografts were established by subcutaneously injecting 
2x106 JHU-022 cells suspended in 200 ul Phosphate Buffer Saline (PBS) bilaterally in 
the flank of athymic nude (nu/nu) mice. Tumors were allowed to grow for 2 weeks to 
reach an average diameter of 7 mm. A dose of 5x10 PFU of Ad-CMV-LacZ was 
administered to mice with SELP-415K (10.8 wt%), SELP-47K (8 wt% and 10.8 wt%), 
SELP-815K (4 wt%, 8 wt%, and 10.8 wt%), or physiological saline. Virus-polymer 
solutions were prepared by thawing SELP and virus stocks and mixing them gently with 
physiological saline. Mice were anesthetized using 4 wt% isofluorane mixed with 
oxygen, and intratumorally injected with 25^l of the polymer-virus solutions using a 
Hamilton syringe. On day 7, 14, and 21, mice were euthanized and tumor and liver 
tissue were isolated. CPRG P-gal colorimetric assay was performed as described 
previously. Briefly, fresh tissue samples from the tumor and liver of animals were 
collected, snap-frozen in liquid nitrogen, ground with mortar and pestle, resuspended in 
1 mL lysis buffer (50 mM HEPES, 5 mM CHAPS, pH 7.4) followed by sonication on 
ice in 10-15 second bursts for a total of 1 minute. Recovered tissue lysates were then
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centrifuged for 45 minutes at 14,000 rpm and subsequently, upper aqueous layers were 
used for P-gal quantification. Colorimetric assays were then performed as outlined in the 
protocol provided with the kit. The optical density (OD) dynamic study was performed 
to assay the enzyme substrate kinetics, and time point of measurements were set at 40 
minutes for tumor P-gal expression and 110 minutes for liver expression which represent 
the time points of peak interactions, respectively.
3.2.3 Tumor histology 
For spatial distribution of P-gal in tumors, tissues were cryo-sectioned at 5 ^m 
and stained with a P-gal reporter gene staining kit. Kit manufacturer instructions were 
modified as follows: tissue sections were fixed for 3 minutes in fixation buffer, and then 
rinsed twice with PBS. Fixed sections were then stained with staining solution for 24 
hours at 37o C, rinsed with PBS, and observed under light microscope. X-Gal stains P- 
galactosidase expressing cells and tissue areas dark blue.
3.2.4 Bioluminescence imaging of gene expression in vivo 
Bioluminescent imaging was used as a secondary method of assessment of 
spatial control over gene expression in JHU-022 tumor-bearing athymic nu/nu mice as 
established above. Tumors were then injected with 25 ^l of SELP-415K (10.8 wt%), 
SELP-47K (4 wt%, 8 wt%, and 10.8 wt%), SELP-815K (4 wt%, 8 wt%, and 10.8 wt%) 
or physiological saline containing 5x10 PFU of Ad.CMV.Luc. Imaging was performed 
on days 4, 7, 10, 14, and 21 by injection with 200 ^l of 15 mg/ml luciferin
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intraperitoneally. Luminescence was imaged after 30 minutes, using Xenogen IVIS100, 
and images were analyzed using IgorPRO v.2.2.0.
3.2.5 In vitro assessment of hydrogel degradation 
50|il SELP hydrogels were made by drawing 250|il of 12 wt% SELP-47K, 
SELP-415K, and SELP-815K, and 8 wt% SELP-815K solutions into separate 1 ml 
syringes. Syringes were placed in a 37°C incubator and allowed to gel for 24 hours. 
After incubation, the end was cut off of each syringe and 50 ^l gel disks were cut from 
the 250 |il cylinder. These gels were placed in the inner wells of a 48-well plate 
containing 800 ^l of PBS + elastase, with a 1:6 dilution curve of elastase starting at 1000 
ng/ml. The empty wells of the plate were filled with 1.5 ml PBS to control evaporation, 
and then the plates were sealed with self-adhesive sealing foil and agitated at 120 RPM. 
At each time point (1, 3, 7, 10, 14, 17, 21, 24, and 28 days) the full sample volume of 
800 |il was removed from each well, placed in a separate 1.5 ml microcentrifuge tube, 
and stored at -80°C. In order to assess the degradation of the SELPs, the micro BCA 
protein assay was used according to manufacturer’s instructions to measure the soluble 
protein for each sample, followed by measuring absorbance at 561 nm.
3.2.6 Statistical analysis 
The results of the quantitative evaluation of viral gene expression in vivo and 
comparative degradation rate in vitro are expressed as the mean ± SE. Student’s T test 
was used to analyze the significance of difference in reporter gene expression in 
different SELP treatment groups compared to plain Ad-LacZ treatment, and to analyze
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the significance of SELP structure’s influence on degradation rate. P values of < 0.05 
were indicative of statistically significant differences.
3.3 Results and discussion
3.3.1 Spatio-temporal control of gene expression as a function 
of polymer structure
Selective delivery of a sufficient number of therapeutic gene copies to cancer 
cells remains a challenge in gene therapy. Current data from clinical trials using 
adenoviral vectors for gene delivery show that acute liver toxicity and immunogenicity 
are the major adverse effects limiting the dose of adenovirus that can be given to the
2, 9patients. These challenges indicate the need for tailor-making polymeric systems that 
can limit delivery of adenoviruses to solid tumors, prolong gene expression, and that are 
degraded and eliminated from the body over a specified period of time. In this study, we 
compared the duration and extent of gene expression in head and neck tumors when 
adenoviruses were delivered from hydrogels made from three SELP analogs. These 
polymers (Figure 1.1) were produced by recombinant techniques such that molecular 
weight of each linear chain remained constant while the sequence of silk and elastin 
repeats within each chain varied.6, 7, 10 SELP-47K has 8 elastin units less in each 
monomer repeat than SELP-415K (Figure 1.1). As the temperature is raised, silk units 
hydrogen bond and elastin units self-assemble, forming hydrogels. At equivalent 
polymer concentrations, SELP-47K forms more robust hydrogels than SELP-415K, as 
evidenced previously by a lower degree of swelling and higher mechanical strength. 
SELP-815K has a higher number of silk units per monomer repeat compared to SELP-
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415K (Figure 1.1). At equivalent polymer concentrations, we had previously observed 
that hydrogels made from SELP-815K have intermediate degrees of swelling and 
storage moduli between SELP-47K and SELP-415K.7 This is despite the fact that SELP- 
815K has a similar ratio of silk to elastin units compared to SELP-47K, providing 
evidence that in addition to the ratio of silk and elastin units, the sequence of these units 
in the polymer chain influences the physicochemical properties of the resulting 
hydrogels. We had also observed previously that polymer concentration influences the 
network properties of SELP hydrogels where a lower polymer concentration resulted in 
increased degree of swelling and release of bioactive agents.6, 7, 11-13 Based on these 
observations, we hypothesized that by controlling both polymer structure and 
concentration, the location and duration of gene expression can be controlled when 
adenoviruses are delivered by SELPs to head and neck tumors.
Lac Z gene expression after co-injection of adenoviral vectors with each SELP 
structure and as a function of polymer concentration was evaluated in tumor and liver 
tissues of mice. Strong dependence of structure and concentration effect on gene 
expression was evident in terms of transfection levels and duration of gene expression 
(Figures 3.1-3.3). The results of the enzymatic assay in tumor lysates (Figure 3.1) show 
that SELP-815K at 4 wt% exhibits the highest transfection levels at all time points, with 
a greater than 10-fold increase of transfection over free virus after 1 week and 6-fold 
increase at 2 weeks. As the concentration of SELP-815K increased from 4 wt% to 8 
wt% and 10.8 wt%, transfection levels decreased for the duration of study. The 
increased concentration leads to increased crosslinking density of hydrogel network, 
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Figure 3.2: SELP-structure dependence of hepatic beta-galactosidase expression
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Figure 3.3: Ratio of intratumoral to hepatic beta galactosidase expression
mediated adenoviral delivery from SELP-47K hydrogels resulted in a lower transfection 
efficiency than delivery with SELP-815K polymers at equivalent polymer 
concentrations. Compared to SELP-815K, SELP-47K has shorter elastin segments 
between the silk crosslink points, leading to lower pore size and virus release.
Due to longer elastin units, the loose network of SELP-415K can only form 
stable hydrogels at the higher concentration of 10.8 wt%.6, 14 At this concentration, 
higher transfection levels were observed compared to the virus-only group, 
demonstrating that some virus was trapped in the hydrogel network that influenced 
release. However, lower transfection was observed compared to other polymeric 
analogs, demonstrating that increased silk units in more robust gels made from SELP- 
47K and -815K prolong release of adenoviruses in vivo. In the case of plain Ad-LacZ 
injection, burst-release out of the tumor tissue is the most plausible explanation in which 
the bulk of the virus was released over the first week following injection, and was 
cleared before significant transfection could take place at week 1 and beyond.
The utility of SELP matrices in limiting virus distribution into the liver was 
evaluated at various polymer structures and concentrations. No significant differences in 
liver expression were observed for SELP polymers compared to free virus (Figure 3.2). 
However, when considering the tumor / liver ratio of gene expression, SELP-815K at 4 
wt% exhibited 55-fold higher tumor expression than liver (Figure 3.3). In the case of 
plain viral injection, the highest tumor / liver expression ratio was only 5-fold. Clearly, 
SELP hydrogels localize gene expression to tumors and can augment the dose of 
adenoviruses that can be delivered up to 11 times for the same liver distribution as that 
of free viral injection. The spatial and temporal patterns of P-galactosidase expression in
146
SELP-415K, -815K, and plain virus treatment groups were evaluated by staining with 
X-gal of both tumor and liver tissues (Figure 3.4A-F). The observed patterns of gene 
expression in these tissues were in good agreement with the transfection data. In the 
SELP-415K group (Figure 3.4A,B), expression was apparent throughout the tissue, 
although in a lighter intensity than in the more localized and intense SELP-815K group 
(Figure 3.4C,D). The virus only group also had a high area of expression with a less 
dense staining (Figure 3.4E,F). Expression patterns in the SELP-415K and SELP-815K 
tumors showed prolonged expression through week 3 (Figure 3.4B,D), whereas 
expression in the virus only group was undetectable by week 3 (Figure 3.4F).
3.3.2 Bioluminescent imaging of SELP-mediated gene expression 
Bioluminescent imaging of live tumor-bearing animals allows gene expression to 
be monitored in the same animal over the study period without the need to sacrifice the 
mouse for analysis. Unfortunately, issues with light attenuation, scattering, and 
reflection reduce the value of this technique for quantitative measurement. In this study, 
both methods were used to provide a more comprehensive assessment of gene 
expression by SELP-mediated delivery of adenoviruses to head and neck tumors. 
Representative images are shown in Figures 3.5-3.10. Figure 3.5-3.7 show postinjection
4, 14, and 21 days, respectively, of the SELP-815K 4 wt%+Ad.CMV.Luc group. Each 
animal expresses luciferase in the tumor at day 4, and that expression continues for all 
animals up to day 14. The two patches of expression anterior to the tumor in Figure 3.6 
and 3.7 are due to liver expression, which appeared in only one animal in each group 






















Figure 3.4: Histological analysis of beta galactosidase expression.
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Figure 3.6: Bioluminescent imaging for SELP-815K 4 wt%+Ad.CMV.Luc Day 14
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Figure 3.7: Bioluminescent imaging for SELP-815K 4 wt%+Ad.CMV.Luc day 21
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Figure 3.8: Bioluminescent imaging for Ad.CMV.Luc day 4
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Figure 3.9: Bioluminescent imaging for Ad.CMV.Luc Day 14
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Figure 3.10: Bioluminescent imaging for Ad.CMV.Luc day 21
luciferase at day 4 (Figure 3.8). At day 21 (Figure 3.7), there is still tumor expression 
in all but one animal in the SELP-mediated group, illustrating the ability of SELP to 
prolong gene expression compared to free virus injection at the same time point, which 
shows only one animal with appreciable expression starting on day 14 (Figure 3.9). The 
bioluminescent images of gene expression correlate with the data acquired through 
enzyme assay and confirm the influence of SELP on controlling gene expression, which 
would likely improve the efficacy of treatment of head and neck cancer with a 
virus/prodrug system. Additionally, based on these results, SELP could improve the 
safety of this treatment, as SELP causes lower cumulative transfection in the liver, the
2 9primary organ affected by adenovirus toxicity.
3.3.3 In vitro enzymatic degradation of SELP hydrogels 
To successfully develop SELPs for matrix-mediated delivery, the biodegradation 
of these polymers needs to be studied. An ideal matrix is one that prolongs gene 
expression and degrades to amino acids for elimination from the body after gene 
delivery. The structure of the linear SELPs influences their degradation rate. We 
evaluated in vitro the influence of elastase concentration, polymer structure, and 
polymer concentration on degradation of the hydrogels. Degradation was measured as 
percent protein loss from the hydrogels. Protein loss is a function of release of soluble 
proteins that do not participate in the polymer network. An increase in degradation 
results in increased protein release. Figure 3.11 shows the time-dependent protein 
release of SELP hydrogels in a solution of human leukocyte elastase. Figure 3.12 shows
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Figure 3.11: Protein loss over time from SELPs degraded by human leukocyte elastase
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Figure 3.12: Total protein loss due to elastase degradation as a function of SELP 
composition and elastase concentration
a concentration-dependence of degradation with degradation increasing with increasing 
elastase concentration. After 1 month of incubation, SELP-47K 12 wt% and SELP- 
415K 12 wt% each lost more than 10% of their total weight, while SELP-815K at 12 
wt% lost 6.1% of its weight and SELP-815K 8 wt % lost 7.5% of its weight in 1 ^g/ml 
elastase. In 285 ng/ml elastase, SELP-47K 12 wt% lost only 3.6%, SELP-415K 12 wt% 
lost 3.2%, and SELP-815 12% and 8 wt % lost 2.6% and 3.5%, respectively. These 
results show that, in general, SELPs with lower numbers of silk units degrade faster than 
SELPs with higher numbers of silk units. This is likely due to a combination of two 
factors: presence of less elastin units causes less degradation, and hydrogels with more 
silk units have a higher crosslinking density, leading to potentially less diffusion of the 
enzyme in the matrix and subsequent degradation. Pore size of the hydrogels is likely to 
influence the diffusion of elastase molecules which are around 25kDa. The differences 
in protein mass loss are due to differences in the three-dimensional network of the 
hydrogels. The longer silk units potentially form a more extensive network which can 
contribute to steric hindrance and hence physically shield the more degradation- 
susceptible elastin units, causing SELP-815K to degrade more slowly than both SELP- 
47K and SELP-415K. Similarly, the higher crosslinking of SELP-815K at 12 wt% 
results in a lower degradation rate.
In assessing the elastase-driven degradation of SELP hydrogels, another 
important parameter is the concentration of the enzyme in the media. An increase in 
concentration of elastase led to increased degradation of the hydrogels. This effect was 
more pronounced for hydrogels SELP-47K and SELP-415K where at the lower 
concentrations of 285 ng/ml, protein loss was minimal and similar or equal to the base
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line loss of soluble fraction of the hydrogels. The differences in degradation and protein 
release from SELP hydrogels play an important role in the selection of appropriate 
structures for matrix-mediated gene delivery. The next logical step is to investigate the 
degradation of SELP hydrogels in vivo to help further understand the rate of SELP 
degradation in solid tumors and correlate polymer structure with in vivo degradation, 
gene release, transfection efficiency, and therapeutic efficacy.
3.4 Conclusions
The studies in this chapter demonstrate the utility of silk-elastinlike protein 
polymers in matrix-mediated gene delivery to head and neck solid tumors. By using 
genetic engineering techniques it is possible to tailor-make the structure of the hydrogels 
to control gel formation, mechanical properties, release, in vivo transfection, and 
degradation. In the series studied, viruses released from SELP-815K at 4 wt% polymer 
concentration showed the highest transfection efficiency and prolonged gene expression 
up to day 21. These hydrogels also minimized dissemination of the viruses to the liver. 
Future studies will be focused on investigating how the enhanced localization of 
adenoviral transfection offered by SELP-815K 4 wt% translates to reduced toxicity of 
therapeutic adenovirus.
The degradation of SELP was shown to be structurally dependent. At equivalent 
concentrations of polymers and elastase, degradation rate of SELP-815K was lower than 
SELP-415K and SELP-47K. Further work on the degradative properties of SELP will 
focus on other HNSCC-relevant enzymes, such as MMP-2 and MMP-9 which are 
commonly found in HNSCC and used as prognostic biomarkers.15’ 16
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CHAPTER 4
SILK-ELASTINLIKE HYDROGEL IMPROVES THE SAFETY 
OF ADENOVIRUS-MEDIATED GENE-DIRECTED 
ENZYME-PRODRUG THERAPY
4.1 Introduction
In spite of its superior transfection efficiency, the application of adenoviruses as 
gene delivery vectors has been plagued with problems of toxicity which have delayed 
their advancement to clinical use, as previously mentioned in Section 2.2.2.2.1. Based on 
the results discussed in Chapter 3, delivery of adenoviruses in SELP hydrogel 
significantly improves the distribution profile of gene transfection; however, it is also 
necessary for a successful adenoviral delivery material to improve the safety of this 
treatment.
One way of achieving this goal would be to surface-modify or package the viruses 
such that they do not activate the immune system, which would require surface antigen 
molecules to be modified or covered to avoid detection. This approach has previously
1 2, 3been attempted by conjugation of HPMA copolymers or poly(ethylene glycol) (PEG) ’ 
for disguising of adenovirus from detection and neutralization by host immune system. 
These approaches do accomplish the goal of reducing neutralization of the viral particles 
by various mechanisms, and in the case of HPMA copolymers actually affect an increase
in uptake by cells.1 However, reduced immunogenicity comes at a cost of reduced 
efficacy of gene transduction. PEG showed similar results in vitro, almost completely 
eliminating transfection of cells in a coxsackie and adenovirus receptor (CAR)-dependent 
manner. It is important to note that some organ-specific gene transduction is unaffected
2 3or even aided by surface functionalization of the viruses. However, this will not be 
appropriate for most applications of gene therapy, as it is a result of interactions with the 
surface hexon proteins with specific blood components (primarily clotting factors), 
leading to increased uptake by the liver.4, 5 In terms of CAR-dependent transfection, 
surface functionalization thus far appears to completely ablate transfection.
Delivery of the viruses in a noninterfering depot such as SELP hydrogel may 
share the benefits of these systems by reducing the off-target distribution of adenovirus 
and thereby reducing its toxicity. The experiments described in this chapter investigate 
the ability of SELP hydrogel to perform this function. The specific enzyme-prodrug 
model therapeutic system under investigation is the herpes simplex virus thymidine 
kinase (HSVtk) -  ganciclovir (GCV) system, discussed in Section 2.2.1.1 (Figure 2.1). In 
this enzyme-prodrug system, cells are transfected to produce HSVtk, which enables the 
cell to metabolize GCV to produce GCV-monophosphate.6"9 GCV otherwise has a very 
low affinity for nonviral thymidine kinases, and therefore causes little to no conversion in
7-9cells not expressing HSVtk. ~ GCV-monophosphate can freely pass between cells via 
cell-cell junctions, and additionally can be further phosphorylated by native cellular
7-9kinases to produce GCV-triphosphate. ~ GCV-triphosphate is a potent inhibitor of DNA 
elongation by competing with guanosine for incorporation while significantly slowing the 
elongation of DNA, resulting in apoptotic cell death.
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4.2 Materials and methods
4.2.1 Adenoviruses
Human adenovirus serotype 5 encoding for herpes simplex virus thymidine kinase 
(Ad.HSVtk) was purchased from Vector Biolabs (Philadelphia, PA) and used at a viral 
titer of 1.5x10!1 PFU/ml. Viruses were stored at -80°C and used immediately following 
defrosting to avoid unnecessary freeze-thaw cycles.
4.2.2 Animals
All animal studies were carried out with the permission and under the rules and 
guidelines of the University of Utah Institutional Animal Care and Use Committee. All 
mice used in this study were 4-6-week-old female standard CD-1 mice, purchased from 
Charles River Laboratories (Boston, MA). CD-1 mice have an intact immune system, 
which was anticipated to show adverse reactions to the viral vectors comparable to those 
observed in human trials. Mouse cages and bedding were changed weekly and food and 
water was checked and replenished daily as needed.
4.2.3 Injection of therapeutic Ad.HSVtk
For the toxicity studies, Ad.HSVtk was prepared by dilution in either sterile 0.9% 
physiological saline for injection (Baxter, Deerfield, IL) or SELP-815K which was 
previously synthesized10 to a final concentration of 1.5x1011 PFU of virus per ml of 
solution. SELP-815K was used at a final concentration of 4 wt%, determined to be the 
leading candidate, as described in Chapter 311 and for improvement of virus-mediated 
GDEPT described in previous studies.12 Mice were anesthetized and maintained in
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anesthesia with 3% isofluorane in oxygen. After shaving and cleaning the injection site 
with 60% isopropanol, mice were subcutaneously injected with 50^l of solution in the 
right flank via a 26G needle on a 250^l Hamilton syringe. This resulted in an actual viral 
titer of ~7.6x109 PFU administered per mouse. The injection site was gently clamped for 
10 seconds to prevent leakage, after which mice were returned to their cages. For 
consistency, the day of viral injection was considered day 0. The exact conditions 
administered are shown in Table 4.1.
4.2.4 Injection of ganciclovir (GCV)
For treatment groups, a suspension of 1mg GCV (Sigma Aldrich, St. Louis, MO) 
per milliliter of 0.9% physiological saline was prepared and sterilized through a 0.22 ^m 
filter. Each day, animal weights were recorded, injection sites cleaned with 60% 
isopropanol, and mice injected i.p. with 1mg/ml GCV suspension through a 26G needle 
sufficient for a total dose of 25 mg/kg. Average dosing volume for these studies was 
approximately 0.6 ml. Mice were injected daily for the first 4 weeks of the 12 week 
recovery study, and for the entirety of the 1-, 2-, and 4-week studies.
4.2.5 Necropsy and data collection 
Upon completion of each study, mice were individually euthanized using 70% 
CO2 in oxygen, with euthanasia confirmed by lack of breathing for 10s. Blood was taken 
via inferior vena cava stick, and drawn into a heparinized syringe through a 25G needle 
and deposited into a heparinized plastic blood tube. Minimal evidence of hemolysis was 




Animals per study group and end points for toxicity studies
Group 1 week 2 weeks 4 weeks 12 weeks
Control (saline only) 3 9 9 3
Ad.HSVtk+GCV 4 9 9 4
SELP-815K 4% + 4 9 9 4
Ad.HSVtk + GCV
inflammation. Complete blood counts (CBCs) were performed within 2 hours of blood 
sample collection using a CBC-DIFF (Heska, Loveland, CO) blood count analyzer. 
Following CBC, samples were centrifuged at 10,000 rpm for 2.5 minutes and rapidly 
frozen at -80°C for future analysis. A blood chemistry panel consisting of blood urea 
nitrogen, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
total bilirubin, total protein, and albumin was used as indicators of both kidney and liver 
toxicity. Additionally, globulin was calculated by subtracting albumin from total protein, 
and albumin/globulin ratio was calculated. Blood chemistry assessments were made 
using a DRI-CHEM (Heska, Loveland, CO) veterinary blood chemistry analyzer.
4.2.6 Data interpretation 
Mouse weight data were used to compare with values on day 0. The percentage 
weight gain was calculated for each mouse and used as a general indicator of animal 
health. Animal weight, blood count, and chemistry data were compared using two-tailed 
Student’s t-tests, with results considered significant if p-values of <0.05 were obtained. 
Only data reflecting significant changes compared to control are included here. 
Specifically, animal weight, differential white blood cell count, and ALT/AST values are 
reported.
4.3 Results and discussion
Virus mediated GDEPT administered in SELP hydrogels for the treatment of 
cancer has been shown to be an effective treatment in a xenograft model of human head 
and neck cancer.12 Due to legitimate concerns in the presence of a fully intact immune
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system, it becomes necessary to carefully assess the ability of the delivery system to 
improve the safety of this treatment in an immunocompetent model. The toxicity of 
SELP-controlled, virus-mediated GDEPT was examined in the acute (1 week) phase, and 
a 12-week recovery study was performed to investigate the ability of the mice to return to 
normal weight and blood count after treatment had been stopped. Two additional time 
points were selected, 2 weeks and 4 weeks, corresponding to the apparent peak and 
resolution of toxicity based on mouse weight data gathered in the recovery study. It was 
considered that examination of the specific indicators of toxicity and organ 
inflammation/damage at these time points would allow diagnosis of the mechanism of 
toxicity, or at the very least the specific organs affected. This information could 
potentially be useful in the design of future systems and strategies for controlled delivery 
of viral gene therapy to localized diseases.
4.3.1 Acute toxicity
Figures 4.1 and 4.2 show animal weight data for the toxicity studies. Acute 
toxicity was assessed with an endpoint of 7 days, at which time a lower weight gain was 
observed for the free viral delivery group compared to control. SELP-mediated delivery 
did not show statistically significant weight loss at any point during the first 7 days 
compared to both free viral delivery and control, although the mean values were less than 
control. It is noteworthy that virus injected without the hydrogels stopped gaining weight 
for 24 hours after injection, while this effect appeared at day 3 in the SELP-mediated 
group. White blood cell counts, shown in Figure 4.3, indicated a significant increase in 
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Figure 4.1: Animal weights from day 0-84 for SELP-mediated GDEPT toxicity study.






Figure 4.2: Animal weights from day 0-14 for SELP-mediated GDEPT toxicity study.
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Figure 4.3: Differential white blood cell count at week 1 for SELP-mediated GDEPT 
toxicity study. C: Control (saline only injection), VG: Ad.HSVtk administered in 
saline with daily GCV injections, SVG: Ad.HSVtk administered in SELP-815K 4%
with daily GCV injections
condition and the control. This overall increase is primarily due to elevated granulocyte 
and lymphocyte counts in the virus group, suggesting an acute immune response to the 
administered virus. The absence of this increase in total white blood cell count and 
differentials in the SELP-mediated group could potentially indicate that locally 
controlling viral gene delivery using SELP-815K hydrogel reduces or eliminates the 
systemic immune response to the adenoviral vectors.
Blood chemistry results for the acute toxicity study indicated the beginnings of 
hepatotoxicity (Figure 4.4) with elevated AST levels appearing in some mice in the free 
virus group. It is possible that this increase in AST is a result of damage to liver cells, 
which would likely be attributed to the therapeutic activity as opposed to immune 
mechanisms. This is because adenoviruses are known to be removed from circulation by 
the liver, increasing the probability of gene transfection in this organ. This phenomenon 
is consistent with our observations discussed in Chapter 3.11 Statistical analysis did not 
yield any significant differences between groups in either ALT or AST, however. At this 
early stage, substantial liver toxicity is unexpected. It has been shown that adenoviral 
gene expression in vivo peaks at 6 days following exposure to the virus13; however, as the 
therapeutic gene itself does not cause cytotoxicity in our system,9 it requires additional 
time for sufficient quantities of converted prodrug to accumulate and cause toxicity. 
SELP matrix appears to reduce the overall acute systemic toxicity of the treatment. Its 
apparent ability to reduce the magnitude of the acute systemic immune response to the 
adenoviral vector, as evidenced by reduced leukocytes (Figure 4.3), highlights the utility 






Figure 4.4: Liver enzyme levels at week 1 for SELP-mediated GDEPT toxicity study. 
C: Control (saline only injection), VG: Ad.HSVtk administered in saline with daily 
GCV injections, SVG: Ad.HSVtk administered in SELP-815K 4% with daily GCV
injections
4.3.2 Subacute toxicity -  2-week time point 
A 2-week time point was selected in order to monitor the progression of toxicity 
of this system, as only initial phases appeared to occur in the 1-week study. Animal 
weight data over the first 2-weeks of study (Figure 4.2) showed the difference in the 
progression of toxicity between the SELP-mediated release and free virus conditions. 
Weight gains were significantly reduced for the free virus group compared to the control 
group for days 10-14. SELP-mediated delivery reduced this effect to only a single day 
(day 11) on which weight gain was significantly reduced compared to control.
Figure 4.5 represents the white blood cell count data gathered for animals at the 2- 
week time point. While the primary mechanism of toxicity in the free virus delivery case 
at 1 week appeared to be immune-response-related based on significantly elevated 
lymphocytes, monocytes, and granulocytes, at 2 weeks, this response appears to have 
resolved as levels returned comparable to control. In contrast, at 2 weeks, there was a 
significant elevation in total white cell and lymphocyte counts in the SELP-mediated 
delivery case compared to both control and free viral delivery. However, in both cases, 
the levels were less than those at 1 week in the free virus group. These results suggest 
that delivering the virus in SELP delays the onset of an immune response, and possibly 
reduces its magnitude.
The results of blood chemistry analysis at the 2-week time point are displayed in 
Figure 4.6. The elevated ALT and AST levels in the two treatment groups as compared to 
control suggest that liver damage is occurring. Hepatotoxicity is indicated most readily 
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Figure 4.5: Differential white blood cell count at week 2 for SELP-mediated GDEPT 
toxicity study. C: Control (saline only injection), VG: Ad.HSVtk administered in 
saline with daily GCV injections, SVG: Ad.HSVtk administered in SELP-815K 4%




Figure 4.6: Liver enzyme levels at week 2 for SELP-mediated GDEPT toxicity study. 
C: Control (saline only injection), VG: Ad.HSVtk administered in saline with daily 
GCV injections, SVG: Ad.HSVtk administered in SELP-815K 4% with daily GCV
injections
control. This evidence is supported by ALT levels, which were also elevated for several 
animals in the virus treatment groups. While not statistically significant, the AST and 
ALT levels were reduced in the SELP-mediated delivery group versus free virus. This 
damage is likely caused by transfection of the cells of the liver and subsequent cell death 
due to sensitivity to the prodrug and the bystander effect,9 as opposed to an immune 
reaction to the viral constructs themselves.
4.3.3 Subacute toxicity -  4-week time point 
The next time point considered was 4 weeks after the initial injection of virus, 
chosen based on results discussed in Chapter 3 11 indicating that viral load is essentially 
completely released by the end of 4 weeks, making this a likely “turning point” after 
which toxicity should resolve. Between 2 weeks and 4 weeks, all groups displayed 
weight gain; however, the order of weight gain between the groups established early in 
the study remained. Based on the animal weight data (Figure 4.1) at 4 weeks (28 days), 
the free virus group appeared to be delayed in growth by 7-14 days as compared to the 
control group, while the SELP-mediated group appears to be delayed by less than 7 days. 
This demonstrates an advantage of SELP-mediated delivery over free viral injection in 
terms of general health as measured by body weight increase.
White blood cell counts, shown in Figure 4.7, did not indicate any significant 
differences in immune state of the mice at 4 weeks postinjection, possibly due to 
complete or near-complete clearance of the virus. There was a minor elevation, although 
not statistically significant, of the mean values for all three differential counts and in the 



















Figure 4.7: Differential white blood cell count at week 4 for SELP-mediated GDEPT 
toxicity study. C: Control (saline; only injection), VG: Ad.HSVtk administered in 
saline with daily GCV injections, SVG: Ad.HSVtk administered in SELP-815K 4%
with daily GCV injections
activation. Further evidence of SELP’s utility in improving the safety of this treatment is 
shown in Figure 4.8. It is apparent from these data that at 4 weeks, the uncontrolled 
delivery of virus in combination with prodrug was still causing hepatotoxicity, as 
evidenced by AST elevation in the free virus group compared to the control and the 
SELP-mediated conditions. The significance of this effect suggests that there was some 
lingering toxicity of the initial free viral delivery.
4.3.4 Recovery study 
A 12-week time point served as an indication of how well animals are able to 
recover from the effects of the treatment previously observed. Animal weight is the 
primary indicator of recovery at this point, as CBC and blood chemistry evidenced 
toxicity is very likely to be resolved, particularly considering the rapid metabolism and 
healing capability of mice. As shown in Figure 4.1, between 4 and 12 weeks following 
viral injection, signs of toxicity had generally resolved and except for two instances, 
animals in all groups gained weight at a steady rate. However, between days 36 and 44 
and between days 72 and 86, the mean weight gains for the free virus group decreased; 
the only weight losses recorded throughout the entire study. In contrast, the weight gains 
of the SELP-mediated group actually surpassed the control group from day 36 through 
the end of the study. CBC analysis of the animals at 12 weeks, shown in Figure 4.9, 
reveals no overt evidence of toxicity, although mononuclear leukocytes appear to be 
depressed slightly in the two treatment groups compared to control. These low values are 
not particularly of concern as their quantity can fluctuate significantly for any number of 


























Figure 4.8: Liver enzyme levels at week 4 for SELP-mediated GDEPT toxicity study. 
C: Control (saline only injection), VG: Ad.HSVtk administered in saline with daily 
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Figure 4.9: Differential white blood cell count at week 12 for SELP-mediated GDEPT 
toxicity study. C: Control (saline only injection), VG: Ad.HSVtk administered in 
saline with daily GCV injections, SVG: Ad.HSVtk administered in SELP-815K 4%
with daily GCV injections
These data indicate that animals were able to completely recover from the toxic effects 
previously observed in the treatment time points.
4.4 Conclusions
Administration of Ad.HSVtk in SELP-815K 4 wt% hydrogel was shown to 
reduce the systemic toxicity of gene-directed enzyme-prodrug therapy compared to free 
viral injection. This reduction in toxicity in conjunction with previously collected data 
showing improved efficacy in a nude mouse/human xenograft HNSCC model12 makes 
SELP-mediated delivery a promising approach for viral cancer gene therapy.
Supporting this conclusion is a set of unpublished data described in the Appendix, 
which investigated the efficacy of SELP-mediated delivery compared to aqueous viral 
injection in a short pilot study in immunocompetent mice. This brief experiment 
illustrated a significant reduction in tumor growth rate in an aggressive fibrosarcoma and 
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CHAPTER 5
SYNTHESIS AND CHARACTERIZATION OF A MATRIX- 
METALLOPROTEINASE RESPONSIVE SILK- 
ELASTINLIKE PROTEIN POLYMER
5.1 Introduction
The field of genetically engineered polymers has grown steadily over the last 
several decades such that current research has expanded into using this powerful polymer 
design and production platform to produce materials with highly specific properties. Silk- 
elastinlike protein polymer (SELP) is one of these materials which is composed of 
repeating units of silkworm silk fibroin domains (GAGAGS) interspersed with repeating 
units derived from mammalian elastin (GVGVP). Monomer units of SELP are composed 
of several silk units in a diblock arrangement with elastin units.
Previous work has demonstrated that modifying the number of silk and elastin 
units in a monomer can have very specific effects on the properties of the polymers and 
hydrogels assembled from them.1-5 One specific structure of SELP, namely SELP-815K, 
was identified as an effective material for improving the safety, efficacy, and 
biodistribution of adenoviral delivery for the treatment of head and neck squamous cell 
carcinoma (HNSCC). In an effort to further improve the viral gene delivery capability of 
SELP-815K, work described in this chapter investigates the effects of adding a matrix-
metalloproteinase (MMP)-responsive peptide sequence to the monomer unit. MMP- 
degradable sequences in hydrogels have been used successfully for growth factor 
delivery,6 tissue ingrowth scaffolds,6-8 and drug delivery.9 Several products incorporating 
this technology have reached the clinical research stage, and have garnered significant 
attention from large biosurgery companies for licensing agreements.10
The amino acid sequence GPQGIFGQ has been shown to be highly degradable by 
both MMP-2 and MMP-9, and is derived from a sequence ubiquitously found in collagen 
to promote its ability to be degraded and remodeled.11 This sequence is intended to 
provide a similar property to SELP-815K by allowing it to respond to local intratumoral 
changes in MMP levels to affect increased release rate in response to the increased 
aggression and invasiveness of the disease state. Here, the biosynthesis, scale up, and in 
vitro characterization of SELP-815K containing an MMP-responsive sequence is 
described. The effects of degradation on the mechanical properties of these hydrogels and 
the release of 100 nm polystyrene particles from them are evaluated. The goal of this 
work is to demonstrate that adding the MMP-responsive sequence to SELP will allow it 
to increase release rate of nanoparticulates in the size range of viruses in the presence of 
MMP-2 and MMP-9, which would impart the capability of this delivery system to 
respond to disease state with increased delivery of therapeutic adenovirus.
5.2 Materials and methods
5.2.1 Materials
Restriction enzyme XagI, T4 DNA ligase, and shrimp alkaline phosphatase were 
purchased from Fermentas (Glen Burnie, MD). Restriction enzymes BanI, Avail, Ncol,
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and Xcml, 1 kilobase TriDye DNA marker, and Orange G loading buffer were purchased 
from New England Biolabs (Ipswich, MA). DNA miniprep and maxiprep kits and 
Qiaquick gel extraction kit were purchased from Qiagen (Valencia, CA). MAXEfficiency 
Dh5a E.coli and 100nm fluorescent spheres were purchased from Invitrogen (Carlsbad, 
CA). Active matrix-metalloproteinase 2 and 9 and Terrific Broth powder were purchased 
from EMD (Gibbstown, NJ). BupH borate buffer packs, Lowry assay kit, and GelCode 
Blue staining reagent (colloidal Coomassie formulation) were purchased from Thermo 
Pierce (Rockford, IL). Lysogeny broth agar was purchased from BD Biosciences 
(Franklin Lakes, NJ). 4-15% Bis-Tris precast PAGE gels and Kaleidoscope protein 
standard were purchased from BioRad (Hercules, CA). Antifoam 204 was purchased 
from Sigma Aldrich (St.Louis, MO). All oligonucleotides were purchased from 
Integrated DNA Technologies, Inc. (Coralville, IA). Plasmids pSY1378 (parental) and 
pPT317 encoding for SELP-815K dimer were provided by Protein Polymer 
Technologies, Inc. (San Diego, CA). Polyhistidine protein purification was carried out 
using a Maxwell 16 system equipped with the Polyhistidine Protein Purification Kit 
purchased from Promega (Madison, WI)
5.2.2 Methods
5.2.2.1 Construction of the monomer gene segment
Monomer gene segment construction is summarized in Figure 5.1. Plasmid 
pSY1378 (cloning vector) was digested with BanI and dephosphorylated with shrimp 
alkaline phosphatase (SAP). Plasmid pPT317 containing two copies of SELP-815K 




Figure 5.1: Synthesis of SELP-815K-MMPRS monomer gene segment.
~400bp fragment corresponding to SELP-815K monomer gene was purified using the 
Qiaquick Gel Extraction Kit. SELP-815K monomer gene segments were ligated with 
linearized, dephosphorylated pSY1378 in a 3:1 ratio overnight at room temperature. The 
ligation mixture was used to transform MAXefficiency Dh5a E. coli and the 
transformation was plated on chloramphenicol-selective LB agar plates. Cultures were 
grown overnight and colonies were selected and grown in 4 ml starter cultures in 
chloramphenicol-selective Terrific Broth overnight at 37°C in a shaking incubator at 240 
RPM. DNA was isolated from cultures by Qiaprep Spin Miniprep kit, and screened by 
digestion with BanI. A positive colony was then grown overnight in a 200 ml 
chloramphenicol-selective Terrific Broth culture and DNA was then extracted using a 
Qiagen Maxiprep kit.
Custom oligonucleotides encoding for the matrix-metalloproteinase responsive 
sequence GPQGIFGQ in addition to XagI-compatible overhangs and 5’phosphorylation 
were solubilized in annealing buffer composed of 10mM Tris, 50mM NaCl, and 1mM 
EDTA in 18MQ deionized water to a concentration of 1mM. The sequence of the oligos 
is shown in Table 5.1. Oligos were mixed in a 1:1 ratio and 50^l of oligo mixture was 
annealed by heating to 95°C in an aluminum heating block, then allowed to cool to room 
temperature gradually by switching off the heating block.
Plasmid pSY1378 containing SELP-815K monomer gene segment was digested 
with XagI and dephosphorylated using SAP. Annealed oligos were ligated with the 
linearized pSY1378+SELP-815K monomer gene segment in a 5:1 molar ratio overnight 
at room temperature. This ligation mixture was used to transform MAXefficiency Dh5a 




Oligonucleotide sequences for SELP-815K-MMPRS monomer gene synthesis
Forward 5 ’ AGG ACC GCA AGG AAT TTT TGG ACA GCC TGG 3’ (5’ Phosphorylated) 
Reverse 5’TCC AGG CTG TCC AAA AAT TCC TTG CGG TCC 3’ (5’ Phosphorylated)
and grown overnight at 37°C. Colonies were grown in 4 ml chloramphenicol-selective 
overnight Terrific Broth cultures, DNA extracted, and digested with AvaII to identify 
colonies containing the MMP-responsive insert, which appear as a 311bp fragment in 
Figure 5.2. DNA sequencing was used to confirm correct insertion, after which 200 ml 
terrific broth cultures were grown and pSY1378 containing SELP-815K-MMPRS 
monomer gene segment was isolated using a Qiagen Maxiprep kit.
5.2.2.2 Construction of the polymer gene segment
Construction of the polymer gene segment for SELP-815K-MMPRS is shown in 
Figure 5.3. Plasmid pPT317 (expression plasmid) containing SELP-815K dimer was 
digested with BanI and dephosphorylated using SAP. pSY1378 containing SELP-815K- 
MMPRS monomer gene segment was digested with BanI. Both digests were separated on 
a 1% agarose gel. The bands corresponding to the 4000 bp linearized and 
dephosphorylated pPT317 parental vector and the ~400 bp band corresponding to SELP- 
815K-MMPRS monomer gene segment were purified. Monomer gene segments and 
linearized dephosphorylated pPT317 were ligated overnight at room temperature at a 
42.5:1 molar ratio, with total DNA content of ~650 ng. The ligation mixture was used to 
transform MAXefficiency Dh5a E. coli and the transformation was plated on kanamycin- 
selective LB agar plates and grown overnight at 30°C. Colonies were grown in 
kanamycin-selective Terrific Broth, DNA extracted with Qiagen Minipreps, and screened 
with a double digest with NcoI and XcmI. Screening digests were run on 1% agarose and 
colonies displaying a band at ~2400 bp, corresponding to SELP-815K-MMPRS 6-mer 








Figure 5.2: Agarose gel showing SELP-815K-MMPRS colony screening for monomer 
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Figure 5.4: Agarose gel showing SELP-815K-MMPRS polymer gene segments. 
Colony 12 contains a 6-mer polymer gene segment.
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example of the result of a typical multimerization reaction.
5.2.2.3 Small-scale protein production
The ability of the newly constructed polymer gene containing plasmid pPT317 to 
induce protein production was confirmed by transforming the genetically engineered 
EC3R E. coli with pPT317 encoding SELP-815K-MMPRS 6-mer. 6-mer was chosen 
specifically because it most accurately mimics the molecular weight of previous SELP
2, 5, 12constructs for hydrogel formation, including SELP-815K. ’ ’ EC3R was derived from a 
postfermentation cell culture of pPT317+SELP-815K 6-mer by defrosting a small chip of 
postfermentation cell mass which was grown using the production cell line EC3 from 
Protein Polymer Technologies, Inc. (San Diego, CA). Approximately 25 
subculture/replica plate cycles were performed on cells from this culture until a viable 
kanamycin-sensitive E. coli colony was identified, indicating that the plasmid encoding 
SELP-815K 6-mer had been purged. Following transformation, colony screening, and 
identification of a positive colony, a 4 ml kanamycin-selective MM50 culture was 
inoculated, grown to slightly turbid culture and then divided into two subcultures and 
diluted to 4 ml each with additional MM50 (Protein Polymer Technologies, Inc. San 
Diego, CA). One of these cultures was intended for protein production, while the other 
was earmarked for inoculums development. These cultures were grown at 30°C at 240 
RPM agitation until OD600 indicated that the cells were approaching stationary phase. At 
this point, the inoculum development culture was divided and added to each of two 0.4L 
MM50 cultures and grown at 30°C and 240 RPM, while the culture for protein 
production capacity was heat shocked and outgrown for analysis. Specifically, the culture
was immersed in 60°C water and culture temperature was monitored until it reached 
42°C, at which point it was transferred to a 42°C water bath for 5 minutes. Following 
induction, the culture was grown at 40°C and 240 RPM for 2 hours, at which point 
protein production was evaluated by SDS-PAGE by comparing the induced culture to a 
pre-induction sample and a known SELP-815K 6-mer sample (Figure 5.5). Inoculum 
0D600 was monitored hourly until an OD greater than 4.0 was measured (10mm path 
length, Eppendorf BioPhotometer) at which point it was used to inoculate the fermenter.
5.2.2.4 Large-scale polymer production
SELP-815K-MMPRS was produced in gram quantities by fermentation in a 14 
liter New Brunswick Scientific BioFlo 115 fermenter (Eppendorf, Enfield, CT) with a 10 
liter working volume. An initial volume of 6 liters of MM50 was added sterile to the 
autoclaved fermenter, followed by the 0.8 liter inoculum. Fermentation was initiated at 
30°C and 1000 RPM agitation, with 8-10 liters/minute airflow, pH 6.8. Foam was 
controlled by addition of Antifoam 204 (Sigma Aldrich, St.Louis, MO), and was 
controlled by a foam level probe placed approximately 2 inches above the culture level. 
pH control was done by addition of ammonium hydroxide via the fermenter pH control 
loop. When dissolved oxygen decreased below 60%, agitation was increased to 1200 
RPM. Dissolved oxygen was monitored constantly until it was observed to show a sharp 
drop followed by recovery to nearly 90%, indicating a switch of the bacteria from 
anabolic to catabolic metabolism (depletion of initial glucose charge), at which point 
glucose feed was initiated at 150 ml/min. Culture OD600 was measured every 2 hours 
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In order to heat shock the culture, the fermenter heating blanket was adjusted to 
maximum output, and water heated to 80°C was rapidly pumped through the cooling loop 
by a peristaltic pump. When temperature reached 41°C, the heating blanket was removed 
and cold tap water (approximately 10-15°C) was pumped through the cooling loop 
briefly to purge the hot water from the system. Temperature reached 42°C between 3 and 
4 minutes, with one degree of overshoot. The heating blanket was then replaced, and 
temperature was allowed to gradually decrease to 40°C, approximately 45 minutes. At 
this point, the cooling system was reconnected, and the temperature setpoint was adjusted 
to 40°C.
OD600 was continually monitored following induction, until it was observed to 
decrease, at which point harvest was initiated. Final culture 0D600 was 154, with a 
maximum of 180. Harvest began by removing the heating blanket, stopping glucose feed, 
and reducing agitation to 300 RPM. Ice-cold water was pumped through the cooling loop 
until culture temperature reached 10°C, at which point the culture was pumped into 1 liter 
centrifuge bottles and pelleted at 6000 x g for 30 minutes at 4°C. Wet cell paste was 
stocked in plastic bags, weighed, and frozen at -80°C to aid in cell lysis for SELP 
purification. Approximately 2.2kg of wet cell paste was yielded from fermentation of 
SELP-815K-MMPRS 6-mer.
5.2.2.5 Purification of SELP-815K-MMPRS
Approximately 1.1kg of frozen cell paste from fermentation was defrosted and 
lysed via high-pressure mechanical extrusion using a Microfluidics Microfluidizer 110M 
set to 10,000 psi. The lysed cell solution was then centrifuged at 4°C for 30 minutes to
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remove cell debris, and PEI was used to precipitate nucleic acids and other negatively 
charged contaminants. The PEI-treated supernatant was then centrifuged at 4°C, after 
which the supernatant was subjected to ammonium sulfate precipitation. The precipitated 
protein was solubilized and then further purified by both cation and anion exchange 
chromatography, and tangential flow filtration. Following chromatography and filtration 
steps, the polymer solution was lyophilized in depyrogenated flasks, transferred to 
depyrogenated Teflon jars, and stored at -80°C. Yield from a single SELP-815K- 
MMPRS purification batch was approximately 2.5g.
5.2.2.6 Polymer characterization
Characterization of SELP-815K-MMPRS polymers was performed by MALDI- 
TOF mass spectrometry, amino acid composition analysis, SDS-PAGE, and enzymatic 
digest analysis via HPLC for MMP-2 and MMP-9. MALDI-TOF was performed by the 
University of Utah Mass Spectrometry and Proteomics core facility, while amino acid 
analysis was performed by Alphalyse, Inc. (Palo Alto, CA).
For SDS-PAGE, samples of lyophilized SELP-815K and SELP-815K-MMPRS 
were solubilized in “Reaction Buffer” (RB) containing 50mM Tris-HCl, 150mM NaCl, 
5mM CaCl2, and 0.2mM NaN3, pH 7.6 at a concentration of 1 mg/ml. This buffer recipe 
is sourced from the Molecular Probes EnzChek Gelatinase/Collagenase Assay Kit 
(Invitrogen, Carlsbad, CA), which was used to confirm the activity of MMP-2 and MMP- 
9 prior to use. 2x Laemmli Buffer was supplemented with 5% P-mercaptoethanol and 
added 1:1 by volume to the polymer solutions, which were then placed in a PCR thermal 
cycler and heated to 95°C for 5 minutes to denature the protein. 25^l of each sample was
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added to 4-15% Bis-Tris precast PAGE gel and electrophoresis was performed at 200V 
until the dye front reached the bottom of the gel, approximately 30 minutes. 
Kaleidoscope protein standard was used as a molecular weight marker. Following 
electrophoresis, gels were stained with GelCode Blue (colloidal Coomassie formulation) 
following manufacturer’ s instructions for staining and destaining.
Enzymatic digest was performed by solubilizing SELP-815K and SELP-815K- 
MMPRS in RB at 1 mg/ml. 100 ^l samples of each polymer were digested with a final 
concentration of 10nM and 40nM MMP-2 or MMP-9. MMP samples were incubated at 
room temperature for 2, 4, 12, 24, 36, and 48 hours and samples were run on PAGE gels 
and stained with GelCode Blue to visualize band patterns corresponding to protein 
degradation.
5.2.2.7 Hydrogel characterization
The properties of hydrogels formed from SELPs are strongly dependent on the 
shear applied to liquid solutions of polymer prior to gelation. SELPs solubilized in 
phosphate buffered saline were loaded into a 1 ml luer-lock syringe connected at the hub 
to another 1 ml luer-lock syringe via two 27G needles, joined by a section of .0155” 
HPLC tubing. The SELP solution was passed through this device at maximum hand 
pressure for five full bidirectional cycles, at which point it was used for studies. Polymers 
used for previous studies provided by PPTI were sheared by 15,000 psi pressure through 
a series of micron-scale meshes. This shearing method is not considered to be identical to 
the shearing method used for previously published polymers, and therefore, the
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characteristics of hydrogels studied in this work are expected to differ from those of 
previously published works.
Hydrogels were characterized for their sensitivity to MMP degradation in the 
context of protein loss from the gel, changes in mechanical properties, and release of 
model 100nm fluorescent nanoparticles. Previous applications of SELP-815K have 
investigated its utility as a viral delivery material, and this particle size was chosen as a 
model for the adenoviruses. One limitation of this model of viral release is related to size, 
as adenoviruses are typically 70-90nm. Another limitation is the differences in surface 
chemistry between the beads and viruses which can influence bead-polymer interaction 
and release. For the protein release and mechanical properties, 10 wt% solutions of 
SELP-815K and SELP-815K-MMPRS were sheared according to the above protocol, and 
then loaded into 1 ml tuberculin slip-tip syringe. Syringes were sealed with Parafilm and 
allowed to gel upright overnight at 37°C. Following gelation, the end of the syringe was 
cut off with an autoclaved razor blade and individual 50 ^l test samples were cut off of 
the gel cylinder using a new autoclaved razor blade. Gel samples were placed in round 
bottom 1.8 ml cryovials with gasket-sealed screw caps, and 250^l of test solution 
consisting of RB alone, RB + MMP-2, or RB + MMP-9 was added to each tube. Samples 
were agitated at 180 RPM at room temperature. Test solution was completely withdrawn 
every 32-40 hours and frozen at -20°C, rinsed with RB, and replaced. For the release 
study, gels were formed and treated as above except that when the SELP solutions were 
being made, 6.6 ^l of 0.2% fluorescent bead suspension was added per ml of SELP 
solution, and all agitation and sample manipulation was performed with minimal light to 
avoid photobleaching.
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Protein loss was quantified using a Modified Lowry Assay Kit, and using known 
SELP solutions for the standard curve instead of the supplied bovine serum albumin, as 
SELP contains few Lowry-reactive amino acids. The mechanical properties of SELPs 
were evaluated in cyclic compression at 1Hz and 1% strain, with ~10 grams of 
preloading applied for 10 minutes to eliminate stress relaxation. Stress was measured 
using a 2 lb load cell. Release was quantified by measuring the fluorescence of release 
samples with an excitation/emission of 260/515.
5.2.2.8 Statistical analysis
All statistical analyses were performed using GraphPad Prism software. One way 
ANOVA was used to determine statistical significance, with Tukey’ s post test for all 
pairs of samples within a hydrogel group. For data reported as additive over time, 
standard deviations for each time point were added to the geometric mean of all previous 
time points to calculate the propagation of error. A ll error bars report standard deviation.
5.3 Results
5.3.1 Synthesis of monomer and polymer gene segments
The synthesis of the SELP-815K-MMPRS monomer gene segment was 
successfully confirmed by restriction digest with AvaII, which produces a cut within the 
insert encoding for the GPQGIFGQ sequence, and another 14 base pairs 3’ of the BanI 
site marking the end of the monomer gene, forming a fragment of 311 bp (Figure 5.2). 
Monomer gene segment generation was additionally confirmed by DNA sequencing.
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The synthesis of the polymer gene segment was confirmed by simultaneous 
double digest with restriction enzymes NcoI and XcmI, which cut 4 base pairs past the 3’ 
end of the polymer gene, and 8 base pairs prior to the 5’ end of the polymer gene, 
respectively. An example of an agarose gel image showing SELP-815K-MMPRS 
polymer gene analysis including monomer through 7-mer is shown in Figure 5.4. 
Optimization of ligation conditions (data not shown) revealed that increasing molar ratio 
combined with increasing total DNA content led to longer polymer gene lengths.
5.3.2 Polymer production and purification
The small-scale protein production capability of pPT317+SELP-815K-MMPRS 
6-mer was confirmed by SDS-PAGE (Figure 5.5). The SELP-815K standard, shown in 
lane 8, indicates the approximate position of the band corresponding to SELP production 
among the native E. coli proteins. The postinduction samples for representative colonies
1, 2, and 3 (lanes 5-7, respectively) illustrate an increased band density corresponding to 
SELP-815K as compared to the pre-induction sample for these colonies (lanes 2-4), 
confirming production of SELP-815K-MMPRS. It is important to note in these images 
and all PAGE gels analyzing SELP that, due to a lack of charged residues, SDS binding 
to SELP is significantly lower compared to standard proteins. As a consequence, SELP 
regularly appears to be of higher molecular weight than expected on PAGE gels.
Large-scale fermentation was performed with a wet cell paste yield of 2.2 kg. 
Purification of SELP-815K-MMPRS yielded 2.5 grams of material.
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5.3.3 Polymer characterization
The newly synthesized SELP-815K-MMPRS was initially characterized by 
MALDI-TOF mass spectrometry, which predicted the molecular weight of SELP-815K- 
MMPRS to be 70,645 Da. While this value does differ from the expected molecular 
weight of 70,510 Da, this is within reasonable instrument error for proteins of this size.
Amino acid composition analysis confirmed the addition of the expected 
quantities of amino acids unique to the MMP-responsive insert. Specifically, isoleucine 
and phenylalanine were not detected in the SELP-815K sample, but were detected in 
approximate quantities of 6 and 7 amino acids, respectively, in SELP-815K-MMPRS, 
while 14 additional glutamic acid residues were detected in the responsive sequence, 
approximately equal to expected values for these key indicators (I=6, F=6, Q=12 
expected).
SDS-PAGE analysis of enzymatic digestion of these polymers is shown in 
Figures 5.6-5.13. It is clear that SELP-815K-MMPRS is digested by MMP-2 and MMP-
9, and SELP-815K without the responsive sequence is not. Additionally, this digestion is 
dependent on both time of exposure and concentration of MMP.
5.3.4 Hydrogel characterization
Characteristics of hydrogels formed from SELP-815K-MMPRS were compared to 
SELP-815K in the context of MMP-sensitivity. Initial analysis consisted of comparing 
the loss of protein from each hydrogel in the presence and absence of MMPs as an 
indicator of the sensitivity of the hydrogel to degradation. The degradation and release of 






















































Figure 5.9: SDS-PAGE analysis of 40 nM MMP-2 digest of SELP-815K-MMPRS
over time.
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Figure 5.14, while Figures 5.15 and 5.16 display these results over time for SELP-815K 
and SELP-815K-MMPRS, respectively. SELP-815K displayed statistically insignificant 
levels of increased protein loss in the presence of MMPs, with only minor elevations 
compared to the control soluble fraction. Exposure of hydrogels composed of SELP- 
815K-MMPRS to MMP-2 and MMP-9 resulted in 63% and 44% higher protein loss 
compared to control. Protein loss from control is attributed to soluble polymer chains 
which do not participate in crosslinking. As a percentage of total protein in each gel, 
assuming precise 50 ^l gels at 10 wt% would contain 5 mg of polymer, approximately 
24% of the polymer per hydrogel was lost as soluble fraction, with enzymatic digestion 
increasing this percentage to 39% and 35% for MMP-2 and MMP-9-induced degradation, 
respectively. These results were found to be statistically significant by Tukey’ s post test 
of all pairs of values, which revealed a statistical difference between both MMP-2 and 
MMP-9 and control, and no significance between each other. Results demonstrate that 
hydrogels composed of SELP-815K-MMPRS are degraded by MMP-2 and MMP-9 due 
to the inclusion of the MMP-responsive sequence GPQGIFGQ.
The effects of enzymatic treatment on the mechanical properties of SELP 
hydrogels were examined. Cyclic loading at 1 Hz was chosen as a method to 
simultaneously derive the Young’ s modulus and investigate viscoelasticity of these 
hydrogels with and without enzymatic degradation. Figure 5.17 shows the differences in 
Young’ s modulus for SELP-815K and SELP-815K-MMPRS. Treatment with either 
MMP-2 or MMP-9 significantly affected the modulus of the MMP-responsive hydrogels, 
while there was no significant effect present in the standard SELP-815K polymer. In the 
case of SELP-815K-MMPRS, there was a 41% loss in Young’ s modulus due to MMP-2
213
214
Figure 5.14: Total degradation at 2 weeks for SELP-815K+MMPRS hydrogels. 
Control: Agitation in RB in the absence of MMP. MMP-2: Agitation in RB containing 
10nM activated MMP-2. MMP-9: Agitation in RB containing 10nM activated MMP-
9.
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Figure 5.15: Protein loss over time for SELP-815K hydrogels. Control: Agitation in
RB in the absence o f MMP. MMP-2: Agitation in RB containing 10nM activated
MMP-2. MMP-9: Agitation in RB containing 10nM activated MMP-9.
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Day
Figure 5.16: Protein loss over time for SELP-815K-MMPRS hydrogels. Control:
Agitation in RB in the absence o f MMP. MMP-2: Agitation in RB containing 10nM
activated MMP-2. MMP-9: Agitation in RB containing 10nM activated MMP-9.
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Figure 5.17: Compressive modulus of hydrogels in the presence and absence of 
MMPs. Control: Agitation in RB in the absence of MMP. MMP-2: Agitation in RB 
containing 10nM activated MMP-2. MMP-9: Agitation in RB containing 10nM
activated MMP-9.
treatment, while MMP-9 affected a 24% loss. As a basic model comparison of 
nanoparticulate release between these two hydrogels, the release of 100 nm fluorescent 
polystyrene spheres was monitored over time for hydrogels in the presence and absence 
of MMP-2 and MMP-9. The total fluorescence release at the end of the 2-week study 
isshown in Figure 5.18, and the release over time for this study is shown in Figures 5.19 
and 5.20 for SELP-815K and SELP-815K-MPRS2, respectively. These data show that 
following initial burst release, the release rates between the two polymers are similar until 
Day 8, at which point the release rates for SELP-815K-MMPRS with enzymatic 
treatment begin to increase. The total release at the end of the study for SELP-815K with 
no treatment was 9.3%, while MMP-2 and MMP-9 treatment conditions yielded release 
of 12.1% and 9.4%, respectively. SELP-815K-MMPRS without treatment released 8.2% 
at the end of 2 weeks; however, in contrast to the nonresponsive polymer, treatment with 
MMP-2 and MMP-9 caused release of 13.5% and 16%, respectively, or increases of 65% 
and 95% compared to control. This effect was observed to be statistically significant by 
ANOVA, with paired analysis via Tukey’ s post test revealing significance between either 
of the two MMP treatments and control, but not between the two treatments.
5.4 Discussion
The results presented in this chapter show progress towards the development of 
bioactive genetically engineered biomaterials. This is shown both in the context of single 
polymer chains and in hydrogels self-assembled from these polymers. Studies 
characterizing SELP-815K-MMPRS in comparison to SELP-815K showed all expected 
hallmarks of having successfully added the MMP-responsive sequence to the polymer at
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Figure 5.18: Total release of 100nm nanoparticles from SELP-815K+MMPRS 
hydrogels in the presence and absence of MMPs. Control: Agitation in RB in the 
absence of MMP. MMP-2: Agitation in RB containing 10nM activated MMP-2. 







Figure 5.19: Nanoparticle release over time for SELP-815K hydrogels. Control:
Agitation in RB in the absence o f MMP. MMP-2: Agitation in RB containing 10nM







Figure 5.20: Nanoparticle release over time for SELP-815K-MMPRS hydrogels.
Control: Agitation in RB in the absence of MMP. MMP-2: Agitation in RB 
containing 10nM activated MMP-2. MMP-9: Agitation in RB containing 10nM
activated MMP-9.
six evenly spaced locations, and the confirmation of correct sequence placement in the 
monomer gene ensures that the location of the responsive sequence along the monomer is 
correct. MALDI-TOF mass spectrometry results show an increase in molecular weight 
from SELP-815K 6-mer to SELP-815K-MMPRS 6-mer which corresponds to the 
insertion of six copies of GGPQGIFGQP within reasonable instrument error. These 
results combined with the appearance of characteristic amino acids on the amino acid 
analysis results confirm the identity of SELP-815K-MMPRS 6-mer.
The sensitivity of SELP-815K-MMPRS to MMP-2 and MMP-9 was confirmed by 
SDS-PAGE. Degradation appears to proceed by random cutting of the GPQGIFGQ 
sequence, evidenced by evenly spaced bands for all conditions of SELP-815K-MMPRS 
digestion (Figures 5.7, 9, 11, and 13) which correspond to various lengths of cleaved 
polymer. The appearance of double bands is likely due to the generation of fragments of 
SELP which include the head or tail sequences, which are produced in lower abundance 
than multimers of the repeat unit but still occur in appreciable quantities. In conditions 
using 40nM MMP for digestion, all full-length polymer has been cleaved by 36 hours, 
and at these later time points, the increasing intensity of low molecular weight bands 
indicates increasingly complete digestion of SELP at the GPQGIFGQ sequence (Figures 
5.9 and 5.13). From an individual polymer, one fragment would be generated 
corresponding to the head sequence and the first half of the first monomer, five identical 
fragments corresponding to monomer repeats being separated at the GPQGIFGQ site, and 
one fragment corresponding to half of the last monomer repeat and the tail sequence. This 
analysis confirms the apparent specificity of digestion by MMPs to only the degradable
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sequence, as no condition of MMP digestion of SELP indicated any signs of digestion 
(Figures 5.6, 5.8, 5.10, and 5.12).
Hydrogel degradation studies illustrate the utility of this material as a bioactive 
controlled delivery system. The insertion of the MMP-responsive sequence caused 
significant levels of degradation of the hydrogel to occur in the presence of MMP-2 and 
MMP-9, which are found at high levels in the tumor microenvironment and are 
associated with increased invasiveness and metastasis formation in HNSCC and other 
cancers.13-15 Studies focusing on the degradability of the polymer suggest that following 
administration of a therapeutic in this material, it may have the capability to biodegrade 
and be completely removed from the administration site. This presents a significant 
advantage over standard SELP-815K, which was observed to last up to at least 12 weeks 
in vivo in an immunocompetent mouse model. In addition to the implications of 
degradation on the potential performance of this material in viral gene delivery, the 
manner in which the degradation occurs yields interesting information regarding the 
mechanism of self-assembly of the hydrogel. The release of significant quantities of 
protein following specific cleavage of elastin units supports recent conclusions published 
by Kaplan et al.,16 suggesting that the structure of SELP in a hydrogel is dominated by 
aggregates of silk units interconnected with elastin units in an arrangement similar to a 
micelle. Cleavage of a sufficient number of elastin units interconnecting the nodes of silk 
eventually lead to liberation of these particle-like agglomerates, which appear as released 
protein from the hydrogel. This hypothesis is supported by both the decrease in 
mechanical properties observed, and the increased release rate. The loss of the primary 
intercrosslink material would naturally cause both of these observed effects, as existing
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pores would be enlarged and possibly new pores would be formed by this type of 
degradation. Additionally, the trends indicating increased viscoelastic character of the 
enzymatically treated SELP-815K-MMPRS as well as decreased modulus support this 
type of degradation, as the increased void volume of the hydrogel would cause larger 
amounts of liquid to enter the gel, as well as a breakdown of the crystalline-dominated 
domain structure of SELP.
The increased release of the 100 nm polystyrene beads in the presence of MMP 
degradation suggests that when applied in vivo, this material could provide disease-state 
responsive delivery of nanoparticulate therapeutics. When combined with codelivery of 
nanoscale and/or microscale drug carriers of variable size, this could provide very long­
term delivery with tunable administration of various drugs when certain 
microenvironmental conditions are present. Interestingly, while protein loss from SELP- 
815K-MMPRS appears to occur at a steady rate over the course of the study (Figure 
5.16), the release appears to be slow and constant until between days 8 and 10 for MMP-
9, and 10 and 12 for MMP-2, at which point the release rate increases significantly. This 
type of release profile could be caused by the opening and enlargement of existing pores 
causing more rapid release of particles from the hydrogel void space, or the liberation of 
particles which were entrapped within the hydrogel network. The effect is likely a 
combination of both of these, and indicates that future application of these polymers as 
viral delivery materials could be accomplished by using higher weight percentages than 
previous studies to further extend the duration of release of adenovirus from these 
hydrogels. The mechanism of degradation of these polymers is likely to be surface 
degradation from the interior surface area of the pores of the hydrogel, which would
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result in enlargement of the pores. This type of degradation would occur without 
demonstrating the traditional signs of surface degradation, as much more of the surface of 
the hydrogel is contained within the pore structure than is exposed on the outside of the 
gel. Mechanistic studies for evaluating the pattern of degradation of these hydrogels need 
further investigation. This material can have utility for application as a postsurgery 
treatment to target tumor margins, as it would likely remain in place for a long period of 
time while delivering adenovirus to the surrounding tissue in a slow, constant dose.
5.5 Conclusions
This work illustrates an important step forward in the development of genetically 
engineered silk-elastinlike biomaterials. The ability to precisely insert a bioactive 
sequence into a highly tunable and specifically modified polymer has the potential to 
have significant impact in many areas of research, including applications as therapeutic 
drug delivery materials, in vitro or in vivo diagnostics, or as research tools. The 
advantage to producing polymers in this manner is the control over sequence and length, 
leading to a significant ability to impart very specific properties on the linear polymers. 
Adding to this distinct capability the ability to insert bioactive sites at specific locations 
along the polymer backbone increases the possible applications for such materials, as the 
sites inserted can be selected to respond to specific environmental conditions or cell 
types. The release results indicate that SELP-815K-MMPRS could potentially improve 
current virus-mediated gene therapy approaches by responding to the local environment 
and increasing release rate when the delivery of therapeutics is most needed. Given the 
observations made in this work, it is likely that increasing the number of bioactive sites
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per monomer unit or blending responsive polymers with nonresponsive polymers can 
increase or decrease the release rate, respectively, in a very specific and finely adjustable 
manner. Additionally, the location and specificity of the bioresponsive sequence can be 
modified in order to impart bioactive properties to these polymers and hydrogels.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Conclusions
The results presented in this work, taken as a whole, demonstrate the potential of 
the genetically engineered polymer platform as a powerful method for producing very 
specific polymers with well-defined properties. In addition to this concept, this work 
demonstrates for the first time a sensitive, enzymatically degradable structure of SELP 
which has the potential to lead to a real-time disease state responsive localized drug 
delivery system. Chapter 3 demonstrates the high degree of control over viral gene 
expression magnitude, extent, and location which can be affected by modifying the 
structure of SELP, and the weight percentage of SELP solution injected to form the 
hydrogel.1 Chapter 4 expands on this work by showing that delivery of adenovirus in 
SELP-815K at 4 wt%, which showed the most promising results from the studies in 
Chapter 3, significantly reduces key markers of toxicity associated with viral delivery, 
most importantly acute immune response. In Chapter 5, SELP-815K is modified with a 
MMP-degradable sequence along the polymer chain, which caused hydrogels formed 
from this material to be degradable as well as imparting MMP-specific responses in terms 
of release rate of model nanoparticles and mechanical properties.
The systematic variation of SELP sequence and its ability to affect function of 
these polymers in vivo was demonstrated in Chapter 3. It was shown that the 
biodistribution of adenoviruses delivered in SELP is directly influenced by polymer 
sequence and composition, and that by making small changes to the polymer structure, 
significant changes can be made to viral delivery. Specifically, the increase in length in 
both silk and elastin units from SELP-47K to SELP-815K yielded increased localized 
gene expression from adenovirus.1 Increasing only the elastin unit length, as going from 
SELP-47K to SELP-415K, affected a significant decrease in local magnitude of gene 
expression. The reason behind this pattern is likely related to the release rates of 
adenoviruses from these hydrogels. A very fast release rate, which is the case in SELP- 
415K and saline-administered virus, would produce very high transfection levels very 
early on in the study, with levels potentially diminishing even as early as 1 week. A more 
constant release scenario, as is likely the case in SELP-815K and has been shown for 
SELP-47K, would keep expression rates at an elevated level throughout the early period 
of constant or near-constant release. The observation of decreased expression following 2 
weeks of treatment indicates that the “releasable” quantity of adenovirus is being 
diminished, and by 3 weeks, gene expression levels appear to be at or near background. 
Of note is that, in the case of SELP-47K, substantial fractions of adenovirus are never 
released from the hydrogel in vitro,4 and the in vivo scenario likely mimics this pattern. 
This highlights the need for a degradable system to allow full release of the injected 
adenovirus dose. Further, it is demonstrated that the structure of SELP has a significant 
effect on its degradation properties by elastin, which is not necessarily dependent on the
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elastin content of monomer chains but instead appears to depend more on the length of 
silk units in the monomer.
Chapter 4 demonstrates the ability of a specific SELP hydrogel, SELP-815K at 4 
wt%, to improve the safety of adenoviral gene-directed enzyme-prodrug therapy in an 
immunocompetent animal model. Notably, while viral administration without controlled 
delivery by SELP did not appear to cause significant toxicity in this mouse model, it did 
produce signs of a strong acute systemic immune response, which were eliminated when 
the same viral titer was administered using SELP as a controlled release material. This is 
a significant result as the acute immune response to adenoviral vectors has long been an 
important barrier to entry into the clinic for this otherwise safe and effective vector, as 
discussed in Chapter 2. Work performed concurrently in our lab on this same SELP 
hydrogel demonstrated its efficacy against a human xenograft HNSCC tumor model in 
nude mice,5 which when combined with the results observed in Chapter 4 are 
encouraging for the use of SELP as a viable controlled and localized delivery matrix for 
adenoviral gene therapy, and possibly other types of agents at similar size scale.
The work demonstrated in Chapter 5 further illustrates the possibilities which 
become available when precise control over polymer sequence is acheivable. In the 
presence of MMP-2, the amount of 100 nm polystyrene beads released from SELP-815K- 
MMPRS after 2 weeks was nearly double that of the same polymer without MMP-2 
exposure. Further, the degradation rate of this hydrogel in the presence of MMP-2 and 
MMP-9 was significantly accelerated compared to hydrogel in the absence of MMP-2 
and MMP-9, suggesting that as the therapeutic payload of the injection is continuing to 
be released, the hydrogel is gradually degrading and could potentially be completely
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eliminated over time. The addition of these capabilities only further enhances the utility 
of SELPs as adenoviral delivery materials in addition to serving as an example of the 
design possibilities available with the genetically engineered polymer platform. In the 
context of HNSCC treatment, the addition of the MMP-degradable sequence can be used 
to fine-tune the release rate of adenovirus from SELP-815K hydrogel by either 
introducing the sequence multiple times or in multiple locations to increase the 
degradation rate, or by blending MMP-responsive SELP-815K-MMPRS with the 
nonMMP-responsive SELP-815K to decrease the degradation rate. Further, different 
sequences could be used which exhibit different MMP-specificities or levels of 
sensitivity to MMPs to further tune the response of these materials.
6.2 Future directions
The development of SELPs for adenoviral delivery for the treatment of head and 
neck cancer has been underway for nearly a decade, and a significant quantity of data has 
been gathered to suggest that this is a promising approach to the treatment of this disease. 
Future work on the development of this material will be to examine carefully the effects 
of fibrous capsule formation on adenovirus release kinetics and the ability of the MMP- 
responsive sequence to affect removal of the hydrogel mass from the injection site. This 
potentially important factor has not been considered to this point and could be helpful for 
controlling adenoviral delivery. The presence of a fibrous capsule is likely to slow down 
the transport of adenoviruses to the intratumoral space, while additionally slowing down 
the transport of MMPs into the hydrogel and degradation products out of it. Further, the 
effect of MMP-responsive sequence location and specificity on the biodistribution,
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efficacy, and toxicity of viral delivery in an in vivo tumor model needs to be evaluated. It 
is important particularly in the efficacy study that this treatment be compared to the 
currently employed treatment for head and neck cancer in a relevant and meaningful 
animal model. Translation of this approach will be difficult due to its focus on using 
adenovirus in humans, which even 13 years removed from the most recent adenovirus- 
related fatality still holds a stigma with investors who would be necessary to fund the 
development of such a treatment. Further, the challenges associated with having a novel 
biomaterial approved for use in humans, in this case SELP, should not be understated or 
ignored. It is important that data made available be strong, but more importantly, 
accurately representative. In other words, to truly pursue translation of this treatment, the 
difficult studies must be done first, meaning the “litmus test” type of studies which may 
provide results catastrophic to the translatability of this treatment approach.
In addition to the application of SELP-mediated adenoviral delivery for the 
treatment of HNSCC, there are several other avenues of research which may benefit from 
the high level of control over release, mechanical properties, and degradation offered by 
SELP. One very good opportunity for expanding this work is to create materials with 
very specific degradable sequences which are sensitive to specific cell types. One could 
easily imagine that this could somehow be applied in a tissue engineering application 
where the invasion of only one cell type would be preferable, and applying lithography or 
other patterning methods to scaffold production using various types of these materials 
could lead to a very advanced and potentially viable product. Another area of future 
expansion which would be easily tested and likely to be successful is the application of 
this material as an intra-articular drug delivery material for the management of arthritis.
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The arthritis market is immense and there is a large quantity of public and private funding 
available. The ability to finely tune an injectable biomaterial to have degradation- 
sensitive release of, for example, anti-inflammatory medication, which is triggered by the 
very factors causing the inflammatory and degradative state, could potentially be very 
significant. Further, due to the ability of the material to degrade and eventually disappear, 
the delivery system could be administered on a set timetable based on the disease state of 
the patient, and the release rate in response to disease state could be matched to the 
patient’ s specific needs by either using polymers with more rapidly degraded sequences, 
more occurrences of the degradable sequence, or by blending various responsive and 
nonresponsive polymers to form interpenetrating networks with “averaged” properties. 
There are many more possible directions in which to expand the application of 
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APPENDIX
PILOT DATA FOR EFFICACY OF CONTROLLED DELIVERY OF 
ADENOVIRUS IN IMMUNOCOMPETENT MICE
A.1 Introduction
As was discussed in Section 2.2.2.2.1, the acute immune response to 
adenoviral vectors is the most significant safety and efficacy concern associated with
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this type of vector. Chapter 4 discussed work performed to illustrate the ability of 
silk-elastinlike protein polymers to reduce the severity of this response with the overall 
goal being to improve the safety of cancer treatment using adenoviruses.4 One aspect 
of this treatment that had not been explored to this point was the ability of SELP- 
mediated delivery to improve the efficacy of this treatment in the presence of a fully 
competent immune system. Previous efficacy work had been performed in athymic 
nude mice bearing human patient-derived xenograft tumors, which essentially 
handicap the cancer due to the lack of T-cell responses which have been shown to 
reduce the efficiency of adenoviral gene delivery both in terms of extent and
duration.5, 6
In order to investigate this important question, a small pilot study was 
undertaken to compare SELP-mediated adenoviral delivery to aqueous intratumoral 
injection in the context of efficacy in an immunocompetent tumor model. The model
which was chosen for this study was sarcoma-180 (S-180). This model was chosen 
due to its ability to rapidly induce tumors in standard CD-1, noninbred, fully 
immunocompetent mice. It is acknowledged that this sarcoma cell line is not a suitable 
replacement for a squamous cell carcinoma model; however, there is a lack of 
available HNSCC tumor models which can be used in immunocompetent mice. 
Tumors were treated with high-titer adenovirus encoding herpes simplex virus 
thymidine kinase (Ad.HSVtk) as in the safety studies; however, the dosing schedule of 
ganciclovir (GCV) was conservatively designed to protect the mice following a large 
adenoviral administration. The study produced results which confirmed that 
administration of the adenovirus in SELP does, in fact, improve efficacy in 
immunocompetent tumor models; however, the duration of the study was reduced due 
to unacceptably large tumors, and GCV dosing was not as aggressive as later efficacy 
studies; therefore, this study did not provide publishable data and the following should 
be regarded as preliminary.
A.2 Materials and methods
A.2.1 Materials
Animals used in this study were 4-6-week-old female albino standard CD-1 
mice (Charles River Labs, Cambridge, MA). Custom adenovirus encoding HSVtk and 
luciferase was purchased from Vector Biolabs (Philadelphia, PA). 1cc and 20cc 
syringes, 26G 5/8, 25G 5/8, and 18G 1 1/2 needles were purchased from Becton 
Dickinson (Franklin Lakes, NJ). Cell culture ware including centrifuge tubes was 
purchased from ISC Bioexpress (Kaysville, UT). Sterile 0.9% saline for injection was
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purchased from Baxter, Deerfield, IL. GCV was purchased from Sigma-Aldrich (St. 
Louis, MO).
A.2.2 Methods 
A.2.2.1 Expansion of S-180 fibrosarcoma cells
Frozen stocks of S-180 fibrosarcoma, a generous gift from Dr. Hiroshi Maeda, 
were defrosted at room temperature. CD-1 mice were weighed and prepared for 
injection by swabbing the right lateral, ventral, posterior region with 60% isopropanol. 
Mice were injected intraperitoneally with 1ml of S-180 stock through a 25G 5/8 needle 
slowly to avoid cell lysis. Following injection, mice were inverted for 10-12s to reduce 
injection site leakage. Mice were monitored daily for weight, behavior, and apparent 
increase in girth due to intraperitoneal cell growth. Following weight gain of no more 
than 5 grams, animals were sacrificed by CO2 asphyxiation, placed on their side, and 
an 18G 1 V2 needle on a 20cc syringe was inserted below the midline to draw cells. 
Slow drawing of cell suspension from the peritoneum continued until no further cell 
suspension was removed, at which point the peritoneum was opened and the remaining 
cell suspension was removed by aspiration with or without the needle. Cell 
suspensions were pooled and washed with sterile phosphate buffered saline twice, and 
adjusted to 10 million cells/ml.
A.2.2.2 Induction of S-180 tumors
Mice were prepared for tumor inoculation by isofluorane anesthesia followed 
by shaving of the medial dorsal flanks and swabbing with 60% isopropanol. 200 ^l of
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injection stock (10 million S-180 cells/ml) was administered subcutaneously into each 
flank using a 25G 5/8 needle, for a total of 2 tumors per mouse. The needle entry 
wound was held shut with forceps for 10-12s to reduce backflow of cell suspension 
from the injection site. Tumors were observed approximately 5 days following 
injection, and were measured with calipers every other day until the average size was 
observed to be approximately 7 mm x 7 mm, which occurred 9 days following initial 
inoculation.
A.2.2.3 Virus administration, treatment, and tumor monitoring
Viral stocks containing Ad.HSVtk.Luc were defrosted and mixed appropriately 
with 0.9% injection saline or SELP-815K+injection saline to result in a final viral titer 
of 4.3x109 plaque-forming units (PFU) per 50 ^l injection volume. The final 
concentration of SELP-815K was 4 wt% in the SELP-mediated condition. 
Intratumoral injections of virus were performed by inserting a 26G 5/8 needle attached 
to a 250 |il Hamilton glass syringe into the approximate center of each tumor, and 
injecting 50 ^l of each condition. Control mice received only 50 ^l saline. The day of 
virus injection was considered Day 0.
GCV was dissolved in 0.9% injection saline at a final concentration of 1mg/ml. 
Mice were weighed individually and dosed at 25mg/kg, with a typical dose being 0.6 
ml. The dosing schedule for this initial study was 5 consecutive daily injections 
followed by an “off” day. The dosing schedule was intentionally conservative, as it 
was unknown how the mouse would tolerate such a viral dose in combination with 
daily GCV administration. Tumors were measured every third day with calipers, and
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tumor volumes were calculated by multiplying the longer dimension by the square of 
the shorter dimension, and dividing by two. Animals were sacrificed if either tumor 
reached a volume greater than 2000 mm , the animal exhibited any signs of pain and 
distress, or if extensive necrosis occurred resulting in skin breakage at the tumor 
exterior.
A.3 Results and discussion
The results of this study are shown in Figure A.1. Due to rapid growth of 
tumors in the control condition and a lack of an approved IACUC protocol to perform 
a survival study, it became necessary to end the study on Day 12 following the 
initiation of treatment. While brief, the results of this study revealed that intratumoral 
delivery of adenovirus without a controlled delivery system is not efficacious in the 
presence of a fully competent immune system. Controlled delivery mediated by SELP- 
815K 4 wt%, however, showed significantly reduced tumor growth over the study 
period, as shown in Figure A.1. These results compared to previous efficacy data in an 
immunocompromised nude mouse model bearing human HNSCC tumors6 suggest 
some interesting conclusions which warrant further work. In the previous study 
comparing delivery methods in immunocompromised mice, the virus administered in 
saline alone exhibited nearly the same efficacy as virus delivered in SELP-815K 4 
wt%. This discrepancy between the two studies in the context of controlled delivery 
could be caused by several different factors:
1. The SELP-815K 4 wt% used for controlled delivery offers an 
immunoprotective effect by sequestering virus in pores too small to be 
accessed by T-cells capable of neutralizing them. The distribution pattern of
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Figure A.1: Efficacy gf SELP-mediated GDEPT in immunocompetent mice. Control:
saline injection with no virus or SELP.
SELP in the tumor resulted in a large surface area of virus-releasing hydrogel 
in intimate contact with cells of the tumor, facilitating rapid killing of cells in 
direct contact while additionally distributing the tumor mass affected by the 
bystander effect over a larger area than the single bolus dose of virus.
2. There is no immunoprotective effect, but the slow release of the virus and 
therefore constant reduced level of virus contacting the tumor is more effective 
than a larger bolus dose, of which the same or lower percentage is likely 
neutralized by the immune system.
3. There is a cell-line-dependent difference in susceptibility to initial viral 
transfection, the bystander effect, or both which somehow accounts for the 
discrepancy.
4. The physical presence of the hydrogel inside the tumor caused an appreciable 
reduction in growth rate, and the viruses were not at all involved in this result. 
This conclusion may be corroborated by data collected in the aforementioned 
immunocompromised efficacy study,6 which showed that the presence of a 
SELP hydrogel inside a tumor slightly inhibited growth, although the 
magnitude of the effect observed in the previous study is much less significant 
than the effect observed in the current study.
It is most likely that the efficacy is primarily related to point number 1, with a 
likely small contribution of points 3 and 4. Point 2, while not completely invalid, does 
not apply in this case due to the short duration of the study; i.e., if this hypothesis is 
true, the current study period is insufficient in length to make such a conclusion due to 
the time necessary for this effect to be observed. Point 3 is also a possibility, as in this
case, the primary mechanism of adenoviral transfection would be CAR-receptor 
mediated, and CAR receptor densities can vary widely among cell lines, even from 
anatomically similar locations. If this is the case, however, it is to be expected that the 
relative difference in effect between the two treatment modalities would mirror that of 
the immunocompromised study. Point 1 additionally is supported by the toxicity data 
presented in Chapter 4, as this study suggested that delivery in SELP-815K 4 wt% 
almost completely knocks down the acute immune response to the large administered 
viral dose.4 Therefore, with limited data, controls, and follow-up, it can be tentatively 
stated that delivery of adenovirus in SELP-815K 4 wt% mediates enhanced therapeutic 
efficacy by protecting the delivered viral dose from clearance by the immune system 
while simultaneously increasing the surface area of tumor exposed to the therapeutic 
virus.
A.4 Conclusion
While insufficient in length and breadth to draw definitive conclusions regarding 
the efficacy of this treatment in an immunocompetent scenario, the study does provide 
some promising data as to the potential clinical viability of this treatment approach. 
The combination of the results of this study with the toxicity data reported in Chapter 
4 and the previously published efficacy results in immunocompromised mice6 supports 
the conclusion that SELP-815K 4 wt% offers an immunoprotective environment for 
co-injected adenovirus. This in turn increases the efficacy of adenoviral treatment 
while simultaneously making the administration of large adenoviral doses safer.
243
244
1. Yang, Y.; Li, Q.; Ertl, H. C.; Wilson, J. M., Cellular and humoral immune 
responses to viral antigens create barriers to lung-directed gene therapy with recombinant 
adenoviruses. J Virol 1995, 69, (4), 2004-2015.
2. Yang, Y.; Nunes, F. A.; Berencsi, K.; Furth, E. E.; Gonczol, E.; Wilson, J. M., 
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc 
Natl Acad Sci U S A 1994, 91, (10), 4407-4411.
3. Tripathy, S. K.; Black, H. B.; Goldwasser, E.; Leiden, J. M., Immune responses to 
transgene-encoded proteins limit the stability of gene expression after injection of 
replication-defective adenovirus vectors. Nat Med 1996, 2, (5), 545-550.
4. Gustafson, J. A.; Price, R. A.; Greish, K.; Cappello, J.; Ghandehari, H., Silk- 
elastin-like hydrogel improves the safety of adenovirus-mediated gene-directed enzyme- 
prodrug therapy. M ol Pharm 2010, 7, (4), 1050-1056.
5. Worgall, S.; Wolff, G.; Falck-Pedersen, E.; Crystal, R. G., Innate immune 
mechanisms dominate elimination of adenoviral vectors following in vivo administration. 
Hum Gene Ther 1997, 8, (1), 37-44.
6. Greish, K.; Frandsen, J.; Scharff, S.; Gustafson, J.; Cappello, J.; Li, D.; O'Malley,
B. W., Jr.; Ghandehari, H., Silk-elastinlike protein polymers improve the efficacy of 
adenovirus thymidine kinase enzyme prodrug therapy of head and neck tumors. J Gene 
Med 2010, 12, (7), 572-579.
7. Li, D.; Duan, L.; Freimuth, P.; O'Malley, B. W., Jr., Variability of adenovirus 
receptor density influences gene transfer efficiency and therapeutic response in head and 
neck cancer. Clin Cancer Res 1999, 5, (12), 4175-4181.
A.5 References
